Development of WWP2 ubiquitin ligase inhibitors using biophysical, structural and synthetic approaches. by Hughes, Gregory
Development of WWP2 ubiquitin ligase
inhibitors using biophysical, structural
and synthetic approaches.
Gregory Richard Hughes
School of Chemistry
University of East Anglia
This thesis is submitted for the degree of
Doctor of Philosophy
September 2019
© This copy of the thesis has been supplied on condition that anyone who consults it is understood to
recognise that its copyright rests with the author and that use of any information derived therefrom must be in
accordance with current UK Copyright Law. In addition, any quotation or extract must include full attribution.
Acknowledgements
I would first like to thank Dr Andrew Chantry for his help and guidance over the past
four years. I thank Dr Andrew Hemmings for introducing me to the dark art of protein
crystallography. For the chemistry, I thank Professor Phil Page (I miss the parties), Dr
Richard Stephenson and Dr Tom Storr. I would like to make a special thanks to the NMR
group of Dr Jesus Angulo, Dr Sam Walpole and Dr Serena Monaco, who’s collaboration in
this project really helped to steer it in the right direction. I thank Dr Clare Stevenson for her
help and assistance in the SPR. For my time at Charnwood, I thank Dr James Hitchin, who’s
experience and expertise in medicinal chemistry was particularly useful. I thank my mentor
and friend, Dr Elvis Maduli. I would also like to give thanks to Carlos Lence, for welcoming
me into his home for three months. I have met and worked with many friends over the past
four years who I have made my time enjoyable. Dr Jess Watt and Dr Tiffany Yim, who first
showed me the ways of working in a biology lab. (Dr to be) Adam Wright, for persuading
me to do Cabaret 2018 (“It will be easy. . . ”). I give a special mention to those who there
from the very start; (Dr to be) Tom Bridge, Dr Ross Goodyear, Dr Gerald Keil and (Dr to be)
Gareth Hughes. Also give thanks to members of the Page lab and third floor. Finally, I would
like to thank my family and friends for their support, and a special mention to Alison.
Declaration
I hereby declare that except where specific reference is made to the work of others, the
contents of this dissertation are original and have not been submitted in whole or in part
for consideration for any other degree or qualification in this, or any other university. This
dissertation is my own work and contains nothing which is the outcome of work done in
collaboration with others, except as specified in the text and Acknowledgements.
Gregory Richard Hughes
September 2019
Abstract
The ubiquitin- proteasome pathway (UPS) involves the targeting of proteins for their degra-
dation by the 26S proteasome. Ubiquitin is covalently attached to targeted proteins via a
three step enzymatic cascade. The three enzymes involved in this process are known as E1
activating, E2 conjugating and E3 ligases. The key to substrate selectively is within the E3
ligases. E3 ligases can be divided into three domain containing groups: HECT, RING and
RING between RING (RBR). Of particular interest is the Nedd4 group of HECT ligases.
The Nedd4 group all share similar domain make up where they have substrate recruiting
WW domains and a catalytic HECT domain, responsible for transferring ubiquitin onto the
substrates. The mis-expression of a member of this group, WWP2, has been linked to tumour
growth in various cancers. Targeting the UPS for cancer therapeutic use has already been
shown to be achievable with the proteaseome inhibitor Bortezomib. Targeting the more
specific WWP2 ubiquitin ligase could lead to less side effects and greater efficacy. Research
into developing inhibitors for WWP2 could lead to the discovery of novel therapeutics.
The aim of this thesis is to design, synthesise and evaluate novel WWP2 ubiquitin ligase
inhibitors. Different methodologies are explored in order to reveal WWP2 small molecule
binding events. A thermal shift screen is employed to search for binders, and orthogonal
methods for validation are tested. Using these methods, novel WWP2 ligands are discovered
with inhibition activity. Crystallography is used to structural elucidate a novel binding site for
WWP2 ligands. Data acquired from ligand NMR techniques is used to validate this binding
site. The combined X-ray crystallography and ligand NMR data is used to inform organic
synthesis of analogues for a particular inhibitor. These analogues are tested for inhibition
against WWP2 and Nedd4 autoubiquitination. IC50 values generated from this analogue
series further validate the novel binding site and also offer higher levels of activity of below
1 µM.
v
Table of contents
List of Figures xv
List of tables xix
1 Introduction 1
1.1 Ubiquitination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.1.1 Ubiquitin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.1.2 E1 activating and E2 conjugating enzymes . . . . . . . . . . . . . 6
1.1.3 E3 ligases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.1.3.1 RING ligases . . . . . . . . . . . . . . . . . . . . . . . 10
1.1.3.2 HECT ligases . . . . . . . . . . . . . . . . . . . . . . . 13
1.1.3.3 Nedd4 E3 ligases . . . . . . . . . . . . . . . . . . . . . 16
1.1.3.4 WWP2: Structure, function and role in cancer . . . . . . 18
1.2 Therapeutic targeting of the UPS . . . . . . . . . . . . . . . . . . . . . . . 21
1.2.1 Proteasome inhibitors . . . . . . . . . . . . . . . . . . . . . . . . 21
1.2.2 E1 and E2 inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . 22
1.2.3 Targeting the E3 ligases . . . . . . . . . . . . . . . . . . . . . . . 24
1.2.3.1 PROTACs . . . . . . . . . . . . . . . . . . . . . . . . . 24
1.2.3.2 RING inhibitors . . . . . . . . . . . . . . . . . . . . . . 25
1.2.3.3 HECT inhibitors . . . . . . . . . . . . . . . . . . . . . . 25
1.2.3.4 Other HECT ligase inhibitors . . . . . . . . . . . . . . . 31
1.3 Thesis aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2 Biological materials and methods 33
2.1 DNA techniques . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.1.1 Plasmids and primers . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.1.2 Phusion PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.1.3 DNA Gel electrophoresis . . . . . . . . . . . . . . . . . . . . . . . 35
2.1.4 Plasmid digest . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.1.5 In-Fusion ligation . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.1.6 DNA extraction and purification . . . . . . . . . . . . . . . . . . . 37
2.1.7 DNA transformations . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.1.8 Plasmid purification . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.2 Protein techniques . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.2.1 Protein expression . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.2.2 Protein purification . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.2.2.1 His tagged proteins . . . . . . . . . . . . . . . . . . . . 38
2.2.2.2 GST tagged protein . . . . . . . . . . . . . . . . . . . . 38
2.2.2.3 Dialysis . . . . . . . . . . . . . . . . . . . . . . . . . . 39
2.2.2.4 GST cleavage . . . . . . . . . . . . . . . . . . . . . . . 39
2.2.2.5 Gel filtration . . . . . . . . . . . . . . . . . . . . . . . . 39
2.2.3 Protein crystallisation . . . . . . . . . . . . . . . . . . . . . . . . 40
2.2.3.1 Crystal formation . . . . . . . . . . . . . . . . . . . . . 40
2.2.3.2 Crystal harvesting . . . . . . . . . . . . . . . . . . . . . 40
2.2.3.3 X-ray data collection . . . . . . . . . . . . . . . . . . . 40
2.2.4 SDS-PAGE gel electrophoresis . . . . . . . . . . . . . . . . . . . . 41
2.2.5 Plate coating . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
vii
2.2.6 Autoubiquitination assay . . . . . . . . . . . . . . . . . . . . . . . 42
2.2.7 Differential scanning fluorimetry . . . . . . . . . . . . . . . . . . . 43
2.2.8 Hydrogen peroxide detection assay . . . . . . . . . . . . . . . . . 43
2.2.9 Surface plasmon resonance . . . . . . . . . . . . . . . . . . . . . . 44
2.2.10 Statistics and repeats . . . . . . . . . . . . . . . . . . . . . . . . . 44
3 Efforts towards the discovery and development of WWP2 inhibitors through
biophysical and synthetic methods 45
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.1.1 Biophysical techniques . . . . . . . . . . . . . . . . . . . . . . . . 47
3.1.1.1 Differential scanning fluorimetry . . . . . . . . . . . . . 47
3.1.1.2 Surface plasmon resonance . . . . . . . . . . . . . . . . 48
3.1.1.3 Saturation transfer difference NMR . . . . . . . . . . . . 48
3.1.2 Experimental aims . . . . . . . . . . . . . . . . . . . . . . . . . . 50
3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.2.1 Utilising a thermal shift assay to identify WWP2 ligands . . . . . . 51
3.2.1.1 WWP2 HECT protein purification . . . . . . . . . . . . 51
3.2.1.2 Thermal shift buffer screen . . . . . . . . . . . . . . . . 52
3.2.1.3 Compound screen . . . . . . . . . . . . . . . . . . . . . 53
3.2.1.4 Biological testing of hit compounds . . . . . . . . . . . . 56
3.2.2 Orthogonal approaches to validate ligands . . . . . . . . . . . . . . 60
3.2.2.1 Orthogonal validation by STD NMR . . . . . . . . . . . 60
3.2.2.2 Using surface plasmon resonance to investigate binding to
WWP2 . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.2.2.3 Purification of WWP2 FL . . . . . . . . . . . . . . . . . 62
3.2.2.4 WWP2 SPR experiments . . . . . . . . . . . . . . . . . 63
3.2.2.5 Detection of ligand binding to WWP2 by SPR . . . . . . 64
viii
3.2.3 Synthetic approaches . . . . . . . . . . . . . . . . . . . . . . . . . 67
3.2.3.1 Heclin synthesis . . . . . . . . . . . . . . . . . . . . . . 67
3.2.3.2 Vilsmeier-Haak reaction . . . . . . . . . . . . . . . . . . 68
3.2.3.3 Knoevenegal condensation Doebner modification . . . . 69
3.2.3.4 Amide bond formation . . . . . . . . . . . . . . . . . . 70
3.2.3.5 Synthesis of the purpurogallin scaffold . . . . . . . . . . 70
3.2.3.6 Purpurogallin analogue testing . . . . . . . . . . . . . . 74
3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4 Towards the solving of the first ligand bound WWP2 crystallographic structure 80
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4.1.1 Crystal formation . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4.1.2 X-ray diffraction . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
4.1.3 Protein ligand structures of the HECT ubiquitin ligases . . . . . . . 83
4.1.4 Chapter aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
4.2.1 Identification of putative binding sites . . . . . . . . . . . . . . . . 85
4.2.2 Attempting WWP2 HECT crystallisation . . . . . . . . . . . . . . 87
4.2.3 WWP2 WW2-2,3 linker HECT purification and crystallisation . . . 89
4.2.4 Initial WWP2 crystal harvesting . . . . . . . . . . . . . . . . . . . 90
4.2.5 Further soaking experiments leads to improved search model . . . . 93
4.2.6 First potential protein ligand structure . . . . . . . . . . . . . . . . 96
4.2.7 Optimising of soak experiments to reveal further protein ligand
structures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
4.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
5 Utilising ligand NMR in the synthesis of isoalloxane based WWP2 inhibitors 116
ix
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
5.1.1 Discovery of novel WWP2 inhibitors by biochemical approaches . 117
5.1.2 Ligand NMR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
5.1.2.1 STD Epitope maps . . . . . . . . . . . . . . . . . . . . . 118
5.1.2.2 DEEP STD NMR . . . . . . . . . . . . . . . . . . . . . 119
5.1.3 Experimental aims . . . . . . . . . . . . . . . . . . . . . . . . . . 120
5.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
5.2.1 In silico modelling of NSC288387 into WWP2 HECT . . . . . . . 121
5.2.2 NMR validation of the WWP2:NSC288387 in silico model . . . . . 123
5.2.3 In silico modelling of NSC288387 into WWP1 HECT . . . . . . . 126
5.2.4 NMR validation of the WWP1:NSC288387 in silico model . . . . . 126
5.2.5 In silico modelling of NSC288387 into Nedd4 HECT . . . . . . . . 129
5.2.6 Design of NSC288387 analogues . . . . . . . . . . . . . . . . . . 129
5.2.7 Organic synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
5.2.7.1 Amine protection and alkylation . . . . . . . . . . . . . 131
5.2.7.2 Nucleophilic aromatic substitution . . . . . . . . . . . . 132
5.2.7.3 Reduction of nitro group and condensation with alloxan
monohydrate . . . . . . . . . . . . . . . . . . . . . . . 133
5.2.7.4 Chan- Lam coupling . . . . . . . . . . . . . . . . . . . . 134
5.2.8 Testing of analogues against WWP2 autoubiquitination . . . . . . . 139
5.2.9 Testing of compounds against Nedd4 . . . . . . . . . . . . . . . . 143
5.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
6 Final Discussion 152
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
6.2 Gaining a starting point . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
6.3 The PAIN argument . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
x
6.4 A novel allosteric binding site . . . . . . . . . . . . . . . . . . . . . . . . 157
6.5 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
7 Chemistry experimental 161
7.1 General chemistry experimental . . . . . . . . . . . . . . . . . . . . . . . 162
7.1.1 Preparation of solvents and glassware . . . . . . . . . . . . . . . . 162
7.1.2 Compound characterisation . . . . . . . . . . . . . . . . . . . . . 162
7.1.3 Chromatographic techniques . . . . . . . . . . . . . . . . . . . . . 163
7.1.4 Compound numbering . . . . . . . . . . . . . . . . . . . . . . . . 163
7.2 Individual procedures and characterisation . . . . . . . . . . . . . . . . . . 164
References 186
xi
Abbreviations
AKT- Protein kinase B
AMP- Adenosine monophosphate
ATP- Adenosine triphosphate
BARD1- BCRA1 associated RING domain protein 1
BRCA1- Breast cancer type 1 susceptibility protein
BIRC7- Baculoviral IAP repeat containing protein 7
C2- Calcium binding domain
cCBL- Casitas B lineage lymphoma
DEEP- Differential epitope mapping
DMSO- Dimethylsulfoxide
DNA- Deoxyribonucleic acid
dNTP- Deoxynucleoside triphosphate
DSF- Differential scanning fluorimetry
DCM- Dichoromethane
DMF- N, N dimethylformamide
ELISA- Enzyme linked immunosorbent assay
EtOAc- Ethyl acetate
FL- Full length
GST- Glutathione s-transferase
HECT- Homologous to the E6AP carboxyl terminus
IPTG- Isopropyl-β -D- thiogalactoside
ITCH- Itchy E3 ubiquitin protein ligase
kDa- Kilodalton
LB- Lysogeny broth
LCMS- Liquid chromatograph mass spectrometry
MES- 2-(N-morpholino) ethanesulfonic acid
MMT- Malic acid, MES, Tris
mRNA- Messenger RNA
MW- Molecular weight
Nedd4- Neural precurser cell expressed developmentally down regulated protein 4
NMR- Nuclear magnetic resonance
NSC- Cancer chemotherapy national service center number
NOE- Nuclear overhauser effect
PAGE- Polyacrylamide gel electrophoresis PCR- Polymerase chain reaction
PDB- Protein data bank
PROTAC- Proteolysis targeting chimera
PTEN- Phosphatase and tensin homolog
RBR- RING between RING
RING- Really interesting new gene
RMSD- Root mean square deviation
RNA- Ribonucleic acid
SDS- Sodium dodecyl sulfate
SMAD- Small mothers against decapentaplegic
SMURF- Smad ubiquitin regulatory factor
SNAr- Nucleophilic aromatic substitution
SPR- Surface plasmon resonance
xiii
STD- Saturated transfer difference
TGFβ - Transforming growth factor beta
THF- Tetrahydrofuran
TMB- Tetramethylbenzidine
tRNA- Transfer ribonucleic acid
UBA- Ubiquitin like modifier activating enzyme
UBC- Ubiquitin conjugating
UPS- Ubiquitin proteasome system
VHL- Von Hippel Lindau
WWP1- WW domain containing E3 ubiquitin protein ligase 1
WWP2- WW domain containing E3 ubiquitin protein ligase 2
xiv
List of Figures
1.1 Schematic of the ubiquitin-proteasome pathway . . . . . . . . . . . . . . . 4
1.2 The structure of ubiquitin . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.3 Bound structure of UBA1 and two ubiquitin molecules. . . . . . . . . . . . 7
1.4 Structure of E2 bound structures . . . . . . . . . . . . . . . . . . . . . . . 9
1.5 Structure of RING complexes . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.6 Structural representation of the L and T shape conformation of HECT . . . 15
1.7 Schematic showing the Nedd4 superfamily of HECT E3 ligases. . . . . . . 17
1.8 Structure of WWP2 HECT domain . . . . . . . . . . . . . . . . . . . . . . 19
1.9 Genomic analysis of WWP2 and the highly homologous WWP1 in prostate
cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.10 Selection of proteasome inhibitors . . . . . . . . . . . . . . . . . . . . . . 22
1.11 Small molecule inhibitors of E1 and E2. . . . . . . . . . . . . . . . . . . . 23
1.12 Inhibitors of E3 RING ligases. . . . . . . . . . . . . . . . . . . . . . . . . 26
1.13 Inhibitors of E3 HECT ligases . . . . . . . . . . . . . . . . . . . . . . . . 27
1.14 Structure of the Nedd4 inhibitor . . . . . . . . . . . . . . . . . . . . . . . 30
3.1 Nickel NTA purification of WWP2 HECT. . . . . . . . . . . . . . . . . . . 52
3.2 Condition screen for thermal shift . . . . . . . . . . . . . . . . . . . . . . 53
3.3 Thermal shift screen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.4 Thermal shift hit compounds IC50’s . . . . . . . . . . . . . . . . . . . . . 59
xv
3.5 STD spectrum of NSC35676 . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.6 NMR sprectum showing the degradation of NSC401005 in the presence of
WWP2 HECT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.7 WWP2 FL protein purification . . . . . . . . . . . . . . . . . . . . . . . . 63
3.8 SPR sensorgram of WWP2 fl and WWP2 HECT . . . . . . . . . . . . . . 64
3.9 Compound binding to WWP2 HECT . . . . . . . . . . . . . . . . . . . . . 65
3.10 R-max equation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.11 R-max values of compound binding to WWP2 HECT . . . . . . . . . . . . 66
3.12 Scheme 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
3.13 Scheme 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
3.14 Scheme 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
3.15 Scheme 4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
3.16 Scheme 5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
3.17 Scheme 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
3.18 Purpurogallin analogue testing . . . . . . . . . . . . . . . . . . . . . . . . 74
3.19 Purpurogallin analogue testing against Nedd4 autoubiquitination . . . . . . 75
3.20 HS-152 and NSC215718 . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
3.21 Purpurogallin containing the catechol moeity . . . . . . . . . . . . . . . . 79
4.1 Nedd4 HECT bound to "Compound 1" . . . . . . . . . . . . . . . . . . . . 83
4.2 Predicted small molecule binding sites for WWP2 HECT. . . . . . . . . . . 86
4.3 WWP2 HECT purification for crystallography . . . . . . . . . . . . . . . . 88
4.4 Key steps in the WW2-2,3 linker HECT purification . . . . . . . . . . . . . 90
4.5 PDB validation of new search model . . . . . . . . . . . . . . . . . . . . . 97
4.6 WWP2_6_1 double difference Fourier electron density map. . . . . . . . . 98
4.7 Protein ligand interactions present in WWP2_6_1. . . . . . . . . . . . . . . 100
4.8 Double difference Fourier electron density of NSC2805 in WWP2_34_3. . 105
xvi
4.9 WWP2_34_3 protein ligand interactions. . . . . . . . . . . . . . . . . . . . 107
4.10 NSC2805 electron density in WWP2_38_1. . . . . . . . . . . . . . . . . . 110
4.11 Electron density map comparison between apo (A) and soaked NSC2805 (B) 115
5.1 Schematic of the WWP2 autoubiquitination assay . . . . . . . . . . . . . . 118
5.2 Equations used for calculating ligand epitope maps . . . . . . . . . . . . . 119
5.3 Equation used to calculate the DEEP STD factor . . . . . . . . . . . . . . 120
5.4 Structure of NSC288387 . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
5.5 NSC288387 docked into WWP2 HECT. . . . . . . . . . . . . . . . . . . . 123
5.6 Ligand epitope map of NSC288387 bound to WWP2 HECT . . . . . . . . 124
5.7 DEEP STD factors for 288387 bound to WWP2 HECT . . . . . . . . . . . 126
5.8 Ligand epitope of NSC288387 when bound to WWP1 HECT . . . . . . . . 127
5.9 DEEP STD factors for 288387 bound to WWP1 HECT . . . . . . . . . . . 128
5.10 Scheme 7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
5.11 Scheme 8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
5.12 Scheme 9 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
5.13 Scheme 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
5.14 A simplified Chan Lam catalytic cycle. . . . . . . . . . . . . . . . . . . . . 136
5.15 Scheme 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
5.16 Scheme 12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
5.17 Scheme 13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
5.18 Scheme 14 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
5.19 Scheme 15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
5.20 WWP2 autoubiquitination IC50 curves . . . . . . . . . . . . . . . . . . . . 140
5.21 Nedd4 autoubiquitination IC50 curves . . . . . . . . . . . . . . . . . . . . 144
5.22 In silico structure of compound 21 docked into the binding site. . . . . . . . 150
6.1 Phenol red assay. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
xvii
6.2 Preliminary data showing the thermal shift screen using the WWP2 WW2-2,3
linker-HECT construct . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
xviii
List of tables
2.1 Plasmids used throughout this project . . . . . . . . . . . . . . . . . . . . 34
2.2 Primer sequences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.3 PCR reaction mixture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.4 PCR cycle conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.5 Restriction enzyme digest reaction . . . . . . . . . . . . . . . . . . . . . . 36
2.6 Plasmid ligation reaction mixture . . . . . . . . . . . . . . . . . . . . . . . 36
2.7 Protein expression conditions . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.8 Ni NTA purification buffer recipes . . . . . . . . . . . . . . . . . . . . . . 39
2.9 GST purification buffer recipies . . . . . . . . . . . . . . . . . . . . . . . 40
2.10 10 % and 15 % acrylamide gel components and volumes for 2 gels . . . . . 41
3.1 Structures and ∆TmD of Diversity set hits . . . . . . . . . . . . . . . . . . 56
3.2 Structures and ∆TmD of Natural product set hits . . . . . . . . . . . . . . . 57
3.3 IC50 values of thermal shift hit compounds for the WWP2 autoubiquitination
assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
4.1 Summary of first soaking experiments . . . . . . . . . . . . . . . . . . . . 92
4.2 Summary of the solved data from the first soaking experiments . . . . . . . 92
4.3 Summary of second soaking experiments . . . . . . . . . . . . . . . . . . 94
4.4 Summary of second soaking experiments . . . . . . . . . . . . . . . . . . 95
xix
4.5 Validation data comparison of the new search model and the published structure 96
4.6 WWP2_6_1_3 validation . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
4.7 Summary of glycerol titration soaking experiments . . . . . . . . . . . . . 102
4.8 Summary data collected from glycerol titrations . . . . . . . . . . . . . . . 102
4.9 Summary of the DMSO soaking experiments . . . . . . . . . . . . . . . . 102
4.10 Summary of the solved data from the DMSO soaking experiments . . . . . 103
4.11 Summary of the NSC2805 soaking experiments in the improved soak conditions103
4.12 Summary of the solved data from the improved soaking experiments . . . . 104
4.13 WWP2_34_3 validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
4.14 Summary of long soak experiments . . . . . . . . . . . . . . . . . . . . . 109
4.15 Summary of the solved data from the long soaking experiments . . . . . . . 109
4.16 WWP2_38_1 validation table . . . . . . . . . . . . . . . . . . . . . . . . . 111
5.1 WWP2 HECT: NSC288387 STD epitope values . . . . . . . . . . . . . . . 125
5.2 WWP2 DEEP STD factors . . . . . . . . . . . . . . . . . . . . . . . . . . 125
5.3 WWP1 HECT: NSC288387 STD epitope values. . . . . . . . . . . . . . . 127
5.4 WWP1 DEEP STD factors . . . . . . . . . . . . . . . . . . . . . . . . . . 128
5.5 Ranked analogues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
5.6 Chan Lam substrate yields . . . . . . . . . . . . . . . . . . . . . . . . . . 135
5.7 NSC288387 analogue WWP2 autoubiquitination IC50’s . . . . . . . . . . 142
5.8 NSC288387 analogue Nedd4 autoubiquitination IC50’s . . . . . . . . . . . 146
xx
Chapter 1
Introduction
1
The central dogma of biology describes how genetic material of an organism codes
for biological function. DNA is the language used to encode this information. The DNA
sequence is converted to mRNA by RNA polymerase in a process known as transcription.
The mRNA is then decoded by matching up with complementary tRNA. The tRNA molecules
hold the specific amino acid which is coded for by the three lettered DNA sequence. The
aligned amino acids join via a peptide bond to form a polypeptide chain. The final polypeptide
chain is folded into the chosen structure, the protein. Proteins are natures machines, armed
with the ability to do a vast range of functions. Proteins can have enzymatic capability to
catalyse reactions. They can be involved in controlling cell signalling pathways in order
to produce the desired response. Proteins can also act a structural scaffolds to change the
physical properties of tissue. Proteins can undergo post translational modifications which
can in turn modify a proteins role. One such post translational modification is ubiquitination.
Ubiquitination involves the labelling of proteins with a small protein named ubiquitin. The
labelling of ubiquitin can have protolytic and non protolytic consequences. The attachment of
ubiquitin is carried out by the E3 ubiquitin ligases. WWP2 (WW domain containing protein
2) is a HECT E3 ligase member of the Nedd4 family. The currently known role for WWP2 is
to attach ubiquitin to the target substrates through its intrinsic activity, labelling the target
for degradation by the proteasome. Mis-regulation of WWP2 has been linked to disease,
prominently cancer. Cancer is globally one of the leading causes of death, approximately 1 in
6 deaths are associated with cancer (statistic from the World Health Organisation). Genetic
mutations at the protein level can lead to cellular transformation, leading to uncontrolled
cell growth which has damaging effects on the body. WWP2 targets the tumour suppressors
Smads and pTEN in the TGFβ pathway and PI3K/AKT pathway respectively.
This chapter introduces the process and functional roles of protein ubiquitination. A
current insight regarding inhibitors of the ubiquitination pathway, mainly focusing on the E3
ligases are summarized.
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1.1 Ubiquitination
Maintaining control over protein levels is key to cellular homeostasis. The rate at which
proteins are synthesised and degraded determines protein turnover. In eukaryotic cells, protein
degradation is conducted by two major pathways; lysosomal proteolysis and the ubiquitin
proteasome pathway. Lysosomes are membrane enclosed organelles which hold a selection
of digestive enzymes. Cellular proteins are taken up by the lysosome and degraded (Cooper
et al., 2000). The ubiquitin proteasome pathway (Figure 1.1) provides a greater level of
specificity in protein degradation, and will be discussed here in further detail. Ubiquitination
is the sequential cascade of enzymatic events which labels proteins with ubiquitin. Ubiquitin
is a small 76 amino acid protein found in most eukaryotic organisms. The seminal work
by Ciechanover, Hershko and Rose discovered the role of ubiquitination in ATP activated
protein turnover (Ciehanover et al., 1978) (Hershko et al., 1979) (Hershko et al., 1980). The
pathway has later been found to be involved in other processes such as protein trafficking
and DNA repair (Chantry, 2011). The three key enzymes involved in ubiquitination are
known as E1 activating, E2 conjugating and E3 ligases. Ubiquitination begins with the ATP
catalysed formation of a thio-ester bond between an E1 activating enzyme and ubiquitin.
Ubiquitin is subsequently bound to an E2 conjugating enzyme which leads onto the formation
of an isopeptide bond between the ubiquitin carboxyl terminus and a lysine residue of the
target substrate. The process as to how the substrate is ubiquitinated from the E2 enzyme
is mediated through the E3 ligases (Scheffner and Kumar, 2014). Target substrates can be
mono-ubiquitinated or poly-ubiquitinated, and the latter marks the protein for degradation
by the 26S proteasome. The 26S proteasome is the large multi component complex which
degrades proteins via proteolysis.
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Fig. 1.1 -Schematic of the ubiquitin- proteasome pathway. The HECT and RING pathways
are differentiated by the HECT’s intrinsic ability to transfer ubiquitin, whilst the RING
ligases mediate the transfer of ubiquitin from E2 to the substrate. Not to scale.
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1.1.1 Ubiquitin
Discovered in 1975 (Goldstein et al., 1975), ubiquitin is a 8.6 kDa protein consisting of 76
amino acids. The tightly folded structure (Figure 1.2) contributes to a significant number of
intramolecular hydrogen bonding. It is the high degree of hydrogen bonding which confers
its stability over a broad range of pH and temperature values, and resistance to digestion
(Vijay-Kumar et al., 1987). The carboxyl group on the C-terminal glycine of ubiquitin
forms an isopeptide bond with the ε amino group of lysine on the substrate. The building of
ubiquitin chains can occur at any one of the seven lysine residues on ubiquitin. The lysine
residue chosen, and the degree of polymerisation dictates the fate of the substrate, which
include DNA repair, kinase activation and proteasomal degradation (Sun and Chen, 2004).
Fig. 1.2 -The structure of ubiquitin. The predominant secondary structure of ubiqutin consists
of an α- helix, a 5 stranded β - sheet and a 310 helix. Other features include a parallel G1
β -bulge, two reverse Asx turns and a symmetrical hydrogen bonding region between two
reverse turns and two helices. Structure solved by X-ray crystallography to 1.8 Å (Vijay-
Kumar et al., 1987). PDB:1UBQ . Image generated by UCSF Chimera (Pettersen et al.,
2004).
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1.1.2 E1 activating and E2 conjugating enzymes
The ubiquitination cascade starts with the E1 activating enzyme. There are 8 E1 enzymes,
but only 2 are known to interact with ubiquitin; Ubiquitin- like modifier activating enzyme 1
(UBA1) and ubiquitin- like modifier activating enzyme 6 (UBA6) (Schulman and Harper,
2009). Both UBA1 and UBA6 are known to initiate the ubiquitination pathway by the ATP
dependent recruitment of ubiquitin. However, the several fold higher expression levels of
UBA1 suggests the majority of ubiquitin pathways are dependent on UBA1 (Yang et al.,
2013). UBA1 is a highly conserved protein which exists in two isoforms: UBA1a and UBA1b.
The expression of UBA1 is essential and its deletion is fatal (Groen and Gillingwater, 2015).
The E1 is a 110-120 kDa monomeric protein consisting of the two adenylation domains,
the catalytic cysteine domains and the E2 recruitment domain. E1 initiates the ubiquitin
cascade by catalysing the adenylation of the C-terminus of ubiquitin in an ATP dependent
manner. The catalytic cysteine of the E1 then forms a thioester bond with the ubiquitin
molecule. A second ubiquitin molecule will then attach to the adenylation site and remains in
that intermediate state until thiolation can occur (Lee and Schindelin, 2008). This is shown
structurally in Figure 1.3 with the two bound ubiquitin molecules on UBA1.
The second ubiquitin binding E1, UBA6 has been implicated in having overlap with
UBA1 activity (Groettrup et al., 2008). Liu et al. have also recently showed UBA6 suppresses
epithelial mesenchymal transition in mammary epithelial cells highlighting the potential for
this gene to be used as a biomarker. There is a need for further investigation in the impact this
E1 has on cellular regulation, UBA1 isoform interaction and any potential implications in
disease. Following from the E1 enzymes in the ubiquitination cascade, are the E2-conjugating
enzymes. There are around 40 human E2’s presenting an increase in the complexity in the
pathway. All E2s are characterised by the distinctive ubiquitin conjugating cysteine (UBC)
domain which holds the catalytic cysteine. Structurally, the domain consists of 4 α-helices
and a 4 stranded β - sheet. The E2 enzyme forms a non-covalent interaction with the E1-
6
Fig. 1.3 -Bound structure of UBA1 and two ubiquitin molecules. Complex of Saccharomyces
Cerevisiae UBA1 (blue) bound to ubiquitin-AMP and thioesterified ubiquitin. The ubiquitin
on the left is in its adenylated form, located in the adenylation site. The ubiquitin on the right
has formed the thioester bond with the catalytic cysteine of E1 (Cys600). Structure solved
by X-ray crystallography (Schäfer et al., 2014). PDB: 3CMM. Image generated by UCSF
Chimera (Pettersen et al., 2004).
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Ub complex and the ubiquitin is transferred through a transthiolation reaction. Figure 1.4
shows the tertiary complex formed between E1, E2 and Ub. The E2-Ub complex will then
interact with a specific E3 ligase to transfer the ubiquitin onto the target substrate. Not
all E2s maintain functionality with all E3 ligases; the E2 UbCh7 will only show reactivity
towards the HECT catalytic cysteine and not lysine residues presented by RING ligases. The
implications of this is that whilst the UbCh7-Ub complex will interact with RING ligases,
it will only function as an E2 with HECT ligases (Stewart et al., 2016). The E2 which is
selected in a given pathway, determines the level of ubiquitination of the final substrate,
whether that be mono or poly ubiquitination (Windheim et al., 2008). The control E2s have
in the recruitment of E3s and the level of substrate ubiquitination, adds a layer of specificity
in the ubiquitin pathway.
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Fig. 1.4 -Structure of E2 bound structures (A) Structure of Schizosaccharomyces Pombe
Uba1 (blue)-Ub (red)-Ubc4 (brown)/ ATP-Mg complex. Solved by x-ray crystallography
(Olsen and Lima, 2013). PDB: 4II2. (B) Structure of bound UbcH5b (brown)- ubiquitin (red).
The catalytic Cys85 was substituted to a serine residue as the thioester linked conjugate is
unstable and unsuitable for crystallisation. Hence, the linkage is an ester bond. The structure
was solved by X-ray crystallography (Sakata et al., 2010). PDB: 3A33. Image generated by
UCSF Chimera (Pettersen et al., 2004).
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1.1.3 E3 ligases
At the final step of the enzymatic cascade lies the E3 ligases. With over 600 human E3s, it
is the E3 ligases which give the greatest level of diversity and highest level of specificity in
the ubiquitin proteasome system (UPS). E3s can interact with E2s, ubiquitin and the target
substrate to deliver the final ubiquitinated target. Based on their molecular architecture and
mechanism of action, E3s can be divided into three classes: really interesting new gene
(RING), homologous to the E6AP C-terminus (HECT) and RING between RING (RBR).
RBR is the smallest of the three groups and the least investigated, therefore only RING and
HECT ligases will be discussed in further detail.
1.1.3.1 RING ligases
With around 600 known members, the RING-type ligases constitute the majority of E3 ligases.
RING type ligases can be more specifically divided into the RING and RING-like U-box
families. RINGs adopt a cross-braced arrangement with eight centrally co-ordinated Zn2+,
whilst the RING-like take on a similar structure but without the Zn2+ co-ordination (Metzger
et al., 2014). RING-type ligases mediate the attachment of ubiquitin via substrate recruitment
and E2-Ub complex interaction, RINGs do not intrinsically transfer ubiquitin. RINGs can
exist and function not only in a monomeric form, but also as a homodimer and heterodimer.
It is interesting to note that each RING in homodimeric RINGs maintain individual activity
with E2 whilst some hetereodimeric RINGs do not. One RING will interact with E2 whilst
the other serves to control activity, recruit substrates or stabilize the complex. One such
example is the BRCA1- BARD1 complex, BCRA1 interacts with E2 and BARD1 lacks
the crucial structural features necessary for E2 interactions (Brzovic et al., 2001). RINGS
and U-box share common architectural features for E2 binding. Two loop regions surround
a central α-helix groove providing a platform for E2 binding. RING-E2 binding consists
of weak non covalent interactions through hydrophobic side chains. A key question in the
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field was whether RINGs simply act as a mediator to E2-Ub and substrate, or whether they
have the ability to enzymatically activate the E2-Ub complex. Initial crystallographic efforts
revealed how RINGs position E2s relative to the substrates (Zheng et al., 2000) (Zhang et al.,
2005) (Mace et al., 2008) (Yin et al., 2009) (Bentley et al., 2011). These structures did not
reveal any conformational change to the E2, however the E2 was not charged due to the
instability of the thioester bond. Later experimental efforts were designed to have E2 charged
with ubiquitin through an ester or iso-peptide bond. Eventually, Plechanovová et al. and
Dou et al. solved the complete structural complexes of dimeric RNF4 with UbcH5a-Ub and
BIRC7 with UbcH5b-Ub, respectively. These structures revealed the E2-Ub complex in a
closed conformation confirming RINGs activate E2s. This closed conformation geometrically
favours the E2-Ub thioester bond for nucleophilic attack by the target substrate lysine (Pickart
and Eddins, 2004). The structures showing RING ligase interactions with E2 and ubiquitin
are shown in Figure 1.5. The mechanism for substrate recruitment is far more complex.
Multiple RINGs can be active for the same substrate and multiple substrates can interact
with the same RING ligase. Substrate control is conferred by a variety of processes such as
domain recognition, post translational modifications and quaternary structure. Investigation
into the role RING ligases have on cellular processes has uncovered their implications in
human disease. The efforts to therapeutically target RING ligases are discussed in Section
1.2.3.2.
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Fig. 1.5 -Structure of RING complexes (A) Structure of the interaction between the RING
ligase c-Cbl and UbcH57 (blue). c-Cbl consists of a RING domain (brown), the substrate
recognition domain TKB (turquoise) connected by the linker region (yellow). The structure
was solved by x-ray diffraction to 2.9 Å (Zheng et al., 2000). PDB: 1FBV. (B) Structure
of Rnf4 (brown)- Ubch5a (blue)- ubiquitin (red) hetereotrimeric dimer. The structure was
solved by X-ray diffraction to 2.21 Å. Image generated by UCSF Chimera (Pettersen et al.,
2004).
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1.1.3.2 HECT ligases
Unlike the RING ligases, HECT ligases intrinsically deliver ubiquitin onto target substrates
by use of a catalytic cysteine. There are 28 known HECT E3 ligases, characterised by a
C-terminal domain termed HECT (Lorenz, 2018). It is the HECT domain which holds the
ability to form an E3:Ub complex during the final transfer of ubiquitin. The discovery of the
E3 ligase E6AP led onto the first structural characterisation of the HECT domain (Huang
et al., 1999). The HECT domain is bilobal, consisting of a large N-terminal lobe for E2
interaction and a smaller catalytic cysteine holding C-terminal lobe which are connected
by a flexible linker region. The conformational flexibility between these lobes is critical
to its ligase activity (Verdecia et al., 2003). Figure 1.6 shows a complex of E6AP and
UbcH7. The N-lobe-E2 interaction is dominated by a key Phe residue in the loop region
of E2, docking into a hydrophobic groove present in the HECT N-lobe. Ronchi et al. have
presented evidence based on kinetic data for a second E2 binding site, however this has yet
to be structurally defined. The flexibility of the hinge loop is clearly evident in the UbcH5b-
Ub-Nedd4L complex where there is a change in E2-E3 conformation in order to bring the
catalytic cysteines of E2 and E3 into close proximity, priming for the trans-thioesterification
reaction (Kamadurai et al., 2009). Once the ubiquitin is charged onto the C-lobe, the ubiquitin
C-lobe takes on a locked extended conformation, priming itself for nucleophilic attack from
lysine residues of either target substrates, or further ubiquitin chains. Substrates can either
be ubiquitinated in a processive or distributive manner. Processive refers to when substrates
can be polyubiquitinated in one E3-substrate encounter, distributive refers to when only one
ubiquitin can be attached during one enzyme- substrate encounter. Which mechanism of
action dominates the HECT ligases is still subject to investigation, however Maspero et al.
(2011) revealed a processivity site within Nedd4-1 that is used for building polyubiquitin
chains. This site has later been targeted for enzyme inhibition by small molecules (Kathman
et al., 2015). The domains located to the N-terminal of the HECT domain are responsible for
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substrate recruitment. Based on the similarities and differences in these domains, the HECT
group can be further be split into HERC, Nedd4 and the ‘other’ HECT E3s. The HERC
family consists of 6 members containing the RLD domain. The subfamily is split into 2 large
HERCs and 4 small HERCs. The two large HERCS contain two and three RLDs and the four
small RLDs only have one RLD domain. HERCs have been implicated to be involved in a
diverse range of cellular functions such as neurodevelopment and DNA repair (Sánchez-Tena
et al., 2016). The ‘other’ HECT ligases do not share much commonality between each other
and contain a wide range of N-terminal domains. The largest group is the Nedd4 subfamily,
comprised of nine ligases. All nine ligases contain 2-4 WW domains, a C2 domain and the
HECT domain. It is the Nedd4 ligases which form the basis of study for this thesis, and will
be reviewed in greater detail.
14
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Fig. 1.6 -Structural representation of the L and T shape conformation of HECT(A) Bound
structure of E6AP HECT domain (brown) and UbcH7 (blue). (B) Bound structure of Nedd4L
HECT domain (brown) and UbcH5B (blue)- ubiquitin (red). Complexes solved by x-ray
diffraction (Huang et al., 1999) (Kamadurai et al., 2009). PDB:1C4Z and 3JW0 respectively.
Image generated by chimera (Pettersen et al., 2004).
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1.1.3.3 Nedd4 E3 ligases
The Nedd4 supergroup of E3 ligases is made up of nine members: Nedd4 (also known as
Nedd4-1), Nedd4L (Nedd4-2), Nedd4L1 (HECW1), Nedd4L2 (HECW2), WWP1, WWP2,
Smurf1, Smurf2 and ITCH. The ligases share the common domain architecture of a N-
terminal C2 domain, 2-4 WW domains and the HECT domain (Figure 1.7). The N-terminal
C2 domain is an approximately 120 residue protein folded into 8 β -sheets in a β -sandwich.
The C2 domain is responsible for membrane localisation and ligase/substrate trafficking
by having the ability to interact with Ca2+, phospholipids and membrane proteins (Rizo
and Südhof, 1998). Plant et al. (1997) underlined the importance of the C2 domain as
removal of the domain in Nedd4 resulted in loss of plasma membrane localization. The
C2 domain is also a key regulator in controlling Nedd4 ligase activity, and solution NMR
analysis showed the C2 domain of Smurf2 interacted with the catalytic c-lobe of HECT
modulating its autoinhibition (Wiesner et al., 2007). Further structural studies elucidated
these autoinhibition mechanisms to be that the C2 domain causes a conformational change
of HECT into an inactive state. This inactive state prevents the Ub-thioester bond formation
precluding substrate ubiquitination (Mari et al., 2014). The control in substrate recruitment
and selectivity lies with the WW domains. They are termed as such as they contain two
conserved tryptophan residues spaced 20-22 residues apart. The WW domain is made up
of three antiparallel β -sheets forming a hydrophobic groove suited for ligand binding. WW
domains interact with proline rich motifs in target substrates, more specifically Leu/Pro-
Pro-X (any amino acid)-Tyr (L/PPXY) sequences (Chen and Sudol, 1995). It is increasingly
evident the importance of the Nedd4 ligases in regulating a variety of aspects in cancer.
Nedd4-1 is found to be overexpressed in human cancers such as breast, colorectal and lung
cancer (Zou et al., 2015). Hansen et al. (2007) showed that the suppression of the ITCH gene
in certain tumour cells can increase the effect of chemotherapeutic drugs. Smurf1 has shown
to promote cancer metastasis in pancreatic, prostate, ovarian and breast cancer. The mis-
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Fig. 1.7 -Schematic showing the Nedd4 superfamily of HECT E3 ligases. The C2 domain is
represented in purple, the WW domains in blue and the HECT domain in red. Not to scale.
expression of Smurf2 has been found in breast, prostate, lymphoma, esophageal and renal
cancers. WWP1 has frequently been found to be overexpressed in breast and prostate cancer
(Bernassola et al., 2008). The work done by Soond et al. (2013) showed the mis-expression
of WWP2 isoforms in breast, melanoma and prostate cancer cell lines.
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1.1.3.4 WWP2: Structure, function and role in cancer
WWP2 was first identified in 1997 during a screen for WW domain containing proteins
(Pirozzi et al., 1997). WWP2 is formed of the typical Nedd4 ligase architecture with a C2
domain, four tandem WW domains and the HECT domain. The HECT, WW2 and WW4
domains and the WW2-3 linker region has been structurally solved. The first WWP2 HECT
structure was reported by Gong et al. (2015) (Figure 1.8) with the removal of five residues
in the C-terminus necessary for producing high quality crystals. WWP2 HECT shares high
homology with the HECT domain of WWP1, a structure-based sequence alignment revealed
83 % sequence similarity. The reported structure is missing residues 661- 702aa due to a lack
of electron density, in which the authors predict is a result of intrinsic flexibility. The relative
position of the N and C lobes is homologous to WWP1 HECT in adapting the inverted T
conformation. During the discovery that the polypeptide chain between the WW2 and WW3
domains (termed ‘linker region’) acts as an autoinhibitory module; the WWP2 WW2 domain
and 2,3 linker were structurally solved (Chen et al., 2017). WWP2 exists as three isoforms:
full length (FL, all domains), N-terminal isoform (-N, WW1 and C2 domain) and C-terminal
isoform (-C, WW4 and HECT).
All three isoforms have been linked in the growth and development of cancer and
interestingly have differential activity in oncogenic pathways (Soond et al., 2013) WWP2 has
been found to interact with PTEN and Smads, both key regulators in oncogenic signalling
pathways. PTEN is a lipid phosphatase that acts as a tumour suppressor protein. PTEN acting
as a tumour suppressor has been linked to have a key role in prostate cancer, with up to 70 %
of primary prostate cancer tumours losing a copy of the PTEN gene. Maddika et al. found
that the ubiquitin dependent degradation of PTEN is mediated by WWP2. The regulation
of PTEN by WWP2 has been linked to tumour growth and metastasis. Cancer genomic
analysis of patients (Figure 1.9) with prostate cancer shows almost 40 % of patients with
castration resistant prostate cancer have the WWP2 gene amplified. A Kaplan-Meier plot of
18
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Fig. 1.8 -Structure of WWP2 HECT domain resolved to 2.51 Å (PDB: 4y07).
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survival percentage shows there is a decreased chance of survival in patients over-expressing
WWP1/2.
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Fig. 1.9 -Genomic analysis of WWP2 and the highly homologous WWP1 in prostate can-
cer.(A) 38.57 % of 70 patients with castration resistant prostate cancer and 27.78 % of 54
patients with pr state neuroendocrine show amplification of WWP2/1. (B) Kaplan-Meier
plot showing estimated survival. Blue shows patients without WWP1/2, red shows patients
with WWP1/2. Data retrieved from a combined study of 4180 patients accessed through
cBioPortal (Cerami et al., 2012) (Gao et al., 2013). Figure rendered by the cBioPortal
platform.
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1.2 Therapeutic targeting of the UPS
Over the past 25 years, there has been an increasing effort in targeting the ubiquitin protea-
some system for therapeutic purposes. There is research focused on all aspects of the UPS
regarding the use of small molecules as inhibitors. Since the first FDA approved proteasome
inhibitor Bortezemib, research has extended to the enzyme cascade with E3 ligase inhibitors
now in clinical trials. Recently, the pathway itself has been highjacked to ubiquitinate target
proteins of choice- PROTACS. This section will review the development of small molecule
inhibition of the UPS for cancer therapy.
1.2.1 Proteasome inhibitors
Those proteins targeted for degradation await the fate of the proteasome. The proteasome
breaks down polyubiquitinated proteins into their constituent polypeptides. It is comprised
of two subunits, the 19S particle directing the deubiquitination of substrates and the 20S core
particle responsible for protein breakdown. The role the proteasome holds in cell proliferation
and in cell apoptosis made it an interesting target for inhibition. Peptide aldehydes were the
first class of proteasome inhibitors discovered (Vinitsky et al., 1992), followed by peptide
vinyl sulfones (Bogyo et al., 1997) and the more potent peptide boronates (Adams et al.,
1998). The boronate compound Bortezemib became the first FDA approved proteasome
inhibitor for treatment of multiple myeloma in 2003. Natural products such as lactacystin
(Fenteany et al., 1995), salinosporamide (Gulder and Moore, 2010) and epoxomicin (Meng
et al., 1999) are known to inhibit proteasomal activity. The discovery of epoxomicin led to the
derivative Carfilzomib being the second FDA approved proteasomal inhibitor. Lactacystin
was the first non-peptide inhibitor of the proteasome and subsequent derivatives are the
subject of further organic synthesis (Bulman Page et al., 2017) and ongoing clinical trials
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(Teicher and Tomaszewski, 2015). The chemical structures of selected proteasome inhibitors
are shown in Figure 1.10.
Fig. 1.10 -Selection of proteasome inhibitors (A) Bortezemib. FDA approved for multiple cell
myeloma and mantle cell lymphoma. (B) Carfilzomib. FDA approved for multiple myeloma.
(C) Salinosporamide A (also known as Marizomib). Currently undergoing clinical trials for
multiple myeloma. (D) Lactacystin. The first non-peptide based proteasome inhibitor.
1.2.2 E1 and E2 inhibitors
During a screen for MDM2 dependent p53 ubiquitination, the compound PYR-41 was
identified as an E1 inhibitor (Yang et al., 2007). PYR-41 is a pyrazolone based compound
where the nitro group on the furan ring is suggested to block the catalytic cysteine of E1.
The E1-Ub thioester formation has also found to be disrupted by the nitric oxide producing
prodrug JS-K (Kitagaki et al., 2009). There remains concern for cysteine attacking inhibitors
to interact with other thiol dependant enzymes. PYR-41 was tested against E2 and other
catalytic cysteine depending enzymes and was found to have no activity. However PYR-
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41 can partially reduce HECT E3 ligase activity, maintaining specificity concerns (Yang
et al., 2007). E2 inhibition can be achieved either through interactions in the active site or
allosterically. Ceccarelli et al. found that the compound ‘CC 0651’ (Figure 1.11) allosterically
inhibited the E2 enzyme hCdc34 by binding in a site located 19 Å away from the active
site. The binding perturbed the secondary structure of E2, resulting in the loss of ability to
unload ubiquitin onto substrates. The inhibitor BAY 11-7082 on the other hand is found
to covalently modify the catalytic cysteine of Ubc13 via a Michael addition with the vinyl
sulfone (Strickson et al., 2013).
Fig. 1.11 -Small molecule inhibitors of E1 and E2. (A) The E1 inhibitor PYR-41 (B) The E1
inhibitor JS-K. (C) The E2 inhibitor CC0651 (D) The E2 inhibitor BAY 11-7082.
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1.2.3 Targeting the E3 ligases
Targeting the final step in the cascade offers the greatest level of specificity and control. This
approach is desirable in developing cancer treatments as inhibiting a single E3 ligase could
potentially lead to less side effects. This section reviews the current research in targeting E3
ligases. However, one cannot discuss the current landscape of E3 ligase inhibitors without
mentioning proteolysis targeting chimeras (PROTACs). This section will briefly describe
PROTACs before going into more depth about the current E3 ligase inhibitors, as the overall
scope of this thesis is driven towards ’traditional’ small molecule inhibitor discovery.
1.2.3.1 PROTACs
There is an emerging interest in hijacking the ubiquitin proteasome pathway to target specific
proteins. Instead of inhibiting a target proteins activity with a small molecule, the UPS is
used to remove the target protein (Sakamoto et al., 2001). This is done by using a hetereo-
bifunctional molecule consisting of two ligands joined by a linker group; the PROTAC. One
ligand is specific for the target protein and the other is specific for the E3 ligase of choice.
The PROTAC can simultaneously bind to the E3 ligase and target protein, forming a ternary
complex. This recruiting of an E3 ligase causes ubiquitin from E2 to be transferred onto
the target protein, consequently labelling it for its degradation. The main appeal to this
strategy is that ‘undruggable’ proteins can be targeted, such as proteins without enzymatic
activity (Crews, 2010). All of the E3 ligases used in PROTACS are currently from the RING
group of ligase. The main ligases used are MDM2, cIAP1, CRBN and VHL (Burslem and
Crews, 2017). There is a need to discover more ligands for E3 ligases owing to the limited
number of E3 ligands available. Whilst the focus of these PROTACs have mainly been for
oncology, there is a desire to move to longer term chronic diseases. The limited number
of ligands makes this difficult owing to the undesirable properties of the ligands (e.g. the
CRBN inhibitor thalidomide being teratogenic). It would be interesting to investigate whether
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the HECT ligases still have the ability to ubiquitinate substrates via a PROTAC. A recent
comprehensive review of current PROTACs can be found at Wang et al. (2019).
1.2.3.2 RING inhibitors
RING ligases have been the more extensively studied ligase for small molecule inhibition.
The RING ligase MDM2 is known to target the tumour suppressor p53. Nutlins were the
first class of compounds identified as MDM2 inhibitors and are now undergoing early stage
clinical trials (Burgess et al., 2016). They are a collection of cis substituted imidazole
analogues. Nutlins bind to the p53 binding site of MDM2, disrupting the protein- protein
interactions. The VHL complex is another RING ligase in which extensive medicinal
chemistry is currently ongoing (structural development shown in Figure 1.12). Through the
process of structure based drug design, inhibitors with initial moderate potency have been
developed to have nanomolar activity in cells (Buckley et al., 2012) (Galdeano et al., 2014)
(Soares et al., 2017). Although there are still few RING ligases which have been targeted,
inhibitor development is further through the pipeline than the HECT ligases.
1.2.3.3 HECT inhibitors
The first small molecule inhibitor for HECT was reported in 2014 by Mund et al. (2014).
Originally, a phage display approach was used to identify bicyclic peptides as specific
inhibitors for Smurf2, Nedd4, Huwe1 and WWP1. However, work with these peptides
could not progress beyond in vitro as they could not be delivered into cells. Intuitively, the
authors exploited the binding properties of the peptides and used Alpha Screen technology
to search for small molecules which would disrupt the HECT-peptide interaction. After
a screen of around 17500 compounds, the molecule termed ‘heclin’ was identified as the
leading inhibitor, with an IC50 of 6-7 µM for several HECT ligases. Hydrogen-deuterium
exchange and mutational studies concluded a predicted model of action where heclin binds
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Fig. 1.12 -Inhibitors of E3 RING ligases. (A) Nutlin 3, the MDM2 inhibitor currently in
clinical trials. (B) (i) The first small molecule targeting the VHL. (ii) Using a structure- based
design approach, this compound exhibited nanomolar affinities. (iii) Optimised structure
showed improved cellular permeability.
to HECT causing a conformational change within the C-lobe to expose the catalytic cysteine.
Exposure of the catalytic cysteine makes it prone to oxidation, rendering its ligase activity
defunct. The location of the heclin binding site is not known, but the cleft between the
C-lobe and E2 binding site is stated as a possible contender. Despite showing selectivity
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for HECT ligases over RING ligases, there is no specificity between each individual HECT
ligase. Furthermore, the heclin molecule contains medicinal chemistry red flags, such as
the metabolically unstable furan ring and the acrylamide Michael acceptor (Chen et al.,
2018). The potential promiscuity and metabolic stability in vivo remains to be investigated.
It is interesting to note that in a recent study reporting WWP1 as a biomarker for acute
myeloid leukemia, heclin was found to supress leukemic blast growth (Sanarico et al., 2018).
This exemplifies the importance for research into HECT ligase inhibitors as therapeutics.
Rossi et al. (2014) used a high throughput ELISA based assay to screen for inhibitors of
ITCH autoubiquitination and found the antidepressant drug clomipramine to inhibit ITCH
autoubiquitination and ITCH mediated p73 ubiquitination. Clomipramine analogues were
tested in the same ELISA assay and small structural alterations had a significant effect.
Increasing the alkyl chain on the terminal side chain amine decreased levels of inhibition. In
contrast the inhibitory effects could be increased fivefold by addition of a chloride on the
phenyl ring. This is in accordance with the proposed mechanism of action which is driven by
a nucleophilic aromatic substitution reaction with the catalytic cysteine and chloro substituted
phenyl moiety of clomipramine. Structures of clomipramine and heclin are shown in Figure
1.13.
Fig. 1.13 Inhibitors of E3 HECT ligases (A) Heclin, the first HECT inhibitor. (B)
Clomipramine, the antidepressant inhibitor of ITCH.
The first crystal structure of a bound HECT ligase inhibitor complex came in 2015 from
Kathman et al. (2015) (Figure 1.14). The group used their previously reported ‘covalent
27
tethering’ approach which screens electrophilic fragments against cysteine residues (Kathman
et al., 2014). These electrophilic compounds act as Michael acceptors and covalently bond
with the thiol group present in cysteines. Nedd4 was treated with a mixture of electrophilic
compounds, identifying 2 compounds (Figure 1.14) as direct hits to the non catalytic Cys627.
A crystal structure was obtained with Nedd4 HECT and "compound 1" (Figure 1.12),
elucidating the binding mode of this compound. The structure clearly shows the formation of
a covalent bond between the ligand and Cys627. The α , β - unsaturated carbonyl sidechain
acts as the Michael acceptor to the reactive thiol. The aromatic edge to face interactions
between the indole moiety and the local tyrosine provide stability to the complex. As this
compound sits in the allosteric steric site involved in non covalent bonding with ubiquitin
during the build up of polyubiquitin chains, it was theorized this compound would disrupt
Nedd4 HECT: Ub interactions and inhibit ubiquitination. However, when incubated with the
approximate concentration of ubiquitin found in cells (approximately 60 µM) the ligand was
inactive. In the search for more potent analogues it was found substitutions were tolerated
on the N-methyl of the indole, so a series of N- subsititued indoles were synthesised. The
cyclopentane derivative was the most potent in disrupting the Nedd4 HECT: Ub interaction
with a KI of 29.3 µM.
28
AB
29
NNH
O O
O
O
N
NH
O O
O
O
i ii
C
D
Fig. 1.14 -Structure of the Nedd4 inhibitor. (A) Structure of compound 1 bound to Nedd4.
Compound 1 is covalently bound to N lobe Cys657, shown in red. The catalytic Cys867 is
shown in green. (B) Zoomed in representation of the binding pocket. (C) Electron density
(black mesh, contoured at 1 σ ) of compound 1 bound to Cys627. Image generated using
CCP4MG (McNicholas et al., 2011). (D) (i) The initial N-methylated compound, used in
the crystallography experiments. Optimisation to ii by the substitution of the N-methyl to
N-cyclopentane.
30
1.2.3.4 Other HECT ligase inhibitors
The natural product indole 3-carbinol has been showed to downregulate Nedd4 mediated
PTEN ubiquitination (Aronchik et al., 2014). Quirit et al. investigated whether this compound
was acting as a direct inhibitor on Nedd4. After finding the compound was interacting
with the HECT domain via isothermal calorimetry, in silico docking using the previous
Nedd4:inhibitor was performed to map the possible binding site. Using this structural
information, a series of analogues was synthesised and tested for biding by protein thermal
shift. The most potent analogue had an ELISA measured autoubiquitination IC50 of 2.71
µM. The indole carbinol compounds were also found to inhibit human melanoma cells to
a level which correlated with their Nedd4 inhibitory activity. Smurf1 has been subjected
virtual screening and cell assay studies in order to find novel inhibitors (Cao et al., 2014).
Whilst these inhibitors could be interpreted to modulate Smurf1 activity, there is yet to be
any structural studies. Moreover, some of these identified compounds also have the ability
to covalently modify cysteines, meaning their specificity would have to be fully assessed.
Zhang et al. (2016) utilised a phage display to search for ubiquitin variants that would have
high affinity to certain HECT domains. A phage library encoding up to a billion ubiquitin
variants which searched for high affinity between 20 HECT domains. Ubiquitins with both
inhibitory and activator effects were identified with their target HECT sites structurally
identified. Whilst not likely to have direct therapeutic potential, these UbV’s can be used as
biological tools to probe HECT mechanisms.
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1.3 Thesis aims
The current state of drugging the ubiquitin proteasome pathway has been explored in this
chapter. This landscape is rapidly growing with already FDA approved treatments and
numerous compounds in all stages of the drug discovery pipeline. Targeting the E3 ligases
not only gives the opportunity for traditional small molecule inhibitors, but to entirely new
concepts such as PROTACs. The link between WWP2 and cancer has been accumulating
evidence over the past few years, presenting itself as a promising novel cancer target. The
previously discovered HECT inhibitors in the high homology Nedd4 family sets a precedent
that WWP2 could be targetable. The presence of the enzymatic HECT domain with a
catalytic active site and probable allosteric sites offers an appealing target for drug design.
There are no inhibitors which target WWP2 and moreover there is no structural evidence for
a non-covalent inhibitor for any of the Nedd4 ligases. The overall aim of this thesis is to
design, synthesise and biologically evaluate novel inhibitors for the WWP2 enzyme. The
design of the compounds will be through small molecule screening approaches collected
through biophysical assays and other data gathered in the Chantry lab. The structural basis of
inhibition will then be revealed through the solving of the first WWP2: small molecule X ray
crystallographic structure. Not only will a crystallographic structure be used, but data from
the newly invented DEEP STD will be exploited to generate an accurate picture of a binding
site. This data will be collated to inform organic synthesis of a selected compound with the
intention of improving activity. The synthesised compounds will then be biologically tested
in vitro against WWP2 and Nedd4. This work hopes to progress the research into WWP2
inhibitors with the intention of using these discoveries to develop novel therapeutics targeting
WWP2, which there are currently none known.
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Chapter 2
Biological materials and methods
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2.1 DNA techniques
2.1.1 Plasmids and primers
Table 2.1 describes the plasmids used during this project with the description and origin.
Plasmid Origin
pGEX2T-WWP2-FL Dr Andrew Chantry’s lab
pOPINF-WWP2-FL Dr Andrew Chantry’s lab
pGEX-5X3-Nedd4-FL Gifted by Shiaw-Yih Lin (Addgene plasmid #45043)
pET3a-UbcH7 Gifted by Professor Martin Scheffner
pET3a-hUBa1 Gifted by Titia Sixma (Addgene plasmid #63571
pGEX6p-2-WWP2-WW2-2,3-linker-HECT Gifted by Professor Philip Cole
pET28a-WWP2-HECT Cloned during this work by In-Fusion
pET28a-WWP1-HECT Cloned during this work by In-Fusion
pET28a-Nedd4-HECT Cloned during this work by In-Fusion
Table 2.1 -Plasmids used throughout this project
Primers (obtained from Eurofins Genomics) designed for In-Fusion cloning contain 15bp
preceding the restriction enzyme site from the pET28a vector were added to the beginning of
the gene specific sequence. Primers were designed for ligation between the restriction sites
Nde1 (sequence CATATG) and Xho1 (sequence CTCGAG) in the pET28a vector. Primers
were re-suspended from their lyophilized form in nuclease free dH20 to obtain a concentration
of 100 nmol mL-1. They were further diluted to a concentration of 10 nmol mL−1 for PCR.
The primers used for this work are described in Table 2.2.
PCR product Primers 5’-3’ Plasmid
WWP1 HECT
FWD- GTGCCGCGCGGCAGCCATATGATGGGCTTTAGGTGGAAGCTTG
REV- GTGGTGGTGGTGGTGCTCGAGTTACTCTGTCTCTTCTATTGCAAAAAG pET28a
WWP2 HECT
FWD- GTGCCGCGCGGCAGCCATATGATGGACCGCAGTTTTCGG
REV- GTGGTGGTGGTGGTGCTCGAGTTACTCGGTCTCCTCAATGG pET28a
Nedd4 HECT
FWD- GTGCCGCGCGGCAGCCATATGATGTCCAGGGATTACAAAAGAAAG
REV- GTGGTGGTGGTGGTGCTCGAGTTAATCAACTCCATCAAAGCCCTG pET28a
Table 2.2 -Primer sequences
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2.1.2 Phusion PCR
Phusion High- Fidelity DNA polymerase reactions were set up as described in Table 2.3. The
cycling conditions used are described in Table 2.4 . Amplification was confirmed by running
the DNA samples on 1 % TAE- agarose gel stained with SYBER Safe (Invitrogen) at a final
concentration of 0.01 %. For larger scale PCR reactions, 5 x 20 µL reactions were carried
out. The resulting solution was mixed and run on agarose gel. The DNA was gel extracted
and purified.
Component 20 µL pcr reaction
dH2O 12.2
HF Buffer 4
10 mM dNTPs 0.4
Forward Primer 1
Reverse Primer 1
Template DNA 0.2
DMSO 1
DNA Phusion polymerase 0.2
Table 2.3 -PCR reaction mixture
Cycle Temperature (oC) Time (s) Number of cycles
Initial denaturation 98 120 1
Denaturaton 98 10 30
Annealing 63 30 30
Extension 72 45 30
Final extension 72 600 1
Table 2.4 -PCR cycle conditions
2.1.3 DNA Gel electrophoresis
DNA samples were mixed with 6 x DNA loading dye (Thermo Scientific) at a final concen-
tration of 20 %. Samples loaded onto the gel were run at 100V for 60 minutes.
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2.1.4 Plasmid digest
The pET28a vector was digested between the restriction sites Nde1 and Xho1 using the
conditions described in Table 2.5.
Component Nde1 digest (µL) Xho1 digest (µL) Xho1 + Nde1 digest (µL)
H2O 8.3 8.3 14.6
Restriction enzyme 1 1 2+2
BSA 0.2 0.2 2
pET28a DNA 8.5 8.5 0.4
Buffer D 2 2 4
Table 2.5 -Restriction enzyme digest reaction
The reaction mixture was left to digest for 4 hours at 37 oC. Agarose gel electrophoresis
was run to confirm the digested vector.
2.1.5 In-Fusion ligation
In-Fusion® HD cloning was used for the ligation of the PCR product into pET28a. The
reaction was set up as described in Table 2.5 and carried out according to the manufacturers
protocol. DNA was transformed into Stellar competent cells and 3- 6 colonies picked for
plasmid extraction.
Component Amount (µL
5 x In-Fusion® HD Enzyme Premix 2
Digested pET28a 3
Insert DNA 1
dH2O 4
Table 2.6 -Plasmid ligation reaction mixture
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2.1.6 DNA extraction and purification
DNA was cut from the agarose gel using a scalpel and purified using the QIAquick Gel
Extraction kit (Qiagen) according to manufacturers protocol.
2.1.7 DNA transformations
The appropriate cells were thawed on ice for 10 minutes. 1 µL of desired DNA was mixed
into 50 µL cells and incubated on ice for 30 minutes. Cells underwent heat shock for 45
seconds at 42 oC and placed immediately on ice for 10 minutes. 150 µL LB was added and
incubated at 37 oC for 45- 60 minutes. 150 µL of the mixture was plated onto the appropriate
antibiotic LB agar plate. The plate was incubated overnight at 37 oC.
2.1.8 Plasmid purification
Plasmids were purified using either the QIAprep Spin Miniprep kit or the QIAprep Spin
Midiprep kit depending on scale. The concentration of DNA was measured using a NanoDrop
spectrophotometer (Thermo Scientific).
2.2 Protein techniques
2.2.1 Protein expression
A single colony from the transformation plate with the desired plasmid was picked and
inoculated with the desired antibiotic in LB. The starter culture was incubated overnight at 37
oC. Starter culture was added to a larger volume of LB in a ratio of 1:25 to 1:50 and grown to
OD600 0.4-1.0. IPTG was added and incubated in the optimum conditions for each construct
as stated in Table 2.7. Cells were pelleted and stored at -80 oC.
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Protein Cell line IPTG concentration Induction temperature Induction length
pGEX2T- WWP2 FL CodonPlus RP 0.75 mM 30 oC O/N
PopinF- WWP2 FL CodonPlus RP 1.0 mM 16 oC O/N
pET28a- WWP2 HECT Rosetta 1.0 mM 15 oC O/N
pGEX6p-2- WWP2 WW2-2,3 linker- HECT CodonPlus RP 0.5 mM 16 oC O/N
pET28a- WWP1 HECT CodonPlus RP 1.0 mM 30 oC 6 hours
pGEX 5X3- Nedd4 FL Rosetta (DE3) 1.0 mM 30 oC O/N
pET28a- Nedd4 HECT BL21 Star (DE3) 1.0 mM 30 oC O/N
pET3a-UBA1 BL21(DE3) 1.0 mM 25 oC O/N
pET3a- UBH7 CodonPlus RP 1.0 mM 25 oC 4 hours
Table 2.7 -Protein expression conditions
2.2.2 Protein purification
2.2.2.1 His tagged proteins
Pelleted cells were resuspended in 35 mL lysis buffer and sonicated until sufficient cell
lysis had been reached. The sample was centrifuged at 18 000 rpm for 45 minutes at 4
oC using the Beckman Ja20 rotor. The clarified lysate was loaded on a prepacked 5mL Ni
sepharose HisTrap HP using a peristaltic pump (Parmachia Biotech). His tagged proteins
were loaded onto an AKTA Pure system. Bound protein was eluted with a gradient of Ni
NTA elution buffer. Eluted samples were analysed by SDS-PAGE gel electrophoresis and
samples containing the desired protein were pooled. Buffer recipes are shown in table 2.8.
2.2.2.2 GST tagged protein
Clarified lysate was obtained in the same manner as His tagged proteins. Buffers are described
in Table 2.9. Clarified lysate was loaded onto a GSTrap FF (GE Heathcare Life Sciences)
using a peristaltic pump. The column was washed with 25 mM Tris Cl pH 8.0, 250 mM
NaCl, 0.1 Triton X-100 before being eluted in 30 mL GST elution buffer.
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2.2.2.3 Dialysis
Protein solution was dialysed using 10 kDa molecular weight cut off SnakeSkin (Thermo
Fisher Scientific) in a 5 L reservoir of the desired buffer. Fresh reservoir solutions were used
at least twice.
2.2.2.4 GST cleavage
PreScission Protease (Thermo Fisher Scientific) was added to a concentration of 1U per 1mg
of GST tagged protein in a buffer consisting of 25 mM Tris-Cl pH 8.0, 250 mM NaCl and
5 mM DTT and incubated overnight at 4 oC. Uncleaved protein and GST was removed by
running the sample down a GS column.
2.2.2.5 Gel filtration
The protein sample was concentrated to 2 mL using a 3 KDa MW cut off Vivaspin protein
concentrator (GE Healthcare). The 2 mL sample was loaded onto the Sephadex 16/600
column through a 2 mL sample loop. A standard run of 1 mL min−1 for two column volumes
was set up. The protein was eluted in the buffer described in Table 2.9. The eluted samples
were monitored by UV absorbance at 280 nm. Analysis by SDS-PAGE on the peak fractions
confirmed the correct molecular weight of the target protein.
Ni NTA lysis buffer Ni NTA elutiuon buffer
50 mM Tris- Cl pH 8.0 50 mM Tris- Cl pH 8.0
500 mM NaCl 500 mM NaCl
10 mM imidazole 250 mM imidazole
10 % Glycerol (v/v) 10 % Glycerol (v/v)
5 mM DTT 5 mM DTT
Table 2.8 -Ni NTA purification buffer recipes
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GST lysis buffer GST elution buffer Gel filtration buffer
25 mM Tris-Cl pH 8.0 25 mM Tris-Cl pH 8.0 25 mM Tris-Cl pH 7.5
250 mM NaCl 250 mM NaCl 150 mM NaCl
1 mM PMSF 50 mM Reduced glutathione pH 8.0 5 mM DTT
1x Roche protease inhibitor cocktail
Table 2.9 -GST purification buffer recipies
2.2.3 Protein crystallisation
2.2.3.1 Crystal formation
Crystallisation trials were set up by using the sitting drop vapour diffusion method in MRC
48 well plates or MRC 96 2 drop plates. For the 48 well plates, 1 µL of protein samples at a
concentration of 1-10 mg mL−1 was mixed with 1 µ l of reservoir solution. The adjacent well
contained 200 µL of reservoir solution. For the 96 well plates, 0.5 µL of protein was mixed
with 0.5 µL reservoir solution and the adjacent buffer well contained 100 µL of reservoir
solution. The plate was sealed with optically clear sheets (Molecular Dimensions or 4titude)
and crystals were left to form at 4 oC or 16 oC. Crystal growth was monitered using a SZX9
Stereo Microscope (Olympus).
2.2.3.2 Crystal harvesting
Single crystals were picked using round LithoLoops at 16 oC. Crystals were soaked in
selected ligands and/or cryoprotected as outlined in Chapter 4 before being subjected to
liquid nitrogen for storage.
2.2.3.3 X-ray data collection
Protein crystals were sent to the synchrotron at Diamond Light Source for data collection.
Beamlines IO3 and IO4 were remotely controlled for data collection. Collected data was
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processed using the available diamond pipelines and downloaded for subsequent molecular
replacement and refinement using PHENIX and COOT respectively.
2.2.4 SDS-PAGE gel electrophoresis
Samples for SDS-PAGE were prepared by adding laemmlli (eq. volume) and DTT (10 mM
final concentration). To denature the proteins, the samples were heated to 98 oC for 3 minutes.
Samples were analysed on 10 % or 15 % acrylamide gels using the Mini-PROTEAN tank
with a 1 % SDS running buffer for 60 minutes at 180 V. InstantBlue (Expedeon) was used to
stain the gels and protein bands appeared after 15 minutes. Acrylamide gels were prepared
according to the amounts describd in Table 2.10.
Component Resolving gel
Stacking gel
6 %
10 % 15 %
dH20 15.3 mL 11.3 mL 11.6 mL
37:5:1 40 % Acrylamide 8 mL 12 mL
1.5 M Tris pH 8.8 8 mL 8 mL
0.5 M Tris pH 6.8 5 mL
10 % SDS 320 µL 320 µL 200 µL
10 % APS 320 µL 320 µL 200 µL
TEMED 32 µL 32 µL 20 µL
Table 2.10 -10 % and 15 % acrylamide gel components and volumes for 2 gels
41
2.2.5 Plate coating
96 or 384 well plates (CorningTM CostarTM EIA) were coated with a 3 % bovine haemaglobin
solution containing 0.05 M Na2CO3 and incubated at 4 oC overnight. The wells were
washed 6 times with phosphate buffer solution (PBS) and the hetereobifunctional cross-
linker sulphosuccinimidyl 4-(p-maleimidophenyl)butyrate (SSMPB) was added to a final
concentration of 0.1 mM in PBS per well. The plates were incubated for 2 hours at room
temperature and washed with PBS 4 times. A solution of 150 mM NaCl, reduced glutathione
10 mM and 1 mM EDTA pH 6.7 was added to each well and incubated overnight at room
temperature. The wells were washed with PBS containing 0.01 % Tween 20 (PBST). Coated
plates were either used immediately, or stored in PBST at 4 oC. At least 50 µL was used for
all components when using 96 well plates and at least 20 µL for all components was used
when using 384 well plates.
2.2.6 Autoubiquitination assay
WWP2 Fl pelleted cells were resuspended in 10 mL PBS per 50 mL of expressed culture
and sonicated until sufficient cell lysis. The cell lysate was centrifuged for 30 minutes at
4300 rcf (Heraeus Megafuge 1.0R). 100 µL of clarified lysate was added to each well of a
glutathione coated 96 well plate and incubated for 1 hour at room temperature. E1 (20 ng per
well), E2 (240 ng per well), ubiquitin (100 ng per well) and ATP (1.25 mM) in a buffer of
25 mM Tris pH 8, 100 mM NaCl, 4 mM MgCl2 and 50 µM DTT were incubated at room
temperature for 40 minutes. The plate was washed three times with PBST and tapped dry. 2
µL of the compound in question was added to the plate at the desired concentration in 10 %
DMSO. 18 µL of the ubiquitination mix was added to each well and the plate was incubated
at room temperature for 2 hours. The plate was washed with PBST. 100 µL of anti-FLAG
HRP (Sigma) (1:10000 PBST) was added to each well and incubated for a further hour at
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room temperature. The plate was washed. 100 µL of TMB substrate (Invitrogen) was added
to each well and incubated for up to 2 minutes. 1 M HCl was added to stop the reaction. The
absorbance was read at 450 nm using a Hidex sense microplate reader. Raw results were
processed in excel. IC50 values were calculated in GraphPad using non-linear regression-
[inhibitor] vs. normalized response.
2.2.7 Differential scanning fluorimetry
A solution of WWP2 HECT (2.5 µM) and SYPRO orange (2.5 x from a 5000 x stock) in 50
mM Tris Cl, 150 mM NaCl and 3 mM DTT was prepared. 45 µL of this mixture was pipetted
into each well of a 96 well plate (MicroAmp Optical 96-well reaction plate or MicroAmp
Fast Optical 96-well reaction plate). 5 µL of compound was added to final concentration of
10 µM, 0.1 % DMSO and the plate was sealed (MicroAmp Clear Adhesive Film). The plate
was briefly centrifuged. The assay was then run on an ABI 7500 or ABI 7500 fast RT-PCR
machine. The thermal profile was programmed to hold for 2 minutes at 25 oC, ramp to 70
oC at 0.5 oC per minute and then hold for a final 2 minutes at 25 oC. The melt temperature
(Tm) was calculated by taking the first derivative of the resulting curve of fluorescence over
temperature. Melt temperatures were calculated using the Thermo Fisher Protein Thermal
Shift Software v1.3.
2.2.8 Hydrogen peroxide detection assay
Using 96 well plates (CorningTM CostarTM EIA), 45 µL of ubiquitination buffer (described
in section 2.1.6) and 5 µL compound (1 % DMSO) were incubated for 30 minutes at room
temperature. 50 µL of HRP-PR (Horseradish peroxidase phenol red, 180 µg mL-1 HRP: 300
µg mL-1 phenol red) was added and incubated for 30 minutes at room temperature. 50 µL of
NaOH was added and the absorbance was read at 610 nm using a Hidex sense microplate
reader.
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2.2.9 Surface plasmon resonance
SPR experiments were carried out using a Biacore T200 instrument (GE Healthcare) on
a Biacore Series S NTA sensor chip. A running buffer consisting of 10 mM HEPES pH
7.4, 150 mM NaCl, 0.005 % v/v tween 20 was used. The chip was generated with 0.5 mM
nickel chloride and washed with 350 mM EDTA after the end of each cycle. The chip was
regenerated for each cycle. SPR experiments were done in collaboration with Dr Clare
Stevenson at the John Innes Centre, Norwich.
2.2.10 Statistics and repeats
All biochemical assay data is shown as a representative data set of at least two separate
experiments. Each data point is shown as the mean of a triplicate. Error bars are calculated
using standard deviation.
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Chapter 3
Efforts towards the discovery and
development of WWP2 inhibitors
through biophysical and synthetic
methods
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3.1 Introduction
To design inhibitors for WWP2, there were two distinct routes that could be taken. As WWP2
belongs to the Nedd4 supergroup, which contain high homology, previous research into other
inhibitors of this group could be utilised. The other approach is to initiate a high throughput
screen with a selected technique which identifies protein ligand binding events. To use
the first approach, there were two main compound "leads"; heclin (Mund et al., 2014) and
"compound 3" (Kathman et al., 2015). Heclin, found through a phage display and peptide
displacement assay, offers specificity towards HECT ligases over RING ligases (Mund et al.,
2014). The presumed mechanism of action is that it causes a perturbation in the C-lobe of the
HECT domain, resulting in exposure of the catalytic cysteine. This exposure is predicted to
cause the cysteine residue to undergo chemical changes such as oxidation, leading to its loss
of activity. There is no known binding site of heclin and no mechanistic explanation as to
how it causes the conformational change. Although, the low solubility of heclin in aqueous
solutions would present itself as a challenge for us to use in our subsequent biochemical
and biophysical assays. Designing and synthesising analogues of heclin may improve the
physiochemical properties, though there first needs to be a synthetic route which is amenable
to analogue design.
The development of a Nedd4-1 covalent inhibitor was a significant discovery in the
area of HECT ligase modulation. Not only did it report a covalent inhibitor with a crystal
structure of the bound complex, the method of inhibition revealed an allosteric site involved
in the building of poly ubiquitin chains (Kathman et al., 2015). Structure comparison of
the Nedd4-1 HECT inhibitor complex and WWP2 HECT could be used to design potential
compounds which would bind to WWP2 HECT. However, the lack of a non-catalytic site in
WWP2 which the compound binds to Nedd4-1 is one of the reasons the compound is specific
to Nedd4-1. It is unknown whether WWP2 HECT would still posses this allosteric site or
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that it builds ubiquitin chains in this processive manner. Derivatives of indole 3-carbinol
(Quirit et al., 2017) have been found to be inhibitors of Nedd4-1. These inhibitors were
derived from "compound 3" and have been speculated to work in the same manner. Whether
these compounds could be altered to target WWP2 remains to be seen. The second approach
is to use high throughput screening to discover small molecules which either inhibit or bind
to WWP2. There are a wide range of biochemical and biophysical techniques which can
be used to identify inhibitors. Hits from the primary screen would be validated through an
orthogonal assay, which has a different mechanism of action. The introduction to this chapter
will briefly outline the biophysical techniques that were used to probe for WWP2 ligands.
3.1.1 Biophysical techniques
3.1.1.1 Differential scanning fluorimetry
Differential scanning fluorimetry (also known as thermal shift) is a common biophysical
technique used for identifying protein ligands. The main principle is that the binding of a
ligand increases the thermal stability of a protein. An increase in temperature causes protein
tertiary structures to unfold, exposing hydrophobic surfaces. In the presence of a particular
dye, the dye will bind to the hydrophobic surfaces. The binding of the dye causes a large
increase in fluorescence. This fluorescence reading over temperature results in a sigmoidal
curve. The mid point of this curve is coined the ‘melt temperature’ (Tm), and the binding
can be evaluated by fitting fluorescence data into the Boltzmann equation or by taking the
first derivative of the curve. If a ligand binds to the protein, there will be an increase in the
melting temperature (Niesen et al., 2007). The assay can be run in 96 or 384 well format in
RT-PCR machines, hence making it a desirable high throughput screening technique.
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3.1.1.2 Surface plasmon resonance
Surface Plasmon resonance (SPR) is a highly sensitive technique used to detect ligand
binding and calculate accurate Kd values. SPR works around the basis that a change in
surface environment causes a change in the optical properties of polarised light. In SPR
applications, the Kretschmann configuration is the common set up. This is where polarised
light passes through a prism and hits the backside surface, the light reflects into the detector.
At a particular incidence angle, known as the resonance angle, electrons on the backside
surface absorb the light and resonate. These resonating electrons are known as surface
plasmons. The result of these surface plasmons is a dip in intensity in the reflected beam and
this dip can be monitored in the SPR reflection intensity. Surface plasmons are sensitive to
their surrounding environment, and changes result in a change in angle of the intensity dip.
Target ligands are immobilised onto the sensor chip, which acts as the backside surface in the
Kretscmann set up. Analyte molecules are flowed over the sensor chip and binding events
are detected as a function of SPR response where 1 resonance/ response unit (RU) equals 1o
change in resonance angle (Patching, 2014). SPR can measure the SPR response over time
meaning the kinetics of binding events can be calculated. The Kd is calculated by measuring
the Kon and the Koff rates (Patching, 2014). SPR experiments are run on BiaCore machines
and the sensor chip is specific to the desired method of capturing the ligand.
3.1.1.3 Saturation transfer difference NMR
NMR spectroscopy is an incredibly useful tool for studying molecules in solution. NMR can
be used to gain structural and mechanistic insight into a wide range of molecular entities
from small molecules to proteins. The versatility of NMR has been expanded to obtain
information about the interactions between ligands and biological macromolecules. It has
become an important step in the drug discovery process where NMR can be used as a
screening purpose and to determine the bound orientation of the ligand. The saturation
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transfer difference experiment is the primary NMR experiment exploited for these purposes.
To understand the principles of STD NMR, the basics of NMR must first be explained.
NMR uses the magnetic properties of particular nuclei, and nuclei in different structural
environments have different magnetic properties. The quantum subatomic property spin
determines the magnetic property of nuclei. Spin is a property of particles which have
angular momentum, but does not describe rotational movement. There is no macromolecular
equivalent to describe quantum spin and it is given a quantum mechanical description, the
description of which is beyond the scope of this thesis. Nuclei with a spin quantum number
greater than 0 are magnetic. The simplest nuclei is 1H with a spin of 1/2, hence the proton
will be magnetic. When the proton is subjected to a strong magnetic external field, the nuclei
will either align parallel or antiparallel to the field. This creates an energy transfer between
the ground and excited state. When spin relaxation takes place, energy is transmitted at the
same frequency as radio waves. These radio waves are processed to produce the typical 1D
NMR spectrum. The energy transition is dependent on the proton magnetic field, which is
affected by the chemical environment of the proton (Jacobsen, 2007). The STD experiment
is based on the nuclear overhauser effect (NOE). The NOE is when the resonance intensity
of a particular spin is affected by other spins in close space. This is known as the transfer
of nuclear spin polarization through cross-relaxation. There are two spectrums obtained for
the STD experiment. The on-resonance spectrum obtained by only irradiating the protein
resonances, at 0-1 ppm. The off-resonance is the spectrum without irradiating the protein.
During the on-resonance experiment, if the ligand is bound to the protein, it will receive
saturation transfer via the NOE. This will cause the signal to disappear. Therefore, when the
on-resonance experiment is taken from the off-resonance, the signals from bound ligands
will remain (Viegas et al., 2011).
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3.1.2 Experimental aims
WWP2 is an enticing novel target for therapeutics. The limited HECT ubiquitin ligase
inhibitors discovered and none specifically for WWP2, makes searching for WWP2 inhibitors
particularly interesting. This chapter sets out to discover, design, synthesise and evaluate
novel WWP2 inhibitors. The layout of this chapter has three distinct sections. The first
section focuses on employing a thermal shift experiment to screen for new WWP2 ligands.
Following from the screen, approaches will be developed to validate binding of any hits,
which is the focus of the second section. The third section of the chapter attempts to develop
synthetic approaches for ligand hit and heclin. It is important to note that when starting this
project, the only known general Nedd4 E3 ligase inhibitor was heclin. The methodology
explored in this chapter combines to produce an experimental toolkit that can be used for the
further development of WWP2 inhibitors.
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3.2 Results
3.2.1 Utilising a thermal shift assay to identify WWP2 ligands
3.2.1.1 WWP2 HECT protein purification
To find novel ligands which could have the potential to be inhibitors, we chose the differential
scanning fluorimetry technique. We focused on finding ligands for the HECT domain of
WWP2. As the HECT domain contains the catalytic cysteine, we envisaged that any ligand
binding event had the strongest chance of affecting its ubiquitination activity. The WWP2
construct reported by Wei Gong et al. (2015) where residues 486-865 correspond to the
HECT domain, minus the last 5 residues, was chosen for thermal shift. As this was the
truncation that produced a crystal structure, we predicted this would be the most stable
truncation of HECT for thermal shift. The DNA sequence corresponding to this construct
was cloned into a pET28a plasmid by In-Fusion cloning. The WWP2 HECT protein was
expressed with an N-terminal 6xHis- tag. The protein was purified as described in Section
2.1.2.2, SDS page gel shown in Figure 3.1. Cleavage of the his tag is not necessary to run
thermal shift experiments, so the protein was simply dialysed into the final stable buffer of
50 mM Tris-Cl pH 8.9, 150 mM NaCl and 3 mM DTT.
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Fig. 3.1 -Nickel NTA purification of WWP2 HECT. The insoluble sample is post cell lysis.
The soluble fraction is the clarified lysate after centrifugation. The flow through and wash
samples is the sample collected after the clarified lysate is loaded on the column. The eluted
fractions are 5 mL fractions collected after the high imidazole elution buffer is added to the
column.
3.2.1.2 Thermal shift buffer screen
Once the protein was in the final Tris buffer, a small screen of conditions was performed.
The protein was kept in the main Tris buffer for the screen due to stability issues in other
buffers. Two protein concentrations (5 µM and 2 5 µM and three dye concentrations (5 x,
10 x and 20 x) were chosen to sample the quality of the melt profiles. Condition A and D
both gave good thermal shift profiles, condition D was chosen as it gave a good profile and
required less protein compared to condition A.
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Fig. 3.2 -Condition screen for thermal shift (A) 5 µM WWP2 HECT, 5 x SYRPO orange. (B)
5 µM WWP2 HECT, 10 x SYRPO orange. (C) 5 µM WWP2 HECT, 20 x SYPRO orange.
(D) 2.5 µM WWP2 HECT, 5 x SYPRO orange. (E) 2.5 µM WWP2 HECT, 10 x SYPRO
orange. (F) 2.5 µM WWP2 HECT, 20 x SYPRO orange.
3.2.1.3 Compound screen
Next, we screened 1584 compounds from NCI diversity V and 419 compounds from NCI
natural product set IV (Figure 3.3). The NCI diversity is a compound set derived from
140 000 compounds from the NIH National Cancer Institute Developmental Therapeutics
Program repository. The large set of compounds is reduced to 1584 based on the criteria
that the structure is rigid, 5 or few rotatable bonds, tendency to be planar, one or less chiral
centres and with pharmacologically desirable features. The ‘diversity’ is derived from the
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large number of possible pharmacophore permutations in the structures. The NCI natural
product set consists of 419 natural product compounds from the NCI repository. The natural
products were chosen based on structural diversity, purity, origin and availability of the
compound. At this point we did not have a positive control for WWP2 HECT as there
was no reported ligands. Therefore distinguishing hits from background noise would be
difficult. Therefore in order to select compounds for triplicate experiments, we chose 2 oC.
It is generally considered the greater the Tm, the higher the affinity of ligand (Mannhold
et al., 2015). We wanted to choose a temperature shift that would be high enough to be
distinguished from background noise and we felt a 2 oC shift would represent a significant
distinguishable binding event. It would also limit the number of compound hits we could
feasibly work with. The compounds in NCI diversity set V were distributed in 10 mM DMSO
stocks. The NCI natural product set was also in 10 mM DMSO stocks but with 5 % added
glycerol. Compound stocks were diluted to a final working concentration of 10 µM, 0.1 %
DMSO for screening. Compounds were added to 2.5 µM WWP2 HECT on 96 well plates
and underwent the thermal shift experiment described in section 2.1.6. DMSO, no DMSO
and no protein controls were run on each plate and the curves were inspected to confirm a
successful run. Compounds with a melt temperature which represented a 2 oC shift above
the average, were visually inspected and those which gave a typical curve were identified as
preliminary hits. Of the diversity set, 22 compounds were picked out to have a temperature
shift equal or greater than 2 oC. These compounds were run in triplicate and 5 compounds
showed a consistent temperature shift (Figure 3.3 and Table 3.1). NSC601359 showed
the greatest shift melt temperature with a 2.65 oC increase. The five compounds are fairly
structurally diverse apart from NSC601359, NSC33005, NSC35676 and NSC215718 being
phenolic compounds. NSC601359 and NSC215718 are the most similar compounds with
hydroxyl substituted naphthalene groups and a bromine containing aromatic ring. NSC35676
is a natural product known as Purpurogallin. From the 419 natural products, 11 compounds
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produced a significant temperature shift. Purpurogallin was also present in the natural product
compound library and was again identified as a hit. This compound was not included in the
11 identified hits as the follow up experiment had already been carried out. Triplicate runs
reduced this number down to 6 natural products (Figure 3.3 and Table 3.2). Five of the six
triplicate validated natural products are phenolic.
Fig. 3.3 -Thermal shift screen (A) Diversity set V thermal shift screen. 1584 compounds
were screened single shot at 10 µM in 0.1 % DMSO. Controls of + DMSO, - DMSO and
NPC (no protein control) were run on each plate. The control Tm was the average Tm of
the + DMSO control. ∆Tm of the screened compounds were calculated by the difference
between single compound Tm and the control Tm. (B) Diversity set hit compound triplicates
(C) Natural product set IV screen. The screen was carried out in the same way at described
for the diversity set screen, but with 0.05 % glycerol added in the control well solution. (D)
Natural product set hit compound triplicates
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NSC number Compound structure ∆TmD (oC)
601359 2.65
33005 1.49
35676 1.14
215718 1.58
107582 1.37
Table 3.1 -Structures and ∆TmD of Diversity set hits
3.2.1.4 Biological testing of hit compounds
The compounds were tested for whether they had any biological activity against WWP2. The
WWP2 autoubiquitination assay was employed. This mimics the ubiquitination cascade in
vitro. GST WWP2 is anchored down by glutathione coated plates, and then incubated in the
presence of E1, E2, flag tagged ubiquitin and ATP. After subsequent washings, flag tagged
ubiquitin can be recognised by the anti-Flag antibody. This antibody also had a horseradish
peroxide (HRP) tag which acts a substrate for 3, 3’, 5, 5’- tetramethylbenzidine (TMB). This
reaction causes a colour change of the TMB of clear to blue. This colour change can be
measured quantitatively by stopping the reaction with HCl and reading the absorbance at
450 nm. Compounds were added to the reaction at the concentrations 1 µM, 5 µM, 10 µM,
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NSC number Compound structure ∆TmD oC
31867 3.19
401005 1.85
5897 1.64
59263 3.49
114344 1.58
30552 4.34
Table 3.2 -Structures and ∆TmD of Natural product set hits
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25 µM, 50 µM and 100 µM . NSC601359, NSC33005, NSC215718, NSC107582 from the
diversity set showed no inhibition and an IC50 could not be calculated (Table 3.3 and Figure
3.4). Purpurogallin, the compound which was picked out as a hit in both the diversity and
natural product sets inhibited WWP2 with an approximate IC50 of 97.57 µM. During the
time of these experiments taking place the same compound libraries were being screened
by the autoubiquitination biochemical assay in the Chantry lab (carried out by Jess Watt).
Pleurotin came out as a hit in the biochemical screen and was reported with an IC50 of 2.67
µM (Jess Watt 2018) (data not shown). Digallic acid inhibited WWP2 with an IC50 of 187.9
µM.
Compound IC50 µM
NSC601359 N/A
NSC33005 N/A
NSC215718 N/A
NSC107582 N/A
NSC35676 97.57
NSC31867 N/A
NSC401005 2.67
NSC5897 N/A
NSC59263 187.9
Table 3.3 -IC50 values of thermal shift hit compounds for the WWP2 autoubiquitination
assay
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Fig. 3.4 -Thermal shift hit compounds IC50 curves for the WWP2 autoubiquitination assay.
Thermal shift IC50 curves corresponding to the values reported in Table 3.3. Only NSC35676
and NSC59263 show a concentration dependent response
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3.2.2 Orthogonal approaches to validate ligands
At this point we chose to narrow down the hit compounds. NSC35676, NSC401005 and
NSC59263 all showed inhibitory activity and therefore were selected for further analysis.
The four other hits from the diversity set were also selected. This was because although they
showed no inhibitory effect, they could still be WWP2 ligands. The structural composition of
these hits were simpler than the hit from the natural products, so we envisaged any validated
ligands could be manipulated chemically to induce inhibition further down the pipeline. It
is commonplace in drug discovery to validate hits through an orthogonal biophysical assay.
The next part of this chapter explores two biophysical techniques; STD NMR and SPR, to
validate selected ligands.
3.2.2.1 Orthogonal validation by STD NMR
The first orthogonal technique we tried was STD NMR. The WWP2 HECT protein was
prepared in 25 mM Tri-Cl pH 8.9, 100 mM NaCl and 1.0 mM DTT. STD NMR experiments
were run in collaboration with Dr Jesus Angulo, Dr Sam Walpole and Dr Serena Monaco.
For the NMR sample, there was 20 µM protein and 100 µM compound in 1 % deuterated
DMSO, 10 % D2O. The results for NSC601359, NSC33005, NSC215718, NSC107582
were deemed inconclusive. The STD results suggested they might be binding but the signal
was too weak to say with confidence that the compounds were ligands. NSC35676 and
NSC401005 showed a positive result and were confirmed as binders. The STD spectum of
NSC35676 is shown in Figure 3.5.
The spectrum of NSC401005, as shown in Figure 3.6, in the presence of the protein had
some of the peaks moving, and /or disappearing. Due to this, we led to believe the compound
was degrading or undergoing a reaction. Whilst it would have been interesting to determine
whether the compound was undergoing chemical changes due to the conditions of the buffer
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Fig. 3.5 -STD spectrum of NSC35676.
or whether the changes were protein induced, limited access to the solid and the 800 MHz
NMR machine meant further experiments were not pursued.
Fig. 3.6 -NMR sprectum showing the degradation of NSC401005 in the presence of WWP2
HECT. Assignment was done by Dr Serena Monaco.
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3.2.2.2 Using surface plasmon resonance to investigate binding to WWP2
To investigate possible binding events to WWP2 we chose to see whether surface plasmon
resonance (SPR) could be used as an alternative biophysical technique. The output of the SPR
is via a direct response to binding, as opposed to thermal shift which is indirect. SPR was an
appealing technique to detect binding to WWP2 because it could be used as a confirmatory
technique, work out Kd and Kon/off rate and the nature of the experimental set up means it
could be adapted to high throughput screening.
3.2.2.3 Purification of WWP2 FL
The full length isoform of WWP2 (WWP2-FL) was chosen for SPR. Compounds which
were discovered in the biochemical assay could be also then be validated using the autoubiq-
uitination assay as the full length construct is used. SPR chips can anchor biological
macromolecules by many bioconjugation methods, but one of the most common is using a
NTA chip. The NTA chip is coated with nickel, which can then bind to His tagged proteins.
WWP2- FL was expressed in the CodonPlus RP cell line after 1 mM IPTG was added
and incubated at 16 oC overnight. The protein was extracted using the Ni NTA procedure
described in section 2.1.2.3. Gel filtration was used to gain a purer sample following elution
from the Ni NTA column. Two prominent bands co eluted around 98 kDa and 70 kDa.
WWP2- FL Curiously, the 70 kDa band eluted first, where the largest protein should elute
first from the gel filtration column. Samples containing both bands were pooled and run
through the Ni NTA column to see whether both samples were His tagged. Both samples
bound to the column and eluted in imidazole buffer suggesting both proteins were His tagged
(Figure 3.7). We were fairly confident that the 98 kDa fraction was WWP2 FL, though the
70 kDa fraction was still unknown. As at least 50 % of the sample was our target protein,
and the other 50 % a probably variation on our protein, we decided to trial SPR with this
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sample. The protein was stored at an assumed concentration of 3.97 µM in 25 mM Tris-Cl
pH 8.0, 250 mM NaCl, and 5 mM DTT.
kDa
200
97.4
66.2
Fig. 3.7 WWP2 FL protein purification
3.2.2.4 WWP2 SPR experiments
The following work was done in collaboration with Dr Clare Stevenson at JIC, Norwich. We
first tried to bind the WWP2-FL sample to the Ni NTA Biacore chip (Figure 3.8). All SPR
experiments used the running buffer consisting of 0.01 M HEPES pH 7.4, 0.15 M NaCl and
0.005 % v/v tween20. WWP2 FL at a concentration of 40 µg mL was run over the chip,
however no response was seen, indicating there was no binding. As we also had the His-
tagged WWP2 HECT construct available, we tried binding this protein at 64 µg mL as an
alternative. A clear response was measured, indicating the successful binding of WWP2
HECT. We therefore went forward for binding experiments with the HECT domain instead
of WWP2 FL.
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Fig. 3.8 SPR sensorgram of WWP2 fl and WWP2 HECT
3.2.2.5 Detection of ligand binding to WWP2 by SPR
Three already validated WWP2 HECT ligands were chosen for SPR analysis; NSC35676,
NSC2883887 and NSC2805. NSC288387 and NSC2805 were WWP2 inhibitors identified
in our lab and reported by Watt et al. (2018). Each compound was flowed over the chip in a
concentration of 1 µM in 0.002 % DMSO. The chip was regenerated with nickel and protein
between each run. A control of 0.002 % was used as a negative control. All three compounds
presented evidence of binding in the sensorgram (Figure 3.9).
The next step was to measure the response of the ligands against the response of non-
binding compounds. This was to ensure the signal from a binding event would be distinguish-
able from background noise during screening. We chose the same compounds as previously
mentioned, at 1 µM and 10 µM concentrations. Eight random compounds were chosen from
the NCI diversity set V, which were not WWP2 ligands. Each random compound was tested
at 10 µM. As the SPR response is dependent on the change in mass on the SPR chip surface,
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Fig. 3.9 -Compound binding to WWP2 HECT
the MW of the compounds is taken into account. The raw response units were converted
to the R-max by the following equation. Where MWanalyte is the molecular weight of the
small molecule, MWligand is the molecular weight of WWP2 HECT, Rligand is the response
from the protein and Vrec is the stoichiometry of the binding event. In this case, the exact
stoichiometry is unknown so is presumed as 1. Each value was normalised by removing the
average buffer value.
Fig. 3.10 -R-max equation
The response from the random eight known non binders were taken as the background
noise level. Significant values of the known ligands were calculated using a two tailed t-test
against the average of the non-binders. NSC2805 showed very good significance with both
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data sets ≤ 0.01. NSC35657 at 1 µM showed good significance at the 0.05 level but at 10
µM showed none. NSC288387 did not show any significant response. It was clear the noise
level was too high to reliably detect all possible binding events in a compound screen (Figure
3.11). Follow up experiments were attempted to improve the noise level, including adding
DMSO into the running buffer and doing dose dependent experiments with more data points
for each ligand. However, no interpretable data was produced. We felt SPR could be used as
a technique to detect WWP2 ligand binding, but there was significant amount of optimisation
required. Due to lack of resource and the limited time scope for this research, this technique
was not pursued further.
Fig. 3.11 R-max values of compound binding to WWP2 HECT
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3.2.3 Synthetic approaches
The next part of this chapter introduces a synthetic chemistry approach to develop WWP2
inhibitors. Initially a route to synthesise heclin is explored, and then there is some further
development on NSC35676, an inhibitor discovered in Section 3.2.1.3.
3.2.3.1 Heclin synthesis
Heclin is the compound identified as HECT specific ubiquitin ligase inhibitor. At the time of
starting this research, it was the only compound reported in the literature as a general inhibitor
for HECT ligases. Interestingly, when researching the compound in the literature, there was
no reported synthesis. Given the relatively simple chemical structure of heclin, we felt there
was scope for a short synthesis to be devised which could later be used to gain access to a
wide variety of analogues (Figure 3.12). Looking at the structure of heclin, the most obvious
bond to break was the amide bond. The corresponding amine would be the commercially
available 4-acetylaniline. The carboxylic acid can be formed by a Knoevenagel condensation
with Doebner modification reaction from 5-methylfurfural. The 5-methylfurfural can be
synthesised from the commercially available 2-ethyl furan via a Vilsmeier- Haak reaction.
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Fig. 3.12 -Scheme 1. Heclin retrosynthesis.
3.2.3.2 Vilsmeier-Haak reaction
The Vilsmeier-haak reaction involved the formylation of electron rich aromatic compounds
using a Vilsmeier reagent. The Vilsmeier reagent is a iminium salt in equilibrium formed
from N,N-dimethylformamide (DMF) and an acid chloride. The reaction favoured the desired
position of formylation on 2-ethylfuran as the Vilsmeier-Haak reaction is regioselective,
favouring the less hindered para position of substituted rings. The Vilsmeier-Haak reagent
was formed in situ by reacting DMF with phosphorous oxychloride. 2-Ethyl furan (1) was
added and the reaction was left for 2 hours. Following the work up, the crude was purified by
fractional distillation to give 2 in a 79 % yield.
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Fig. 3.13 -Scheme 2. The Vilsmaeier Haak reaction. (A) Reaction conditions: (i) POCl3,
Na2CO3, DMF, 0 oC, 79 %. (B) Vilsmeier-Haak reaction mechanism.
3.2.3.3 Knoevenegal condensation Doebner modification
The Knoevenegal condensation is the nucleophilic addition to an aldehyde to form α , β -
unsaturated compounds. The Doebner modification is the use of malonic acid instead of
malonate, and under refluxing pyridine leads to decarboxylation. Compound 2 was reacted
with piperidine and malonic acid in pyridine and upon work up the α , β - unsaturated
carboxylic acid 4 was isolated in 47 % yield without the need for further purification.
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Fig. 3.14 -Scheme 3 (A) Reaction conditions: (i) Piperidine, malonic acid, pyridine, 47 %.
(B) Knoevenegal condensation mechanism.
3.2.3.4 Amide bond formation
Amide bond formation between (4) and 4-acetylaniline was attempted using DCC and DMAP
in dichloromethane at room temperature. Crude NMR suggested formation of the product.
However upon purification by column chromatography, the NMR and MS attributed the
structure to be of the O-acylisourea intermediate (5). This suggested the 4-acetyl aniline was
not reacting with the O-acylisourea intermediate. To our delight, simply heating the reaction
to 50 oC resulted in the formation of 7. The product was purified by column chromatography
in 26 % yield (scheme 4).
3.2.3.5 Synthesis of the purpurogallin scaffold
From the thermal shift hits, there were only two which were orthogonally validated ligands
with inhibitory activity; NSC35676 and NSC401005. Chemically, NSC401005 is complex
with six stereocentres and a six ringed compact cyclic framework. The racemic total synthesis
has been completed in 26 steps (Hart and Huang, 1988); there is still no enantioselective
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Fig. 3.15 -Scheme 4 (A) Conversion to O- acylisourea. Reaction condition:(i) DMAP, DCC,
4- acetyl aniline, DCM, room temperature, 39 %. (B) Conversion to heclin. Reaction
conditions: (i) DMAP, DCC, 4-acetyl aniline, DCM, 50 oC, 26 %.
synthesis. Due to the formidable synthetic challenges faced in any optimisation and the
ambiguous potential structural change upon binding, we chose not to advance this compound
synthetically. Purpurogallin on the other hand is chemically simpler. It is a benzenetriol fused
to a hydroxy ketone substituted seven membered ring called a tropolone. It is possible to the
synthesise purpurogallin scaffold in a single step using a horseradish peroxidase catalysed
oxidation with pyrogallol and catechol. We envisaged this could be exploited to quickly
make analogues to see whether any SAR emerges.
We wanted to attempt to leave one of the hydroxyls free for further functionalisation,
hence we needed to add protecting groups. The hydroxyl groups on phenolic compounds can
undergo methyl etherification. The methyl ether group can act as a protecting group for the
hydroxyl. It would also change the group from a possible hydrogen bond donor/acceptor to
just an acceptor. We chose this group as the resulting compound will not be dramatically
altered and it would still be interesting to biologically test. Starting from 3-methoxycatechol
and methyl 3,4,5-trihydroxybenzoate, the reaction conditions of 3 % H2O2, HRP in citrate
buffer with 5 % acetone gave the resulting purpurogallin analogue crude. Initially purification
by column chromatography was attempted, however the product streaked and stuck to the
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stationary phase, resulting in poor separation and recovery. Recrystallisation in ethyl acetate,
acetone, methanol and ethanol were carried out in order to find an alternative to column
chromatography. Success was achieved by recrystallisation in ethanol (scheme 5).
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Fig. 3.16 -Scheme 5. Reaction conditions: 3 % H2O2, HRP, phosphate citrate buffer pH5, 20
% acetone, 1 hour, 50 % yield
Based on the condition reported in Cheng et al., two of the hydroxyl groups in compound
10 were methylated using methyl iodide, leaving one hydroxyl group free (scheme 6). A
NOESY experiment was run to determine which hydroxyls had been methylated.
Fig. 3.17 -Scheme 6. Reaction conditions: Methyl iodide, potassium carbonate in DMF,
overnight, 64 %.
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3.2.3.6 Purpurogallin analogue testing
The purpurogallin analogues 10 and 11 were tested by the same method as described previ-
ously in Section 3.2.1.4. Concentration dependent assays were set up at 5 µM, 10 µM, 25
µM, 50 µM and 500 µM. The higher concentration was chosen as some of the compounds
may have reduced inhibition than IC50 of purpurogallin which was 97.57 µM. Purpurogallin
was repeated and compared with the analogues at the new range of concentrations. The IC50
curves are shown in Figure 3.18. Compound 11 showed no inhibition, and compound 10
showed an increase in potency by approximately two fold to 51.65 µM. NSC35676 produced
an IC50 of 162 µM, whilst this is lower than previously measured, there is still a compara-
tive increase in potency for 10. There was visible precipitation for 10 when preparing the
concentration solutions.
Fig. 3.18 -Purpurogallin analogue testing against WWP2 autoubiquitination
The purpurogallin analogues were tested for Nedd4 autoubiquitination inhibition. The
compounds were tested at 1 µM, 5 µM, 10 µM, 25 µM, 50 µM and 100 µM in 1 % DMSO.
NSC35676 gave an IC50 of 37.78 uM which is lower than when tested against WWP2. As
with WWP2, compound 10 produced a comparatively lower IC50 than NSC35676 at 4.21
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µM. The same pattern seen with WWP2 is also observed for compound 11, which showed
no inhibition.
Fig. 3.19 -Purpurogallin analogue testing against Nedd4 autoubiquitination
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3.3 Discussion
Rational drug design is the principle of selecting a biological target which has been validated
as a crucial component in the molecular pathways of a chosen disease. The target protein
must be cloned, expressed and purified in sufficient amounts for the multitude of biophysical
and biochemical experiments needed to identify specific inhibitors. Choosing the protein
construct to express is key, as proteins can contain multi domains, and targeting some
of those domains may not be necessary in inducing inhibition. Particular constructs may
be more stable than others, different expression levels and some may have differential
stability depending on the technique used. Once the protein has been successfully purified,
a biophysical technique is used to perform compound screening. Hits from the screening
are further investigated and characterised. These compounds are then optimised to have
the desired drug like properties. WWP2 has been proven to be an interesting therapeutic
target for cancer. Taking WWP2 through the drug design process could lead to potential
cancer therapeutics as well as molecular probes for WWP2. Little work has been previously
published on screening for small molecule inhibitors for HECT proteins, and none on WWP2
(at the time of starting this research). The aim of this chapter was to set up a screening
platform for WWP2 and discover ligands which could be used as a chemical scaffold for
further optimisation. The chapter also sets out to report the first synthesis of the first HECT
inhibitor in a way that could give rapid access to a wide variety of analogues. Three key
biophysical techniques were trialled; thermal shift, STD NMR and SPR. From a practical
sense, thermal shift was the easiest method to be explored for high throughput screening.
Previous work in the Chantry lab by Dr Lloyd Whal (Whal 2015) set a precedent in the
challenges in expressing and purifying sufficient amounts of biologically active isoforms
of WWP2. We therefore chose to just focus on the HECT domain, for which the crystal
structure was published at the time of commencing this work. The HECT domain is still
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biologically relevant as it is the domain within WWP2 which holds the catalytic capability.
Hence targeting this domain should inhibit WWP2 activity. The HECT domain proved to be
easily expressed and purified as a His tagged protein. Brief optimisation resulted in thermal
shift curves which were deemed suitable for compound screening. Not having a positive
control at this point was a significant issue, as we could not determine the level of signal to
noise for the assay. Heclin had been reported as an HECT inhibitor, the proposed mechanism
of action was through forcing a conformation change in the structure of HECT which results
in oxidising the catalytic cysteine, removing the cysteine of its catalytic ability. The authors
did not confirm that heclin was a ligand for WWP2. When tried in the thermal shift assay
(results not shown) there was no shift detected. Therefore, we could not use the only potential
positive control. There remains speculation as to whether heclin is a true inhibitor for WWP2,
or that all HECT ligases can be inhibited by this mechanism of action. Screening of the NCI
diversity set V and natural product set IV resulted in the identification of 11 hit compounds.
Apart from all containing aromatic rings, they were fairly structurally diverse. The biological
testing of these compounds resulted in only NSC35676, NSC401005 and NSC59263 to be
inhibiting WWP2. We still envisaged the other compounds could be ligands. Finding new
ubiquitin ligase ligands is currently of great interest to due the emergence of PROTACs. With
the need to orthogonally validate the inhibitors and ligands, we needed another biophysical
technique. STD NMR offered a robust method in determining whether these compounds
were true binders. STD NMR confirmed pleurotin and purpurogallin as binders. There were
solubility issues for many of the compounds, with visible precipitation when the compounds
was dissolved in aqueous solution. This may be the reason for the poor quality of the NMR
data which meant we could not say with confidence whether they were true ligands or not. It
is however interesting to note the NSC215718 compound. It contains a thiourea group flanked
by a halogenated benzene and hydroxyl naphthalene ring. It is structurally similar to the
compound ‘HS-152’ (Figure 3.20). HS-152 is a compound recently discovered using a cell
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based high throughput screening method by Tian et al as an inhibitor for Smurf 1 and Smurf2
which are part of the Nedd4 ubiquitin ligase family. The authors reported the compound
may be an antagonist of the HECT catalytic capability. HS-152 is structurally similar as
it contains a urea group flanked by two substituted benzene rings, one being halogenated
and the other linked to a piperazine via a ketone. Analogues of HS-152 and NSC215718
could be synthesised and the presence of any SAR could be evaluated. A possible reason for
NSC215718 not showing any inhibition is due to poor solubility.
Fig. 3.20 -HS-152 and NSC215718
This chapter reported the first synthesis of heclin in only 3 steps using readily available
starting materials. Beginning with a Vilsmeier-Haak reaction, 1 was converted to 2. Reacting
2 in a Knoevengal Doebner modification condensation reaction resulted in 4. An amidation
with 4 and 4-acetyl aniline yield the heclin molecule. This synthesis means large quantities
of heclin can be taken forward for further testing. The nature of this synthesis lends itself
to deriving analogues. Various substituted heterocycles could be used as a starting point
for the formylation reaction. There is a multitude of anilines that could be coupled to the
carboxylic acid, or simply any other cyclic amine could be used. The later part of this chapter
described a brief attempt in NSC3567 analogue synthesis. NSC35676 came out as the most
promising compound from the thermal shift assay as it was validated by STD NMR and SPR.
The compound as been reported as an inhibitor for other proteins such as TLR1/2 (Cheng
et al., 2012) and IP5 2-K (Whitfield et al., 2018). Therefore it is particularly important
to derivatise the compound to make it specific to WWP2. Simply adding a methyl ether
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group to the seven membered ring of the tropolone appeared to increase its activity. This
was evident in both WWP2 and Nedd4. There is an argument that NSC3576 is a pan assay
interference compound. The structure contains the catechol moeity (Figure 3.21), which has
been implemented as a moeity which produced false positives (Jasial et al., 2017).
Fig. 3.21 Purpurogallin containing the catechol moeity
It is interesting when this moeity is eliminated in compound 11, that all inhibition is
lost. However the fact that NSC35676 was confirmed as a binder using thermal shift, NMR,
SPR and has inhibitory activity makes a more convincing argument that it is a true inhibitor.
Whilst it would intriguing to carry on synthesing analogues of NSC35676, we felt the need
for structural evidence to guide any future synthesis. This chapter set out to provide an
experimental toolkit which can be used to identify WWP2 ligands and to also synthetically
build upon the previously known inhibitor and a new inhibitor reported in this chapter. The
next step in inhibitor development is to investigate inhibition/ binding mechanisms and to
synthetically modify hit compounds. In order to do this, one must look at how the compounds
are binding from a structural perspective.
79
Chapter 4
Towards the solving of the first ligand
bound WWP2 crystallographic structure
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4.1 Introduction
Obtaining an X- ray structure of a ligand bound to a protein is a significant step in the
development of small molecule inhibitors. It is considered paramount in the validation of hit
compounds identified during high throughput screening. Structural information will unveil
ligand binding sites and the orientation of the ligand. This information can also be used
towards the understanding of any inhibition mechanisms. Interactions with the ligand and
the surrounding amino acids can be deducted. Using organic synthesis, these interactions can
then be exploited by developing the initial ligand into targeting specific residues, with the
aim of developing a superior ligand. In order to gain a structure of a protein ligand complex,
pure homogeneous protein must first be acquired. There are then two main approaches to
introducing the ligand; soaking or co-crystallisation. Soaking involves growing apo protein
crystals and soaking the crystals in a solution of chosen ligand. Co- crystallisation involves
the growing of protein crystals in the presence of the ligand.
4.1.1 Crystal formation
Crystal formation encompasses two key steps; nucleation and growth. Nucleation is the
process where protein molecules undergo the phase transition from the disordered aqueous
phase to the ordered solid state (Garcıa-Ruiz, 2003). The exact process as to how this occurs
is still the subject of some ambiguity (McPherson, 2004) (Garcıa-Ruiz, 2003) (Van Driessche
et al., 2018), however it is presumed protein molecules aggregate into small ordered nuclei.
Once nucleation has occurred, the much better characterised process of macromolecular
crystal growth can start. The formation of what is known as a supersaturated state is key to
both nucleation and growth. Supersaturation is when the solubility limit of the macromolecule
has exceeded. Once supersaturation is reached, protein molecules still face a free energy
barrier to reach the solid phase: crystal nucleus or precipitate. As supersaturation increases,
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the energy barrier to nuclei formation decreases (Garcıa-Ruiz, 2003). The nuclei will continue
to grow into a crystal or precipitate as long as this supersaturation state is maintained. To
achieve supersaturation, one is effectively decreasing the solubility of the macromolecule
in the mother solution (McPherson, 2004). The protein in the mother solution, which is
either at its solubility limit or below, is exposed to a precipitant solution. The composition
of this precipitant solution promotes supersaturation. The precipitant solution can do this
through a variety of ways such as changing the salt concentration, altering the pH and adding
a particular precipitant to alter the interactions between the solute and solvent (McPherson,
2004).
4.1.2 X-ray diffraction
The result of the X- ray diffraction experiment is a map of electron density. Monochromatic
X- rays are directed at the crystalline solid and scatter upon encountering electrons. The
scattering is recorded to produce the diffraction pattern. The diffraction pattern is made up of
numerous spots in different positions and of varying intensities. Measuring the intensities
of each spot is used in the calculation of the electron density map via a Fourier Synthesis.
However the phase shift, which is needed to solve the electron density distribution using
the Fourier Synthesis, is unknown. This is known as the "phase problem" (Taylor, 2003).
One of the simplest methods for solving the phase problem is to use molecular replacement.
Molecular replacement uses a homologous structure (known as the search model) to orientate
the protein within the unit cell. The phases from the search model can then be used with the
experimentally measured amplitudes to generate the initial map (Evans and McCoy, 2008).
Finally, the generated structure undergoes refinement. Refinement represents minimizing
the difference between the experimental and calculated structure factors. The theoretical
values of the physical properties of the polypeptide such as bond angles, bond length, phi
and psi angles, dihedral angles planarity, clashes etc are taken into account when modifying
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the model. This interpretation of the three dimensional electron density map combined with
computational refinement leads to the final model of the target macromolecule.
4.1.3 Protein ligand structures of the HECT ubiquitin ligases
As of 2019, there is still only one published HECT ubiquitin ligase structure with a small
molecule bound. As described in Section 1.2.3.3, this is the Nedd4 HECT bound to the
indole based inhibitor (Kathman et al., 2015). The structure showed the compound covalently
binding to a non catalytic cysteine though a Michael addition reaction. The presence of this
bound inhibitor prevented the ubiquitin chains growing in a processive manner and changed
it to a distributive manner. The structure not only provided a novel mechanistic insight into
inhibiting Nedd4 HECT but also set a basis for further inhibitor development. (Quirit et al.,
2017).
Fig. 4.1 -Nedd4 HECT bound to "Compound 1"."Compound 1" covalently binds to the non
catalytic cysteine of the HECT domain, preventing the build up of ubiquitin chains. PDB:
5C91.
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4.1.4 Chapter aims
Elucidating a protein ligand structure is a substantial milestone in rational inhibitor design.
This chapter sets out to elucidate the first structure of an inhibitor bound to WWP2 by X-ray
crystallography. Inhibitors and ligands described in Chapter 3 and also discovered in the
Chantry lab (Watt et al., 2018) (Watt, 2018). are used in an attempt to generate a structure.
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4.2 Results
4.2.1 Identification of putative binding sites
In silico docking was used to gain an idea as to where we might expect extra electron density
to be picked up which could possibly be attributed to a ligand binding event. The WWP2
HECT (aa 486-865) crystal structure (PDB:4Y07) was used as the model for identifying
putative binding sites. SiteMap software in the Schrodinger Maestro suite (Halgren, 2009)
(Halgren, 2007) was used to search for binding sites. Two binding sites were identified based
on pocket size large enough to accommodate a small molecule, solvent exposure, balance of
region hydrophobicity and hydrophilicity and potential to form hydrogen bonds (Halgren,
2009). Site 1 (Figure 4.2, (A)) is located close to the hinge loop, sitting between the N and C
lobe. The second potential binding site was located in the N-lobe (Figure 4.2 (B)). Neither
sites have catalytic activity or known involvement in ubiquitin and E2 binding.
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Fig. 4.2 Predicted small molecule binding sites for WWP2 HECT. (A) Site 1 is identified as
a region sitting between the interface of the N and C lobe, in close proximity to the hinge
loop. (B) Site 2 is identified as a region within the N lobe. The binding regions are shown in
black mesh. The N lobe is coloured in red, the C-lobe in green and the hinge loop in purple.
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4.2.2 Attempting WWP2 HECT crystallisation
Early efforts to crystallise WWP2 was based on the method described by Gong et al. (2015),
described briefly in Section 3.2.1.1. Unlike the previous biophysical methods we tried with
WWP2 HECT, where the His- tag could be left on, it was deemed the removal of the tag
would most likely preclude crystallisation success. His- tagged WWP2 HECT was treated
with thrombin and incubated overnight at 4 oC. Thrombin is most active at 16 oC, however
the WWP2 HECT protein was unstable at this temperature and precipitated out of solution.
A partial digest was observed, shown in Figure 4.3. In this not uncommon scenario, the
heterogeneous mixture of tagged and untagged protein would be separated by running the
sample down a Ni- NTA column. However, when this was tried with WWP2 HECT, untagged
HECT has a strong affinity to Ni- NTA, preventing the isolation of the untagged variant.
We tried incubating with thrombin for up to 70 hours in an attempt to get a full digest. We
also tried dialysing the protein back into PBS and incubating with thrombin for a further 3
days, as PBS is the standard buffer for thrombin. Eventually a 80-90 % digest was observed
and the protein was further purified by gel filtration (Figure 4.3) and concentrated to 10 mg
mL −1. Sitting drop vapour diffusion plates were set up using a small screen around the
original precipitant conditions. 48 conditions using 0.1 M HEPES, pH 8.2-8.5, 0.2 M MgCl2
and 12-17 % ethanol were trialled. No crystals were observed over the following weeks.
We attributed the lack of success to be most likely due to not yielding a fully homogenous
sample. Conveniently, in 2017, Z.Chen et al published another crystal form of WWP2 while
investigating the role of the WW2 domain and the linker regions mediating HECT activity.
Two constructs were used: WW2- 2,3 linker- HECT and 2,3 linker- HECT produced crystals.
The WW2- 2,3 linker-HECT crystals were reported to give a higher resolution than the 2,3
linker- HECT crystals. We chose to leave the HECT (886-865 aa) construct and choose the
WW2- 2,3 linker HECT construct in pursuit of WWP2 crystals.
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Fig. 4.3 -WWP2 HECT purification for crystallography. (A) Incubating WWP2 HECT with
thrombin overnight resulted in approximately a 50 % digest. (B) Incubating WWP2 HECT
for a further 2-3 days yielded a greater portion of His tag free WWP2 HECT. (C) WWP2
HECT after being dialysed into PBS and incubated for a further 3 days with thrombin. Only
slightly more His tagged protein was digested. (D) WWP2 gel filtration SDS PAGE gel. The
fractions which visibly looked the most homogenous were collected and concentrated for the
crystallography experiments.
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4.2.3 WWP2 WW2-2,3 linker HECT purification and crystallisation
The pGEX6p-2 WWP2 WW2-2,3 linker HECT (WW2-L-H) plasmid was gifted by Professor
Philip Cole. The method described in Chen et al. (2017) was followed with some minor
changes. The protein was expressed in CodonPlus RP as a glutathione s-transferase (GST)
fusion protein and purified using a GS Trap column. Cleavage of GST was carried out using
PreScission Protease overnight at 4 oC. The sample was further purified using size exclusion
chromatography. Any remaining GST could not be separated during gel filtration due to the
small difference between GST and the WWP2 protein. GST is 26 kDa in size but exists
as a dimer, which brings it to a similar size to the WW2-L-H construct, rendering the gel
filtration column unable to resolve the two proteins. Remaining GST could be removed by a
final wash through the GS trap. The protein was initially concentrated at 4 oC using vivaspin
ultracentrifugation tubes. However, there was an increasingly dramatic loss in protein when
concentrating above 1 mg mL−1. We noted a temperature driven effect with the solubility
of the protein. Pure protein sample at 4 oC would begin to precipitate out, upon heating to
room temperature the precipitate would dissolve back into solution. Hence, concentrating
at 20 oC minimised loss of protein and we concentrated the sample to 1-7 mg mL −1 for
crystallisation trials. Various stages of the purification process are shown by SDS-PAGE
in Figure 4.4. Conditions in the sitting drop method were set up around the two published
crystallisation conditions of 0.1M KSCN, 30 % w/v PEG monomethyl ether 2000 (‘condition
1’) and 0.1 M MMT (malic acid, MES and tris in molar ratio of 1:2:2) pH 6.0, 25 % w/v
PEG 1500 (‘condition 2’). Initial efforts produced needle clusters in condition 1 and micro
crystals in condition 2 at 3 mg mL−1. Upon reaching the higher concentration of 7 mg mL−1,
prismatic crystals formed in condition 2 after 1 week.
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Fig. 4.4 -Key steps in the WW2-2,3 linker HECT purification.(A) GS trap purification. (B)
GST digest with PreScission protease. Note the undigested protein at 66.2 kDa and the GST
at 29 kDa. (C) Gel filtration of the protein. (D) Final purified protein for crystallography.
4.2.4 Initial WWP2 crystal harvesting
A total of 28 suitable crystals were picked during the first harvest. 15 crystals were set aside
for apo structure determination and 13 crystals were soaked in three different ligands. All
ligand stocks were dissolved in DMSO-d6 at 50 mM. Crystals were soaked in NSC2805,
NSC288387 and NSC401005 at 10 x their approximate IC50 concentrations at 0.05 %
DMSO. Crystals were cryoprotected in the soak solution with added 30 % glycerol. Data
was collected at the Diamond Light Source (Oxford). The data was processed and integrated
using the automatic pipelines available on ISPyB. Molecular replacement was carried out
using the PHENIX suite and rounds of automatic and manual refinement was done using
COOT. 7 crystals gave suitable data for structural analysis. Initial molecular replacement was
done using the original WWP2 WW2 2,3 linker HECT structure (PDB:5TJ8, NB: no WW2
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domain observed). All the solved structures matched in high accordance with the search
model. Resolutions ranged from 2.05-3.58 Å, with the best data set having better resolution
than the original search model. Close inspection of the 2Fo-Fc electron density maps did not
yield any significant unexplained density.
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Crystal code Experiment type Ligand Ligand concentration µM DMSO concentration %
WWP2_1_1 Apo N/A N/A N/A
WWP2_4_1 Apo N/A N/A N/A
WWP2_5_2 Soak NSC288387 11.5 0.05
WWP2_5_4 Soak NSC2805 2 0.05
WWP2_6_1 Soak NSC2805 2 0.05
WWP2_6_3 Soak NSC2805 2 0.05
WWP2_7_2 Soak NSC401005 13 0.05
Table 4.1 -Summary of first soaking experiments. Information regarding the harvested
crystals for which data was not collected is not shown.
Crystal code Pipeline Resolution Å
WWP2_1_1_2 xia2 3dii 2.74
WWP2_4_1_2 xia2 dials 2.44
WWP2_5_2_2 fast_dp 2.62
WWP2_5_4_2 xia2 dials 2.48
WWP2_6_1_3 autoProc 2.05
WWP2_6_3_2 autoProc 3.58
WWP2_7_2_2 xia2 dials 2.8
Table 4.2 -Summary of the solved data from the first soaking experiments.
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4.2.5 Further soaking experiments leads to improved search model
Further soaking experiments were conducted with higher concentrations of the inhibitors.
Reaching higher concentrations of inhibitor meant pushing the DMSO percentage higher.
Concentrations of 5 mM compound, 10 % DMSO and 2.5 mM compound, 5 % DMSO were
attempted. A greater range of inhibitors were chosen; NSC288387, NSC2805, NSC401005,
NSC35676, Heclin and Aquaymycin. Aquaymycin is a natural product which was discovered
as a WWP2 inhibitor in the Chantry lab (Watt, 2018) whilst this research was being carried
out. Only one crystal subjected to 10 % DMSO gave Bragg diffraction, and at the low
resolution of 5 Å. Initial soaks where the crystal was subjected to 5 % DMSO gave high
resolution structures. This suggested the crystals could withstand this DMSO concentration,
therefore setting the precedent for the remaining soaking experiments outlined in Table
4.3. Crystals which gave bragg diffraction were subjected to data processing, integration,
molecular replacement and refinement as outlined in Section 4.2.4. WWP2_13_2 gave the
highest resolution of 1.99 Å, however no ligand was observed in the electron density map.
As this data set was of a higher quality than previously published, the model was refined
through reiterate rounds of manual and automatic refinement in Coot in order to be used as
an improved search model for molecular replacement.
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Crystal code Experiment type Ligand Ligand concentration mM DMSO concentration %
WWP2_13_1 Soak NSC288387 2.5 5
WWP2_13_2 Soak NSC288387 2.5 5
WWP2_14_2 Soak NSC288387 5 10
WWP2_15_4 Soak NSC2805 2.5 5
WWP2_17_1 Soak NSC401005 2.5 5
WWP2_17_2 Soak NSC401005 2.5 5
WWP2_17_3 Soak NSC401005 2.5 5
WWP2_18_3 Soak NSC2805 2.5 5
WWP2_18_4 Soak NSC2805 2.5 5
WWP2_19_1 Soak NSC2805 2.5 5
WWP2_19_2 Soak NSC2805 2.5 5
WWP2_19_3 Soak Heclin 2.5 5
WWP2_19_4 Soak Heclin 2.5 5
WWP2_21_2 Soak Aquaymycin 2.5 5
WWP2_22_2 Soak NSC288387 2.5 5
WWP2_22_3 Soak NSC288387 2.5 5
WWP2_22_4 Soak NSC288387 2.5 5
WWP2_23_1 Soak NSC288387 2.5 5
WWP2_23_3 Soak NSC401005 2.5 5
WWP2_24_2 Soak NSC401005 2.5 5
WWP2_24_3 Soak NSC401005 2.5 5
WWP2_24_4 Soak NSC401005 2.5 5
WWP2_26_1 Soak NSC35676 2.5 5
WWP2_26_2 Soak NSC35676 2.5 5
WWP2_26_3 Soak NSC35676 2.5 5
WWP2_26_4 Soak NSC35676 2.5 5
WWP2_27_1 Soak NSC35676 2.5 5
WWP2_27_2 Soak NSC35676 2.5 5
Table 4.3 -Summary of second soaking experiments
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Crystal code Pipeline Resolution Å
WWP2_13_1 xia2 3dii 2.21
WWP2_13_2 xia2dials 1.99
WWP2_14_2 autoProc 5.04
WWP2_15_4 xia2 3dii 4.69
WWP2_17_1 xia2 3dii 3.33
WWP2_17_2 xia2 3dii 3.09
WWP2_17_3 autoProc + STARANISO 2.31
WWP2_18_3 xia2 3dii 4.27
WWP2_18_4 fast_dp 3.12
WWP2_19_1 autoProc 3.53
WWP2_19_2 autoProc 4.56
WWP2_19_3 xia2 3dii 3.4
WWP2_19_4 xia2 3dii 3.64
WWP2_21_2 xia2 3dii 3.38
WWP2_21_3 xia2 3dii 4.08
WWP2_21_4 xia2 3dii 5.02
WWP2_22_2 autoProc 2.63
WWP2_22_3 xia2 3dii 3.35
WWP2_22_4 autoProc 3.57
WWP2_23_1 autoProc + STARANISO 2.4
WWP2_23_3 autoProc + STARANISO 2.68
WWP2_24_2 autoProc + STARANISO 2.44
WWP2_24_3 xia2dials 3.04
WWP2_24_4 xia23dii 3.42
WWP2_26_1 xia2dials 2.7
WWP2_26_2 xia2dials 3.01
WWP2_26_3 autoProc + STARANISO 3.08
WWP2_26_4 autoProc 2.82
WWP2_27_1 autoProc + STARANISO 2.47
WWP2_27_2 autoProc + STARANISO 2.51
Table 4.4 -Summary of the solved data from the second soaking experiments
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wwp2_13_2 Published 5tj8
Data collection
Wavelength Å 0.9795 1.0000
Space group P212121 P212121
Cell constraints a, b, c
α ,β , γ
44.23, 91.37, 112.22
90.00, 90.00, 90.00
44.23, 89.27, 111.47
90.00, 90.00, 90.00
Resolution 56.11-1.99 (2.02-1.99) 50-2.3
% Data completeness
(in resolution range) 99.9 (99.6) 95.5
Number of unique reflections 32006 (1539)
Multiplicity 12.9 (13.3)
Rmerge 0.024 (0.531) 0.08
Rmeas 0.116 (2.663)
<I/σ (I)> 12.8 (1.0) 3.02
Wilson B factor 41
Refinement
Resolution range 56.11-1.99 (2.02-1.99)
Completeness 99.9 (99.6)
Reflections used in refinement 31974 (3099)
Reflections used for Rfree 1536
Rwork 0.206 0.215
Rfree 0.251 0.316
Number of non hydrogen atoms 3560
Protein residues 415
RMS(bonds) 0.007
RMS(angles) 0.841
Ramachandran favoured 91.93 92
Ramachandran outliers 1.71 2.3
Rotamer outliers 0 0
Average B factor 70.0 67.0
Table 4.5 -Validation data comparison of the new search model and the published structure.
Data in brackets represents the high resolution bin.
4.2.6 First potential protein ligand structure
Upon re doing molecular replacement and refinement of the data collected outlined in Table
4.2 with the new search model, an area of interesting unexplained electron density was picked
up in the electron density map of WWP2_6_1. Interestingly the area of additional density
was identified in the in silico predicted binding site 1. The corresponding ligand used for the
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Fig. 4.5 -PDB validation of new search model
WWP2_6_1 soak was the biphenyl tetrol compound NSC2805. Restraints for the ligand was
built in eLBOW and the ligand was fitted into the unexplained density. Owing to the available
axial rotation in the symmetrical biphenyl, one of the rings was modelled to have 2 rotomers
with differential occupancy. The electron density maps of the ligand are shown in Figure 4.6.
The ligand is surrounded by Thr801, Cys802, Arg803, Tyr587, Cys588, Asn586, Leu589
and Thr837. π -π interactions can be observed with Tyr587 at a distance of 4.1 Å. Arg803
forms a π- cation interaction. Putative hydrogen bond interactions are present between the
hydroxyls of NSC2805 and Tyr587, Thr801, Cys 588, Leu589, Tyr581 and Arg803. However,
at a distance of 2.88- 3.64 Å these interactions would be weak as their bond lengths stretch
to the limits of conventional hydrogen bonds. The protein ligand interactions are shown in
Figure 4.7.
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AB
Fig. 4.6 -WWP2_6_1 double difference Fourier electron density map. (A) Electron density
of the ligand and surrounding residues (B) Electron density of the ligand. The rotomer at
0.45 occupancy has a RSCC of 0.61 and the rotomer at 0.55 occupancy has a RSCC of 0.68.
Map contoured at 0.9 σ .
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Fig. 4.7 -Protein ligand interactions present in WWP2_6_1_3. (A) π- π stacking between
Tyr587 and NSC2805. (B) π- cation interaction with Arg803. (C) Possible hydrogen bonds
between the ligand and the surrounding amino acids. (D) Structure comparison of the apo
(blue) and ligand bound (brown) model.
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Data Collection
Wavelength Å 0.9795
Space group P212121
Cell constraints a, b, c
α ,β , γ ,
44.03, 89.73, 111.27
90.00, 90.00, 90.00
Resolution 44.86- 2.05 (2.13-2.05)
% Data completeness(in resolution range) 98.75 (89.24)
Total reflections 159627 (12942)
Unique reflections 28278 (2502)
Multiplicity 5.6 (4.7)
Rmerge 0.1006 (1.846)
Rmeas 0.111(2.079)
<I/σ (I)> 10.86 (0.79)
Wilson B factor 41.67
Refinement
Resolution range 44.86- 2.05 (2.13-2.05)
Completeness 98.75 (89.24)
Reflections used in refinement 27980 (2497)
Reflections used for Rfree 1406 (137)
Rwork 0.23 (0.40)
Rfree 0.30 (0.45)
Number of non hydrogen atoms 3553
Protein residues 415
RMS(bonds) 0.008
RMS(angles) 1.19
Ramachandran favoured 91.44
Ramachandran outliers 2.2
Rotamer outliers 2.94
Average B factor 68.95
Table 4.6 -WWP2_6_1 validation. Data in brackets represents the high resolution bin.
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4.2.7 Optimising of soak experiments to reveal further protein ligand
structures
Optimisation of the protein purification by simply shortening the time from expression to
crystal plate set up resulted in a greater number of crystals (2-4 crystals per plate to 100s per
plate). Owing to the availability a greater number of crystals, we investigated further as to
whether high number of sub- standard data sets was due to either ligand, cryoprotection or
soaking condition effects. Apo crystals were cryoprotected in 10 %, 20 % and 30 % glycerol
(summarised in Table 4.7).
Crystal code Experiment type Glycerol content present in cryoprotectant %
WWP2_27_3 Apo 0
WWP2_27_4 Apo 30
WWP2_28_1 Apo 10
WWP2_28_2 Apo 20
Table 4.7 -Summary of glycerol titration soaking experiments
Crystal code Pipeline Resolution Å
WWP2_27_3 autoProc 2.06
WWP2_27_4 xia2dials 2.13
WWP2_28_1 autoProc 2.15
WWP2_28_2 xia2dials 1.96
Table 4.8 -Summary data collected from glycerol titrations
Crystal code Experiment type DMSO content present in cryoprotectant %
WWP2_31_1 Apo 1
WWP2_32_2 Apo 2
WWP2_32_3 Apo 2
WWP2_33_2 Apo 3
WWP2_33_3 Apo 3
WWP2_33_4 Apo 3
Table 4.9 -Summary of the DMSO soaking experiments
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Crystal code Pipeline Resolution Å
WWP2_31_1 Xia2dials 2
WWP2_32_2 Xia2dials 2.1
WWP2_32_3 autoProc 2.48
WWP2_33_3 autoProc 2.23
Table 4.10 -Summary of the solved data from the DMSO soaking experiments
No trend in data quality was observed when altering the glycerol content in the cry-
oprotectant of apo WWP2 crystals (Table 4.8). 20 % Glycerol nominally gave the best
resolution. All subsequent harvested crystals were cryoprotected with 20 % glycerol. Next
we investigated whether the DMSO content was affecting the quality of the crystal. DMSO
titrations in the cryoprotectant at concentrations of 1 %, 2 %, 3 %, and 5 % were carried
out (summarised in Table 4.9). Up to 3 % DMSO, there was no deterioration in data quality
(Table 4.10). However, visible cracking in the crystals was observed over time upon being
subjected to the 3 % DMSO. We chose to pick 2.5 % DMSO concentration for all future
soaking experiments, as we hypothesised this was the maximum DMSO concentration the
crystals can handle without visible deterioration and loss of data quality, whilst being exposed
to the highest concentration of ligand possible. It should also be noted various crystals forms
were being observed at this point. Four main forms were observed; a square, ‘extended
square’ , hexagonal rod and large irregular blocks, there was no correlation in crystal form,
precipitant solution and data quality.
The new soaking and cryoprotection conditions were used in attempting to improve the
protein ligand structure reported in Section 4.2.6 (Table 4.11 and Table 12).
Crystal code Experiment type Ligand Ligand concentration mM DMSO concentration %
WWP2_34_2 Soak 2805 1.25 2.5
WWP2_34_3 Soak 2805 1.25 2.5
WWP2_34_4 Soak 2805 1.25 2.5
WWP2_35_1 Soak 2805 1.25 2.5
Table 4.11 -Summary of the NSC2805 soaking experiments in the improved soak conditions
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Crystal code Pipeline Resolution Å
WWP2_34_2 autoProc 2.51
WWP2_34_3 Xia2dials 2.00
WWP2_34_4 autoProc 2.06
WWP2_35_1 Xia2dials 2.14
Table 4.12 -Summary of the solved data from the improved soaking experiments
The WWP2_34_3 data set presented two areas of additional unexplained electron density
(Figure 4.8). The ligand was fitted into the density and the models were refined through
iterative rounds of refinement. The ligand was bound to the original site reported in Section
4.2.6, albeit with a lower RSCC of 0.61 and an occupancy of 0.83. Unlike the structure
in Section 4.2.6, a single rotamer was fitted. The ligand was present in the same space
but was found to have a different orientation. The difference in orientation favoured the
intermolecular protein ligand interactions. There are hydrogen bonds with Tyr587, Arg803
and three water molecules. The distances of these hydrogen bonds lie in the more typical
range of 2.5-3.0 Å. There is the π-π stacking interaction with Tyr587 and the π-cation
interaction with Arg803. Again, these distances are closer than in the WWP2_6_3 model
at 3.8 Åand 3.7 Å. The new site was located on the outer surface of the N-lobe, close to an
undefined region of the polypeptide chain. The density fit in this second binding site is much
better with a RSCC of 0.75 with an occupancy of 1.0. The closest residues are Ser395 and
Gly486. There is potential for hydrogen bonds with Ser395 and Gly486. The most likely
interaction being the 2.4 Å hydrogen bond with the nitrogen on Gly486. Figure 4.9 shows
the hydrogen bonds present in the two sites.
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AB
Fig. 4.8 -Double difference Fourier electron density of NSC2805 in WWP2_34_3. (A)
Electron density of NSC2805 in the original site. The ligand has 0.86 occupancy and a RSCC
value of 0.61. (B) Electron density of NSC2805 in the second identified site. The ligand has
an occupancy of 1 and a RSCC value of 0.75. Map contoured at 0.9 σ .
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Fig. 4.9 -WWP2_34_3 protein ligand interactions. (A) Structure of WWP2 HECT with
NSC2805 bound in the two sites. (B) Hydrogen bonds present in the original site. There
are hydrogen bonds between 3 three waters at 2.61 Å, 2.34 Å and 2.41 Å. There is a 3.1 Å
hydrogen bond with Arg803 and a 2.61 Å hydrogen bond with Tyr587. (C) Hydrogen bonds
present in the second site. Gly486 makes a 2.48 Å hydrogen bond and Ser395 makes 2.83 Å
and 3.82 Å hydrogen bonds.
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Data Collection
Wavelength A 0.9763
Space group P212121
Cell constraints a, b, c
α , β , γ ,
44.11, 90.45, 111.93
90.00, 90.00, 90.00
Resolution 55.97- 2.0 (2.07- 2.0)
% Data completeness
(in resolution range) 92.33 (62.96)
Total reflections 305911 (10030)
Unique reflections 28674 (1910)
Multiplicity 10.7 (5.3)
Rmerge 0.093 (1.232)
Rmeas 0.097 (1.355)
<I/σ (I)> 13.89 (1.06)
Wilson B factor 36.17
Refinement
Resolution range 55.97- 2.0 (2.07- 2.0)
Completeness 92.33 (62.96)
Reflections used in refinement 28663 (1909)
Reflections used for Rfree 1422 (79)
Rwork 0.21
Rfree 0.25
Number of non hydrogen atoms 3614
Protein residues 415
RMS(bonds) 0.007
RMS(angles) 1.13
Ramachandran favoured 90.95
Ramachandran outliers 1.47
Rotamer outliers 4.01
Average B factor 60.52
Table 4.13 -WWP2_34_3 validation. Data in brackets represents high resolution bin.
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The resulting structures still left us with a desire to improve the resolution around the
ligand to get rid of any ambiguity. All previous soaks had the ligand incubating with the
crystal for a relatively short time, no longer than 1 hour. Therefore, we tried increasing
the length of the ligand soak for 3 hours in our idealised soak conditions. Soaks with 1 %
DMSO was also carried out in the event of the crystal being unable to tolerate the higher
concentration of DMSO for a long period of time. The longer soaking experiments are
characterised in Table 4.14 and data collected summarised in Table 4.15. The WWP2_38_1
data set showed the ligand in the first binding site, there was no improvement in the quality
of electron density around the ligand (Figure 4.10).
Crystal code Experiment type Ligand Ligand concentration mM DMSO concentration %
WWP2_37_4 Soak 2805 0.5 1
WWP2_38_1 Soak 2805 0.5 1
WWP2_38_2 Soak 2805 0.5 1
WWP2_38_4 Soak 2805 0.5 1
WWP2_39_1 Soak 2805 1.25 2.5
WWP2_39_3 Soak 2805 1.25 2.5
Table 4.14 -Summary of long soak experiments
Crystal code Pipeline Resolution
WWP2_37_4 Xia2dials 3.02
WWP2_38_1 Xia2dials 1.98
WWP2_38_2 Xia2dials 2.32
WWP2_38_4 Xia2dials 2.22
WWP2_39_1 Xia2dials 2.55
WWP2_39_3 AutoProc + STARANISO 2.39
Table 4.15 -Summary of the solved data from the long soaking experiments
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Fig. 4.10 -NSC2805 electron density in WWP2_38_1. One rotomer has an occupancy of
0.41 and a RSCC of 0.62 and the other rotomer has an occupancy of 0.59 and a RSCC of
0.67. Map contoured at 0.9 σ .
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Data Collection
Wavelength A 0.9795
Space group P212121
Cell constraints a, b, c
α , β , γ ,
44.09, 91.22, 112.02
90.00, 90.00, 90.00
Resolution 47.73- 1.98 (2.05- 1.98)
% Data completeness
(in resolution range) 99.85 (99.55)
Total reflections 423628 (39665)
Unique reflections 32253 (3135)
Multiplicity 13.1 (12.7)
Rmerge 0.111 (1.784)
Rmeas 0.1159 (1.859)
<I/σ (I)> 11.68 (1.12)
Wilson B factor 40.35
Refinement
Resolution range 47.73- 1.98 (2.05- 1.98)
Completeness 99.85 (99.55)
Reflections used in refinement 32216 (3129)
Reflections used for R free 1607 (164)
Rwork 0.21 (0.30)
Rfree 0.26 (0.34)
Number of non hydrogen atoms 3627
Protein residues 415
RMS(bonds) 0.008
RMS(angles) 1.15
Ramachandran favoured 91.20
Ramachandran outliers 1.71
Rotamer outliers 2.14
Average B factor 64.63
Table 4.16 -WWP2_38_1 validation table. Data in brackets represents the high resolution
bin.
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4.3 Discussion
Structure based drug design is a prominent method in drug discovery. The structure of a target
protein bound to a small molecule is used to direct the design of subsequent compounds with
the aim of delivering a finalised drug compound into clinical trials. Analysis of the structure
can determine what theoretical molecular entities would increase or decrease favourable
properties such as affinity and specificity. The structure data can be used in not only the
hit to lead stage of drug design, but in lead optimisation. If the compound is found to have
undesirable properties such as low aqueous solubility or a high metabolic turnover, alterations
to the compound can be guided alongside the structure assuring the improved compound
would still accommodate the binding pocket. Generation of protein ligand structures can
also unveil the mechanism behind inhibition. Knowledge of inhibition mechanisms can in
turn lead to new or improved types of inhibitors. The primary method for gaining a protein
ligand structure is through X- ray diffraction. This involves growing suitable protein crystals
which give high resolution diffraction. Compounds can be added before the growing of
the crystal or just before the crystal is harvested. The analysis of the electron density map
reveals whether the chosen compound is bound to the protein. The aim of this chapter was to
solve the first structure of WWP2 bound to an inhibitor to aid the design of more drug like
WWP2 inhibitors. First, apo crystals of WWP2 that would diffract to a high resolution would
need to be produced. Following from this, soaking conditions would be trialled in attempt to
bind the ligand and retain crystal integrity. The quality of the data sets produced from these
experiments would then be used to optimise soaking conditions with a chosen compound.
Initial efforts into the crystallisation of WWP2 was fraught with problems in the purifica-
tion. Attempts to yield pure homogenous WWP2 HECT was unachievable due to the His tag
cleavage problem. Zhang et al reported the purification of this construct, however the detail
reported in the protein purification method was slightly brief. L. Wahl (2016) also reported
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difficulties in the purification and crystallisation of WWP2 HECT. The crystallisation of
the new WW2-2,3 linker HECT construct by Z. Chen (2017) sparked our curiosity as to
whether this protein construct would be easier to purify. It was to our delight when sufficient
quantities of pure protein could be produced and grown into diffractable crystals. The first
round of crystal harvesting yielded apo crystals diffracting with a resolution of 2.74 Å and
2.55 Å, and soaked crystals with a resolution between 2.05- 3.58 Å. No extra density was
picked up in the data sets from the soaked crystals. After increasing the DMSO concentration
in an attempt to see the ligand, we obtained a data set of 1.99 Å resolution. Whilst there
was no extra electron density that could be attributed to a ligand in the double difference
map, we decided to use the data as a new improved search model. It was the generation of
this higher quality search model which lead to additional electron density being picked out.
Three data sets appeared to show the presence of NSC2805 bound (Figure 4.11). Two of the
data sets have the ligand placed in one site, and one data set has the ligand placed in two
different sites. All three structures have the ligand bound in the binding pocket which was
predicted in silico. The additional site, located on the surface of the protein, came into vision
when the concentration of the ligand was increased. The general quality of the protein ligand
structures presented in this chapter leaves room for ambiguity. Where the ligand is placed in
site 1, there is missing electron density around part of the phenyl ring. It is also concerning
there is no density present around the two hydroxys in the upper ring. Where the ligand is
placed in the second binding site, whilst the quality of the electron density fit is better (RSCC
value of 0.75 compared to 0.61 in site 1), it is the nature of the site where the ligand is placed
which brings about speculation. It is placed in the disordered part of the N-lobe, between a
gap in the polypeptide chain which has not been modelled. Therefore there is a chance this
electron density could just be a fragment of the polypeptide chain and not the ligand. There
are limited meaningful interactions between the ligand and the protein at this site. There is
only a 2.48 Å hydrogen bond between Gly486 which is a convincing strong interaction. The
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other potential hydrogen bonds with Ser395 have a distance of 3.82 Å and 2.83 Å would
exist as weak hydrogen bonds. Furthermore this site was not predicted in silico.
The first structure which has NSC2805 fitted in has the ligand placed almost exactly
where it was predicted in silico. The presence of hydrogen bonds, π-π stacking and π-
cation interactions around the ligand strengthen the argument that the electron density can
be attributed to the ligand. Only experiments involving NSC2805 resulted in ligand bound
structures. Protein ligand structures of pleurotin and purpurogallin, reported as inhibitors
in chapter 1, were not obtained. Possible reasons for this could be the binding of these
compound results in a conformational change of the protein, or that the protein requires
a conformational change for binding to happen. If this were the case, co- crystallisation
experiments need to be carried out. The purified protein is incubated with the compound
for a set amount of time, at a given temperature, and then set up for crystallisation. As this
may produce a different crystal form, it is more than likely alternate precipitant conditions
would need to be screened. Alternatively, it could be a higher concentration of ligand is
needed in order to see binding. Due to the compounds being dissolved in DMSO, there
was a compromise in the amount of DMSO the crystal could tolerate and reaching high
concentrations of compound. To alleviate this issue, alternate solvents could be used when
dissolving the chosen compounds. Ciccone et al. (2015) reported a range of alternate solvents
for soaking experiments. Crystals of WWP2 would be tested against these solvent mixtures
to see what can be tolerated. If the crystals could tolerate higher concentrations of these
alternate solvents than DMSO, then higher concentrations of the inhibitors could be reached.
However this is assuming large amounts of solid can be obtained. In the case of some of the
natural products tested in this chapter, this would be a significant challenge.
We felt there was a need to explore other techniques that would strengthen the structural
information. Ligand NMR techniques are common place in drug discovery when developing
114
inhibitors. Therefore we shifted a focus onto using NMR to see whether we could validate a
binding site and inform SAR.
A B
Fig. 4.11 -Electron density map comparison between apo (A) and soaked NSC2805 (B). The
double difference is represented in blue and the single difference represented in green/red.
The single difference density in B could not be attributed to water, and suggests weak density
of the ligand is present.
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Chapter 5
Utilising ligand NMR in the synthesis of
isoalloxane based WWP2 inhibitors
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5.1 Introduction
5.1.1 Discovery of novel WWP2 inhibitors by biochemical approaches
In 2018, we reported the discovery of the first WWP2 inhibitors (Watt et al., 2018). An
ELISA based autoubiquitination assay was used to screen 1593 compounds from the NCI
Diversity Set V and 450 compounds from the NCI Oncology Set V. The assay set up works
by anchoring GST tagged WWP2 FL to glutathione coated wells. UbcH7 charged with flag
ubiquitin is then added to the well and WWP2 undergoes autoubiquitination. The wells are
then treated with an anti- flag HRP antibody conjugate. HRP has the ability to mediate the
hydrogen peroxide dependent oxidation of TMB, resulting in a colour change which can be
read at 450 nm. It is this read out which is used to measure autoubiquitination activity in the
presence of potential inhibitors (Fig 5.1). The initial screen yielded 10 hits and subsequent
concentration dependant assays calculated IC50s ranging from 10.28-0.38 µM.
The next step required confirmation of binding to the catalytic HECT domain via an
orthogonal biophysical technique. STD and CPMG (Carr-Purcell-Meiboom-Gill) NMR
experiments confirmed NSC2805, NSC650438, NSC369066, NSC3064, NSC194308 and
NSC288387 to be binding to the HECT domain. The additional compounds which did not
show binding by ligand NMR does not necessarily mean they are not binding to WWP2, as
only the HECT domain is used for these experiments. Whilst it may be interesting to look at
these compounds in the future, the main focus was to target the HECT domain and prevent
its catalytic activity. The absence of unambiguous crystallographic data to elucidate binding
mechanisms and inform analogue design of these compounds meant alternate techniques
were required. The in silico docking of compounds represents the obvious alternative in
the generation of structural data. The results from in silico docking can be strengthened by
ligand NMR techniques.
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Fig. 5.1 -Schematic of the WWP2 autoubiquitination assay
5.1.2 Ligand NMR
5.1.2.1 STD Epitope maps
STD NMR (descibed in Section 3.1.1.3) can be used to produce ligand epitope maps (Mayer
and Meyer, 2001), assisting in the validation of a computational derived protein ligand model.
Ligand epitope maps reveal the binding mode of the bound ligand in the binding pocket. The
ligand protons which are closer to the protein protons receive more saturation and the relative
STD intensity can be analysed to build the epitope map. Epitopes are derived from the initial
rate of STD build up (STD0), which is calculated by fitting an exponential curve of saturation
time against STD intensity. Once the curve has been fitted, the STD0 for a selected proton
can be calculated using the equation B shown in Figure 5.2. The STD0 value is normalised
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by dividing each value by the largest one. Mapping these values onto the ligand produces the
ligand binding epitope map (Walpole et al., 2019).
Fig. 5.2 -Equations used for calculating ligand epitope maps
5.1.2.2 DEEP STD NMR
Monaco et al. (2017) reported the development of a novel STD NMR technique named
DiffErential EPitope mapping (DEEP), utilising the nature of surrounding amino acids to
validate ligand binding poses, aiding further validation of an in silico model. Orientation of
aliphatic, aromatic and polar amino acids around the binding sites can be determined. DEEP
STD works on the basis of selectively saturating a particular type of proton environment and
if that type of proton is present in the binding site, ligand protons close to those particular
residues will receive more saturation relative to protons close to other residues. STD data sets
are acquired at two different on-resonance frequencies. A comparison of aliphatic against
aromatic residues is done by running an on-resonance experiment at 0.6 ppm (aliphatic) and
a second on-resonance experiment at 6.55 ppm (aromatic). The DEEP STD factor for each
proton is calculated by the STD intensity ratio of the two experiments, minus the average
ratio. A positive factor indicates the ligand protons are close to an aliphatic region, whilst
a negative factor indicates the protons are close to aromatics. Proximity to polar residues
are calculated by use of differential solvents as opposed to differential saturation frequency.
The first DEEP STD experiment is performed in D2O and the second in H2O. The ∆STD
is calculated as previously mentioned. Polar protons have the ability to exchange with the
solvent, therefore the polar residues will contain deuterium in the D2O experiment, which is
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inactive in NMR and protons in the H2O experiment, which are active in NMR. Interpretation
of calculated ∆STD from these experiments means negative value indicates ligand protons are
close to polar residues as the STD signal in the H2O experiment would be stronger (Monaco
et al., 2017)(Walpole et al., 2019).
Fig. 5.3 -Equation used to calculate the DEEP STD factor
5.1.3 Experimental aims
Early hit- to- lead development of compounds in drug discovery is when initial hits are
improved to have higher affinity and greater selectivity to the target. By using the techniques
described, a computational derived NMR validated protein ligand model can be established.
NSC288387 was picked out from the 10 initial WWP2 inhibitor hits for further analysis as
it gave the clearest STD signals, suggesting a clear binding epitope map could be built and
used to inform analogue development. NSC288387 is a flavin compound consisting of a
tricyclic isoalloxazine core with a N-substituted phenyl ring.
The NMR validated in silico model can then to be used to drive analogue design and
synthesis, with the aim of bringing the ligand activity down to the sub micromolar range.
IC50s of the synthesised analogues are to be initially generated for WWP2. This information
can be used to investigate SAR for a putative binding site. Activity is then to be tested against
Nedd4 to test for specificity.
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Fig. 5.4 -Structure of NSC288387
5.2 Results
5.2.1 In silico modelling of NSC288387 into WWP2 HECT
The WWP2 HECT (aa 486-865) crystal structure (PDB:4Y07) was used as the model for
docking NSC288387. NSC288387 was docked into the 1st site as described in Section 4.2.1.
We predicted this to be the most likely binding region due to the mechanistic relevance the
site holds. As the site lies close to the hinge loop sitting in the interface of the N and C lobe,
it was theorised targeting this region would hinder the HECTs intrinsic flexibility required for
transferring ubiquitin from the N-lobe bound E2 to the catalytic cysteine in the C-lobe. The
lowest energy solution is shown in Figure 5.5. All docking calculations were performed in
collaboration with Dr Jesus Angulo, Dr Sam Walpole and Dr Serena Monaco in the School of
Pharmacy at UEA. The docking solution shows the compound sitting in the interface of the
N and C lobe, close to the hinge loop. The surrounding residues are His569, Tyr587, Asp623,
Leu795, Thr799, Thr801, Arg803, Pro805, Val806, Glu811, Leu812, IIe813 and Asn840.
There is a 1.9 Å hydrogen bond from Val806 to the methoxy on NSC288387. The carbonyl
on the N substituted ring makes a 2.28 Å hydrogen bond to Arg803. There is potential for π-
π stacking from Tyr587 and the N substituted phenyl ring, however at a distance of 4.61 Å,
this is stretching beyond the limit of conventional π- π interaction distance (Brylinski, 2018).
121
AB
122
CFig. 5.5 -NSC288387 docked into WWP2 HECT. The N and C lobe are shown in blue and
orange respectively, the hinge loop shown in green. (B) Closer view of NSC288387 sitting
in the predicted binding site, the N-substituted phenyl ring is facing in towards the central
cavity of the protein. (C) Labelled residues located around the compound.
5.2.2 NMR validation of the WWP2:NSC288387 in silico model
Ligand NMR was then used to assess the viability of this proposed model of binding. WWP2
HECT was expressed and purified as stated in Section 3.2.1.1. The purified protein was
exchanged into 25 mM deuterated Tris-Cl pH 8.9, 100 mM NaCl and 1 mM deuterated
DTT made up in D2O. All ligand NMR experiments were run with 20 µM protein and 100
µM ligand. Binding epitope mapping and DEEP STD NMR analysis was performed in
collaboration with Dr Jesus Angulo, Dr Sam Walpole and Dr Serena Monaco. The binding
epitope map was obtained by normalising the STD signals (%) against the strongest signal
(Ha). The comparison of the binding epitope map with the structural model is in excellent
agreement. The N-substituted phenyl ring, which is predicted to be sitting deeper into the
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pocket, shows to have the strongest interactions. The aliphatic ether chain shows weaker
interactions, which would suggest the chain is solvent exposed, this is clearly evident in the
structural model.
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Fig. 5.6 -Ligand epitope map of NSC288387 bound to WWP2 HECT (A) Labelled hydrogens
of NSC288387. (B) 2D schematic of the ligand epitope map (Adapted from Watt et al.). (C)
3D representation of the ligand epitope map in context with the predicted binding site.
DEEP STD data was obtained by irradiating WWP2 HECT at 0.5 ppm and 1.5 ppm.
Irradiation of the protein at frequency at the 0.5 ppm corresponds to the methyl groups
of valine and isoleucine, and irradiation at the 1.5 ppm frequency corresponds to the β / γ
arginine protons. These irradiation frequencies were chosen due to the presence of Arg803
and Val806 in close proximity to ring A. Both these residues were singled out as they could be
targeted without overlapping with the ligand frequencies, such as aromatic frequencies. The
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Hydrogen STD% Normalised STD %
a 15.51 100
b 11.57 75
c 11.02 71
d 10.09 65
e 4.95 32
f - -
g 7.53 49
h 13.79 89
i 12.63 81
j 13.01 84
Table 5.1 -WWP2 HECT: NSC288387 STD epitope values. Relative intensity descriptions
are given as 80-100 %= strong, 60-79 %= medium, <60 %= weak.
DEEP STD factor for each hydrogen was calculated as stated in section Section 5.1.2.2 where
0.5 ppm and 1.5 ppm is Exp1 and Exp2, respectively. Positive DEEP STD factors correspond
to interactions at the 1.5 ppm frequency and negative values correspond to interactions at
0.5 ppm frequency. Protons a and b gave a positive signal, and inspection of the model
reveals those protons to be orientated towards Arg803. Protons c, d and e are predicted to be
orientated towards Val803, and they satisfyingly all give negative DEEP STD factors.
Hydrogen STD % 0.5 ppm STD % 1.5 ppm DEEP-STD factor
a 13.66 15.66 0.258
b 11.35 12.76 0.236
c 9.25 5.46 -0.298
d 9.9 6.2 -0.262
e 6.08 4.28 -0.183
f - - -
g 7.61 6.99 0.030
h 12.39 11.46 0.037
i 13.53 14.2 0.161
j 13.14 11.92 0.019
Table 5.2 -WWP2 DEEP STD factors
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Fig. 5.7 -DEEP STD factors for 288387 bound to WWP2 HECT
5.2.3 In silico modelling of NSC288387 into WWP1 HECT
WWP1 HECT shares 83.6 % (Uniprot alignment) sequence homology with WWP2 HECT.
For this reason, it is unsurprising that the putative binding pocket is also present in WWP1.
To investigate whether NSC288387 is predicted to bind differently in WWP1, it was docked
into the WWP1 HECT domain (pdb: 1ND7). The WWP1 binding cleft is narrower than
in WWP2, requiring an induced fit docking method. NSC288387 has the same bound
orientation as predicted in WWP2, with the N-phenyl ring pointing towards the central cavity.
The surrounding residues are Asn638, Tyr639, Cys640, Asp675, Thr851, Thr853, Arg855,
Met865 and Asn892. There are hydrogen bonds between Thr853, Cys640 and Asn638 with
the carbonyls on the tricyclic core. Arg855 makes a hydrogen bond with the oxygen in the
methoxyethyl side chain. Tyr639 forms a π-π stacking interaction with ring A of the tricyclic
core. Arg855 has the potential to form a π-cation stacking interaction with the aromatic
rings.
5.2.4 NMR validation of the WWP1:NSC288387 in silico model
As with WWP2, ligand NMR was used to validate the proposed model. The DNA sequence
corresponding to the WWP1 HECT domain (aa 546-917) lacking the 5 C-terminal residues
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was cloned into the pET28a vector. The protein was expressed as an N-terminal hexa-His
tag construct. The protein was purified using Ni-NTA column and was dialysed into 5mM
Tris Cl pH 8.0, 5 mM DTT. The protein was exchanged into the deuterated version of buffer
for NMR experiments. As with WWP2, 20 µM of HECT to 100 µM ligand was used. The
binding epitope shows the N-phenyl ring to have the strongest interactions, consistent with
the prediction of the ring sitting deeper in the pocket. The more solvent exposed part of the
tricyclic core and the methoxyethyl chain have weaker interactions.
Fig. 5.8 -Ligand epitope of NSC288387 when bound to WWP1 HECT
Hydrogen STD% Normalised STD %
a 45.37 100
b 40.35 89
c 31.01 68
d 26.68 59
e 23.59 52
f - -
g 28.12 62
h 42.79 94
i 44.49 98
j 44.06 97
Table 5.3 -WWP1 HECT: NSC288387 STD epitope values. Relative intensity descriptions
are given as 80-100 %= strong, 60-79 %= medium, <60 %= weak.
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DEEP STD data was obtained by irradiation of WWP1 HECT at 0.5 ppm and 1.5 ppm.
The DEEP STD factor for each hydrogen was calculated in the same manner as WWP2
in Section 5.2.2. The DEEP STD factors showed good agreement with the docked model.
Proton b and c on ring A have positive values and are close to Arg855. Protons d, e and
g have negative values and the model shows the aliphatic chain pointing towards Leu855.
Even though the DEEP STD factors are in good agreement, their values are much lower than
compared to WWP2. We could not validate the docked model with as much confidence as
WWP2 though inspection of the model predicts these irradiated residues to be further from
the ligand than in WWP2, giving a possible reason as to why the values are particularly low.
Hydrogen STD % 0.5 ppm STD % 1.5 ppm DEEP-STD factor
a 48.57 47.63 -0.0163196
b 41.96 41.96 0.05862373
c 34.58 36.25 0.10691755
d 34.18 28.12 -0.1186729
e 27.58 23.14 -0.1023625
f - - -
g 33.2 29.18 -0.0624606
h 48.57 44.93 0.03927022
i 50.51 49.05 0.02971857
j 47.63 47.17 0.04896595
Table 5.4 -WWP1 DEEP STD factors
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Fig. 5.9 DEEP STD factors for 288387 bound to WWP1 HECT
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5.2.5 In silico modelling of NSC288387 into Nedd4 HECT
NSC288387 was docked into the putative binding site between the N and C lobe of Nedd4
HECT. As with WWP1 and WWP2, the binding pose is analogous with the N-phenyl ring
pointing inwards. The surrounding residues are Phe594, Asp653, Phe655, Leu780, Glu818,
Arg822 and Gln825. Arg822 and Gln825 form hydrogen bonds with the carbonyls on ring C.
Phe594 is orientated to make π-π stacking interactions and Arg822 is in a position to form
π-cation interactions. As with the WWP1 and WWP2 HECT domains, we wanted to validate
this model by STD epitope maps and DEEP STD, The DNA sequence corresponding to the
Nedd4 HECT domain was cloned in the pET28a plasmid. Trial induction conditions were
screened across Rosetta (DE3), BL21 (DE3), BL21 Star (DE3), CodonPlus RP and pLys at 20
oC, 25 oC and 30 oC. The optimal condition which gave the highest Nedd4 HECT expression
relative to unwanted bacterial proteins was 30 oC overnight in the BL21 Star (DE3) cell
line. The protein was expressed with a N-terminal 6His- tag and was purified as described
in Section 2.1.2.3. Nedd4 HECT was dialysed into HEPES buffer. Due to difficulties in
concentrating, we were unable to buffer exchange into deuterated buffer. Therefore, STD
experiments were run in 50:50 HEPES: Tris in D2O at a protein concentration of 20 µM. We
were unable to generate interpretable data from these conditions.
5.2.6 Design of NSC288387 analogues
Owing to the fact that the ligand NMR data suggested the N-aryl ring had the strongest
contacts and was sitting deepest into the putative binding site, it seemed the most logical
place to make alterations that would have an effect on activity. A range of substitutions on
the ring were designed and docked into the binding site (Table 5.5). The selected compounds
were ranking according to the addition of any positive interactions. The extension of the
N-phenyl ring into the pocket by the insertion of a short alkyl chain had the best predicted
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binding. Para substitution ranks higher than ortho and meta substitution, with the para
substitutions causing the compound to sit in a different orientation, deeper into the pocket. A
synthetic methodology was devised which would make the isoalloxazine core, from which
various N-substitutions could be made. The first strategy to synthesise the isoalloxazine
was devised according to Carell at al. Starting from 2-nitroaniline, the amino would be
protected with a trifluoro acetyl group using trifluoracetic anhydride. The amine would then
be alkylated via an SN2 reaction and the protecting group removed in a single step. The
reduction of the nitro and ring cyclisation using alloxane monohydrate would happen in a
one pot two step reaction. This would give rise to the tricyclic isoalloxazine core, leaving the
ability for N-C coupling reactions to afford the N-(hetero)aryl analogues.
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Rank Substituent Rank Substituent
1 8
2 9
3 10
4 11
5
6
7
Table 5.5 -Ranked analogues
5.2.7 Organic synthesis
5.2.7.1 Amine protection and alkylation
Compound 12 was first protected with a trifluoroacetyl group. The aniline undergoes a
nucleophilic addition-elimination reaction with trifluoroacetic anhydride. The reaction was
stirred in dichloromethane at 0 oC for 2 hours to afford 13 in 87 % yield. The alkylation of the
NH was achieved by heating 13 with excess 1-bromo-2-methoxyethane, in the presence of
potassium carbonate at 100 oC overnight, to give the desired product in 56 % yield. Mixtures
of mono alkylated and di alkylated products were obtained and separated. We tried directly
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alkylating 12 to 14 in the same conditions. However, LCMS only showed a 1 % conversion to
the product. Due to the start of the synthesis already being relatively inefficient, an alternative
method to make compound 14 was carried out.
Fig. 5.10 -Scheme7. Reaction conditions: (i) (CF3CO)2O, DCM, 0 oC for 2 hours, 87 %. (ii)
1-bromo-2-methoxyethane, K2CO3, DMF, 100 oC overnight, 56 %.
5.2.7.2 Nucleophilic aromatic substitution
Aryl rings with electron withdrawing groups ortho or para to a leaving group can undergo
nucleophilic aromatic substitution via the SNAr mechanism. Ortho and/or para electron
withdrawing groups, such as the nitro group, are necessary in the formation of the resonance
stabilised Meisenheimer complex prior to the elimination of the leaving group. As the
methoxyethylamine group in 14 is ortho to the nitro, we could start from fluoronitrobenzene
and perform an SnAr reaction with 2-methoxyethylamine to produce 14 in 90 % yield.
Fig. 5.11 -Scheme 8 Reaction conditions: (i) 2-methoxyethylamine, NaCO3 in ethanol, 80
oC overnight, 90 %.
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5.2.7.3 Reduction of nitro group and condensation with alloxan monohydrate
The reduction of the 14 to 16 was done by hydrogenation with Pd/C catalyst. Once the
complete conversion to the aniline was observed by LCMS, the condensation reaction with
alloxan monohydrate was carried out without isolation of the aniline. The tricyclic isoalloxine
core 17 was isolated in 53 % yield. The reaction was assumed to be regioselective to give the
single isomer 17 by literature precedent (Epple et al., 1997) (Lacroix et al., 1987).
Fig. 5.12 -Scheme 9. Reaction conditions: (i) Reduction of nitro to amine. H2, Pd/C in acetic
acid, material was carried through to the next synthetic step without further purification. (ii)
Ring formation. Boric acid and alloxan monohydrate in acetic acid, 53 % yield.
133
5.2.7.4 Chan- Lam coupling
Attenberger et al.(2008) reported the N-arylation of flavins using a method under Chan- Lam
conditions. First reported in the simultaneous publications by Chan and Lam, the Chan-
Lam reaction is a cross coupling reaction between aryl boronic acids and amines, catalysed
by copper acetate. Unlike conventional transition metal cross coupling which consists of a
nucleophile and an electrophile (such as organoboron and an organohalide), the Chan- Lam
couples two nucleophiles, organoboron and an amine (Fig 5.13). The Chan- Lam coupling is
an appealing route to N-C coupling owing to its mild conditions. Initially, the phenyl boronic
acid was coupled with 17 in 57 % yield. Giving the moderate yield, we proceeded with the
coupling of range of substrates which represented the scope of the designed compounds in
Table 5.5. A summary of substrates tested with yields is shown in Table 5.6. Yields varied
from 4-57%, with the majority of yields <20% and a number of substrates not working. The
highest yield came from the unsubstituted phenyl boronic acid, any additional substitutions
dramatically lowered the yield. Despite the low yields, at least 20 mg of product from
each successful reaction was obtained, when only approximately only 1 mg was need for
biological testing. Reactions with substituents in the ortho position did not work.
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Fig. 5.13 -Scheme 10. Reaction condition: (i) R-B(OH)2, Cu(OAc)2 and triethylamine in
DMF.
Compound R Yield %
18 57
19 19
20 6
21
Cl
4
22 5
23 17
24 13
25 11
Table 5.6 -Chan Lam substrate yields
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Fig. 5.14 A simplified Chan Lam catalytic cycle. The copper species complexes with the
amine and boronic acid through ligand exchange and transmetallation. There was significant
ambiguity as to whether the coupling by reductive elimination proceeds through Cu(II) Cu(0)
or Cu(II) Cu(III) Cu(I) Cu(0). Recent mechanistic studies suggests it goes through the latter
(Vantourout et al., 2017).
The NSC288387 WWP2 in silico model shows a large amount of space surrounding
ring A. Both Arg803 and His569 can make aromatic interactions with NSC288397, there-
fore subsitutuents on ring A could have an impact on the strength of this interaction. We
therefore attempted to design in electron activating and deactivating groups. Hydroxyl and
trifluromethyl were chosen as they would not only add additional hydrogen bonds, but also
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alter the π-cation interaction. 3-Fluoro-4-nitrophenol underwent an SnAr reaction with
2-methoxyethylamine to give compound 27 in 61 % yield.
Fig. 5.15 -Scheme 11. Reaction conditions: (i) 2-methoxyethylamine, Na2CO3 in ethanol,
80 oC overnight, 61 %.
However, attempting to reduce the nitro and form the tricyclic core with the conditions
used previously, did not work.
Fig. 5.16 -Scheme 12. Failed reduction and cyclisation.
We did however have much better sucess with the trifluromethyl analogue. 4-Fluoro-3-
nitrobenzotrifluoride was reacted with 2-methoxyethylamine to give compound 29 in 86 %
yield.
Fig. 5.17 -Scheme 13. Reaction conditions: (i) 2-methoxyethylamine, NaCO3 in ethanol, 80
oC overnight, 86 %.
The reduction of the nitro by H2 over Pd/C was monitored by LCMS until completion, but
as with 16, the intermediate amine was not isolated and the crude was reacted with alloxane
monohydrate to give 31 in 9 % yield.
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Fig. 5.18 -Scheme 14. Reaction conditions: (i) H2, Pd/C in acetic acid, material was carried
through to the next step without further purification. (ii) Boric acid and alloxan monohydrate
in acetic acid, 9 % yield.
The Chan Lam coupling of compound 31 with phenylboronic acid gave the target com-
pound 32 in 64 % yield.
Fig. 5.19 -Scheme 15. Reaction conditions: (i) Benzene boronic acid, Cu(OAc)2 and triethy-
lamine in DMF, 64 % yield.
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5.2.8 Testing of analogues against WWP2 autoubiquitination
NSC288387 analogues were tested for in vitro WWP2 autoubiquitination inhibitory activity
by using the assay reported in Watt et al. Concentration dependent assays with compounds
at 100 µM, 50 µM, 25 µM, 10 µM, 5 µM and 1 µM at 1 % DMSO-d6 were performed.
Levels of autoubiquitination were measured as the relative activity percentage of the full
autoubiquitination reaction. Curves were generated using the non linear regression of
inhibitor concentration versus normalised response. The addition of a chloro substituent
meta to the isoalloxazine ring produced the greatest improvement in activty. NSC288387
had an IC50 of 2.3 µM, whilst the addition of the chloro increased the activity 10 fold
to 0.23 µM. Removal of the phenyl ring results in loss of activity with both the original
tricyclic core and the trifluormethyl substituted version. Removal of the ring in both versions
decreases the potency by at least 10 fold. Adding the strongly deactivating trifluormethyl
group to the A ring of the isoalloxazine core decreased its activity approximatly 3 fold to 6.68
µM. The electron donating groups methyl and methoxy had negative effects on the original
compounds activity, whilst the electron withdrawing groups chloro, fluoro, nitrile, methyl
ester improved activity. It was assumed addition of electron withdrawing groups in the para
position were having a positive effect. However, the most strongly electron withdrawing
group, the trifluoromethyl, reduces the compounds potency down to 7.43 µM.
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Fig. 5.20 -WWP2 autoubiquitination IC50 curves
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Name Structure IC50 µM
17 33.06
19 117.8
20 0.31
21 0.23
22 7.43
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Name Structure IC50 µM
23 0.55
24 0.55
25 4.26
31 20.31
32 6.68
Table 5.7 -NSC288387 analogue WWP2 autoubiquitination IC50’s
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5.2.9 Testing of compounds against Nedd4
To determine specificity and to help identify lead analogues, it was important to test the
compounds against other Nedd4 ligases. Assays testing in vitro autoubiquitination for WWP1
and Nedd4 has previously been developed in the Chantry lab. The Nedd4 autoubiquitination
assay is analogous to the WWP2 assay, with GST-Nedd4-FL being used. IC50s were
generated in the same way as for WWP2 stated in Section 5.2.8. The most potent analogue is
the methyl ester variant with an IC50 of 0.6 µM. The least potent analogue is the methoxy
variant with an IC50 of 88.57 µM. The analogues follow a similar trend as was seen
with WWP2, where generally deactivating subsitituents improve the potency and activating
substitutents decrease the potency. As with WWP2, removal of the N-phenyl ring has a
negative effect on activity. Addition of the trifluoromethyl group on ring A of the tricyclic
core has little effect on the IC50. The improvement in IC50s is lower compared to WWP2.
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Fig. 5.21 -Nedd4 autoubiquitination IC50 curves
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Name Structure IC50 µM
17 2.08
19 88.57
20 0.92
21 1.29
22 0.92
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Name Structure IC50 µM
23 1.1
24 0.60
25 34.6
31 10.05
32 2.74
Table 5.8 -NSC288387 analogue Nedd4 autoubiquitination IC50’s
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5.3 Discussion
Gaining insight as to where inhibitors bind to proteins is a crucial part of the drug design
process. To improve aspects such as potency and specificity, one must know the nature of
the environment around the inhibitor. Once this is known, modifications can be designed
into the selected compound. Neighbouring amino acids can be targeted for selected non
covalent interactions in order to improve potency. The physical space around the compound
can be viewed and used to fill with desirable moieties which would improve a compounds
characteristics. Crystallographic data of a compound bound to its target is the pre-eminent
method to achieve this. However in the absence of unambiguous crystal data, other methods
must be used in order to distinguish how an inhibitor is binding. The aim of this chapter
was to elucidate a binding site in the WWP2 HECT domain which can be targeted by
small molecules, with limited use of crystallographic data. Once this had been achieved,
modifications to NSC288387 were made with the intention of improving potency and to
begin to shed light on structure activity relationships against WWP2 autoubiquitination.
The synthesised analogues were then to be tested against other Nedd4 ligases to determine
whether any degree of specificity had been acquired. The data received from this could
then be used to inform further analogue development, or to select the best analogue and
begin cellular based experiments. An alternative in gaining a structural view into inhibitor
binding is using in silico methods. We computationally mapped the WWP2 HECT domain
for suitable sites for binding. The site is identified by its appropriate size to accommodate
small molecules and its accessibility. The putative binding site had biological relevance
in terms of a mechanistic view, as it was located on the boundary of the N and C lobe, in
close proximity to the hinge loop. The conformational flexibility between the N and C
lobe of the HECT domain underpins its ability to transfer ubiquitin. We could therefore
theorize ligands bound in this location could prevent the transfer of ubiquitin over to the
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catalytic cysteine in the C lobe. The compounds identified by the Chantry lab (Jessica Watt
2018) were tested using the WWP2 FL autoubiquitination assay. Once the HECT domain
was confirmed as the target domain for the compounds, we chose to focus on the inhibitor
NSC288387. This compound was docked into the putative site. Inspection of the contacts
around NSC288387 yielded positive results. Meaningful interactions in the form of hydrogen
bonds, π-π and π-cation interactions were present. The absence of these interactions would
have cast early doubt on the feasibility of this model as these intermolecular forces can
be the driving force behind ligand binding events. In order to validate the in silico model,
empirical data was needed. Ligand NMR offered the most appealing technique as epitope
maps of the compounds could be built, and the newly invented DEEP-STD NMR technique
can utilise the nature of the surrounding polypeptide chain to gain insight into how the
ligand is binding. The epitope map of the compound matched in excellent agreement with
the proposed model. The strongest contacts were observed on the N-phenyl ring, which
was sitting deeper in the central cavity. The weakest contacts were found on the solvent
exposed regions of the ethyl methoxy chain. It was clear from our NMR validated in silico
model that the N-phenyl ring was sitting deepest in the binding pocket of the protein. The
ligand epitope map showed the strongest contacts on that phenyl ring. Therefore, we felt any
modifications to that ring had the greatest potential to form, or alter, meaningful interactions
with the polypeptide chain. From a synthetic chemistry point of view, we felt modifications
to that ring was the easiest way to quickly build up a small library of analogues. This was
because we could first have a general route to make the tricyclic isoalloxazine core on a
multi gram scale, and then derivatise using the common intermediate. The first attempted
route to the isoalloxazine core started from the 2-nitroaniline. The amine underwent an SN2
reaction with 1-bromo-2-methoxyethane, albeit in a convoluted fashion as a trifluoroacetyl
group was added onto the amine first, and then removed in the SN2 reaction. The reaction
with the just the primary amine and 1-bromo-2-methoxyethane did not proceed, indicating
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the trifluoroacetyl group played an important part in making the reaction go to completion.
The most likely reason for this was that it increases acidity and promotes alkylation. Once
the alkylated nitro aniline was attained, the two step, one pot reduction and condensation
reaction yielded the isoalloxazine intermediate. However, we were not satisfied with the route
used, feeling the initial protection with trifluoroacetyl was unnecessary, and the SN2 reaction
was a relatively poor reaction with the production of side products and low to moderate
yield. Upon re-evaluation of the synthetic strategy, it seemed obvious the most efficient
approach would be to start from the 2-fluoronitrobenzene and form the desired amine via
SNAr reaction. The very nature of the fluoro ortho to the nitro group meant this reaction
would have a high chance of going to completion. To our delight, the reaction proceeded
with ease meaning we could run the reaction on a decagram scale, and using the previously
described reduction and condensation, giving us access to 15 g of the key intermediate. The
conditions for the N- aryl coupling with flavins had previously been reported, using the
Chan Lam system. The first reaction with the unsubstitued phenylboronic acid gave the
NSC288387 compound in moderate yield, suggesting the feasibility of this system to give
us fairly rapid access to a multitude of analogues. To our disapointment, any variations to
the arylboronic acid dramatically decreased the yield to under 20 %. The very low yield for
some of the analogues did not present itself has a major issue at this point, as only very small
quantities of compound was needed for testing and it was envisaged reaction optimization
for any leading analogues would be done further down the pipeline when greater quantities
would be needed. The success rate of the reaction working hovered around 50 %, meaning
some of the target compounds were not synthesised. Whilst this was of some concern, we
had enough compounds to begin biological testing and investigate whether there was any
early indication of SAR. It is a crucial point in hit to lead optimization that the SAR is not flat
Flat SAR would indicate the compound is too difficult to optimize or the compound is not
truly a non covalent inhibitor. Synthesised compounds were tested using the in vitro WWP2
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Fig. 5.22 In silico structure of compound 21 docked into the binding site.
autoubiquitination assay developed in our lab. The assay effectively mimics the enzymatic
cascade of E1, E2 and E3, and the rate of WWP2 autoubiquitination can be quantified via
an ELISA readout. The NSC288387 analogues showed significant differential alterations
in inhibitory activity. Compound 21 with the meta chloro substituent on the N-phenyl ring
showed the greatest increase in activity to 0.23 µM. Inspection of the docked model for
this compound showed an additional protein ligand interaction. The chlorine atom forms
a 3.4 Å halogen bond with either the carbonyl or hydroxy on Thr799, depending on the
orientation. The ten fold increase in activity could possibly be attributed to the formation of
this additional interaction (Fig. 5.22).
Analysis of the compounds for their inhibition against Nedd4 autoubiquitination showed
a similar trend as to WWP2. Whilst there was some difference in activity of the chloro
substituent, there is still fairly significant inhibition for Nedd4. The similar trend in SAR
strengthens the theory of where these compounds are binding in the HECT domain. Gaining
specificity towards WWP2 remains a significant task due to the high homology in amino
acid sequence. However, gaining absolute specificity towards a single ubiquitin ligase may
not necessarily be paramount; one can look towards the current drug targeting the ubiquitn
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system. Bortezemib inhibits the proteasome, which lies at the end of the protein degradation
system, is an approved drug for multiple myloma and mantle cell lymphoma. Targeting the
proteasome offers little pathway specificity and potential leads up the build up of unwanted
proteins. The main issue with this treatment is the potential serious side effects a patient
can experience. Despite this, it still an efficacious treatment for cancer. As the E3 ligases
confer the most specificity in the pathway, potentially only hitting other ligases in the small
Nedd4 family may bring significantly less side effects than targeting the proteasome. The
most obvious next step with these compounds is to start testing them in cells. Information on
cell permeability and whether the compounds are hitting the target in cells is critical. One
possible experiment would be to do a immunoprecipitant assay and look for levels of WWP2
substrate levels. Levels of WWP2 substrates could be analysed by western blotting and they
would be expected to decrease over time, in the presence of an inhibitor it would be expected
the substrate levels remain the same. Using different concentrations of compounds would
determine what concentration the compounds are active in cells. These set of compounds
could also be developed into PROTACs. These set of compounds would be linked with
a target inhibitor such as the BET bromodomain ligand JQ1. The WWP2 inhibitors offer
an alternate to the current limited number of PROTAC E3s (mainly VHL and celebron).
Alternatively, a current E3 PROTAC could target WWP2. Girardini et al reported E3 ligases
hijacking each other. As our WWP2 inhibitors may not be as potent as other E3 inhibitors
(µM vs nM), utilising the inhibitors as PROTACs to remove WWP2 may potentially be more
effective than using the lone WWP2 inhibitors.
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Chapter 6
Final Discussion
152
6.1 Introduction
WWP2 is part of the Nedd4 family of HECT ubiquitin ligases. The role of the highly
homologous Nedd4 family of HECT ligases in disease is becoming increasingly prevalent.
WWP2 targets important oncogenic pathway modulators such as Smads and Pten. Targeting
WWP2 for inhibition by a small molecule could have profound therapeutic potential. There
is a distinct lack of research into the development of HECT ubiquitin ligase inhibitors.
Moreover, there is relatively little research into WWP2 in the context of drug discovery. This
thesis aimed to first develop platforms for which small molecule inhibitors can be discovered
which target WWP2. Once several inhibitors, or ligands, had been identified, elucidating
the binding pocket was achieved by a combination of X-ray crystallography, data obtained
from ligand NMR, molecular docking and structure activity relationship analysis. Lead
compounds have emerged which have the potential for further development into a drug like
compound, with possible therapeutic properties.
6.2 Gaining a starting point
When this research was started, there were no lead WWP2 inhibitors. There was also no
biophysical or biochemical assays developed for WWP2 that would be suitable to detect
small molecule binding. Therefore, it was important to implement a screening strategy that
would be suitable for WWP2 and generate a series of compounds that could be taken further
down the drug discovery pipeline. Thermal shift was the first technique chosen to screen
compounds. Thermal shift offered the most appealing method as it was a simple set up and
could be readily run on qPCR machines. Using the HECT domain of WWP2, over 2000
compounds were screened resulting in 11 compounds being identified as possible ligands.
Validation of these compounds through STD NMR resulted in NSC35676 and NSC401005
as binders. The other identified compounds shouldn’t be completely ruled out, as the NMR
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results were inconclusive due to the poor quality of data. The poor quality of data may
simply be due to the low aqueous solubility of the compounds. The concentration of the
compounds could not be increased without increasing the DMSO concentration. Increasing
the DMSO concentration caused the protein to precipitate out of solution. It was felt the
confirmation of binding could be run on more sensitive techniques which required less
compound. Surface plasmon resonance gave us an opportunity to validate binding, study
kinetics and to develop another high throughput screening platform for WWP2. The initial
experiments were promising, with already known WWP2 ligands (note: SPR experiments
were chronologically done later) showing binding. However, the follow up experiments gave
much more inconclusive results when attempting to run concentration dependent assays.
A possible reason for this is the presence of DMSO required in the buffer. DMSO has a
high refractive index, which can interfere with the SPR signal. So whilst SPR may have its
benefits as a method to detect ligand binding, there is still scope for method development so
it could be used for kinetic experiments or high throughput screening.
6.3 The PAIN argument
In 2010, Jonathan Baell coined the term ‘Pan Assay Interference’ compounds, also known
as ‘PAINs’. PAINs are as the name suggests, promiscuous compounds which appear in
multiple assays as false positives. These compounds are often reactive with elements in
a screening assay. Some mechanisms by which they interfere include reactivity with any
nucleophiles in a bioassay, non-specific reactivity with the protein, redox activity or there may
be even be no proven mechanism. A more comprehensive description of these interference
mechanisms are found in Dahlin et al. (2015). Compounds can have PAIN or close similarity
moieties but still be biologically active. There are still FDA approved compounds which
could visually be classed as a PAIN. During this research, we were aware that some of our
hit compounds could be classed as a ‘PAIN’. We were however confident that our empirical
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data from several orthogonal assays proved that the compounds were in fact true binders.
Whilst working on the synthesis of the NSC288387 analogues, a particular research paper
was made aware to us regarding the possibility of the compound being a PAIN. The paper
in question (Raoof et al., 2013) reported the compound series toxoflavins and deazaflavins
as small molecule inhibitors for a particular therapeutic target. Both are structurally similar
and exhibited clear structure activity relationship. However, the toxoflavin series exhibited
redox activity and produced hydrogen peroxide, proving this would be a troubling series to
follow up in further experiments. What was to our concern was the structural similarities
between NSC288387 and the toxoflavins. Even though we were confident that NSC288387
was a true ligand, due to the convincing NMR data, we sought to check for any possible
redox activity. We set up an assay based on P.A. Johnston et al. (2011) which tests for
hydrogen peroxide generated by redox cycling compounds in the presence of reducing agents
(Fig. 6.1). It works through the hydrogen peroxide dependent HRP mediated oxidation of
phenol red. The change in absorbance of phenol red can be measured at 610 nm. After a
concentration dependent assay with NSC288387 was run, it was found the compound does
produce hydrogen peroxide, but only at the higher concentrations. The concentration at
which this compound was discovered as an inhibitor was at 10 µM. Therefore a concentration
dependent experiment with hydrogen peroxide was run to investigate what concentrations
of H2O2 is needed to affect the biochemical assay. An IC50 of 1.1 mM was calculated.
The amount of hydrogen peroxide produced by NSC288387 at 10 µM is negligible and not
enough to interfere with the biochemical assay. It is possible if this compound or the more
potent synthesised analogues are taken forward for cell based testing, that there may be some
complications if the compound is slightly redox active. It could be of interest to synthesise
analogues of these compounds without the isoalloxazine core. ‘Scaffold hopping’ could
result in an analogous pharmacophore without the undesirable redox activity but retains the
inhibitory activity.
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Fig. 6.1 (A) Hydrogen peroxide standard curve using the phenol red assay. (B) Phenol
red assay using NSC288387. (C) Autoubiquitination concentration dependent assay using
hydrogen peroxide.
Extensive soaking was attempted in order to solve the protein ligand structure. Out of all
the compounds, only NSC2805 gave us a bound structure. In terms of NMR analysis, this
compound was not ideal due to its symmetry. Therefore we could not validate the crystal
structure using the ligand NMR techniques as we could not orientate the molecule with
confidence. Using the crystal structure, unsymmetrical analogues of NSC2805 could be
designed and synthesised. These analogues should contain more proton environments so
meaningful epitope maps and DEEP STD data can be obtained. Combined with IC50 data
of these analogues the extent as to which intermolecular interactions are important can be
assessed. Substantial effort went into generating a bound structure of NSC2805 to HECT
156
because it was the only compound which gave extra density in the binding site that was
predict in silico. A medicinal chemist may view the NSC2805 structure with scepticism.
Quinones have been stated as PAIN compounds and there has been commentary on how they
shouldn’t be followed up as a lead compound. The argument for us to pursue a quinone
compound was to establish and characterise a binding site with HECT that can induce
inhibition. Whilst NSC2805 may not be "drug like", it was a useful tool in the development
of methods for WWP2 inhibitor discovery.
6.4 A novel allosteric binding site
After generating some initial hits through thermal shift it was decided the generation of a
structural model was imperative. The structural model would reveal how the inhibitors could
possibly be built on in order to improve their potency. After harvesting over 150 crystals,
3 data sets eluded to a small molecule being bound to the HECT domain. The site where
the additional electron density was picked up is where the site map predicted there could
be a binding site. The electron density around NSC2805 may not be of the highest quality,
but the potential protein-ligand interactions increase the likelihood that our X- ray structural
models are accurate. The data in Chapter 5 strengthens the argument that the electron density
is due to the ligand, and a new ligandable binding site in HECT has been discovered. This
is because the docking solution of NSC288387 is in the same site as where the additional
electron density was identified for NSC2805 in Chapter 4. The STD NMR derived epitope
map fitted in agreement with the proposed docked solution of NSC288387. The DEEP STD
data matched up with the predicted model with the expected DEEP STD factors for selected
protons being observed. The differential activity of the NSC288387 analogues fits well
with the docked model. For example, when the buried N-phenyl ring was removed, there
was a drop in activity. It is the combination of this data which can give us confidence in
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stating there is an allosteric binding site between the N and C lobe which can be targeted for
inhibition by small molecules.
6.5 Future work
This thesis provides a framework for various avenues that could be pursued in the field
of targeting the ubiquitin ligases. Fully characterising the mechanism of inhibition is an
important step. Mutating key residues in the binding pocket of WWP2 HECT and measuring
activity of the compounds would give an indication as to what interaction are key, and to
also provide more evidence that the binding pocket is real. Improving the biophysical assays
described in Chapter 3 is an obvious route. This is something we have recently started
and obtained preliminary results for. After working with the protein construct explained
in Chapter 2, we theorised this may be a more suitable truncation of WWP2 for thermal
shift. Therefore we revisited the thermal shift assay. A test run with 2.5 µM WW2-l-H, 5
x SYPRO orange in 25 mM Tris-Cl pH 7.4, 150 mM NaCl and 5 mM DTT was carried
out. The resulting thermal shift profile was of a higher quality than the profile produced
from WWP2 HECT. The slope has a steeper gradient and a more pronounced increase in
fluorescence. The Tm of the protein is also higher at around 47.7 oC. The composition of the
buffer is more desirable as it is at 7.4, a neutral pH which is less likely to cause reactions
with certain compounds as well as being more biologically relevant. 866 compounds from
the upgraded NCI diversity set VI have been screened at 10 µM, 0.1 % DMSO. Due to time
constraints the library screen was not completed.
All the developed assays stated in this thesis can be combined and run as a pipeline for
WWP2 drug discovery. A more optimised compound library, perhaps from industry, which
would not only be less likely to contain PAINs, but to be more structurally diverse and contain
a greater number of compounds. They could be screened by thermal shift, validated by STD
NMR. They could be soaked into the crystals which can now be grown routinely and soaked
158
-2
-1
0
1
2
Compounds
Δ
Tm
D
Diversity set VI
Fig. 6.2 Preliminary data showing the thermal shift screen using the WWP2 WW2-2,3
linker-HECT construct
using the ideal conditions developed in this thesis. This could lead to a ‘2nd generation’ of
WWP2 inhibitors, or ligands, which are more amenable to drug discovery. Beginning the
test the more potent NSC288387 analogues in cells needs to be carried out. Whether these
compounds are cell permeable is an important question to ask and whether they actually
inhibit WWP2 in the cell, as opposed to on a plate. The metabolic turnover of the compounds
could be investigated by using mouse liver microsomes. Measuring the turnover can inform
of any future organic synthesis if there is a particular moiety susceptible to rapid metabolic
breakdown A recent paper regarding WWP1 and its implication in prostate cancer brings the
compound indole-3-carbinol into light (Lee et al., 2019). Indole-3-carbinol and its derivatives
were described in Section 1.2.3.4 as a Nedd4 inhibitor, discovered with the help of the Nedd4
ligand structure (PDB:5C91). Kathman et al. (2015) report "compound 3" did not label
WWP1 as only Nedd4 contained the non catalytic cysteine in that particular binding pocket.
However, indole-3-carbinol is predicted to bind in that particular site in WWP1. A possible
reason is that there are non covalent interactions which are stronger in indole-3-carbinol
than in "compound 3". Due to the high homology between WWP1 and WWP2, it could
be feasible that indole-3-carbinol also binds to WWP2. Soaking WWP2 crystals using the
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method described in Chapter 4 could lead to another WWP2 ligand structure. This could
then be used to inform synthetic modifications in order to improve specificity and potency.
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Chapter 7
Chemistry experimental
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7.1 General chemistry experimental
7.1.1 Preparation of solvents and glassware
All reagents obtained commercially were used without further purification, unless otherwise
stated. Reactions under anhydrous conditions were carried out under a nitrogen or argon
atmosphere. Anhydrous solvents were either bought in separately or dried using the following
methods; tetrahydrofuran was distilled over the sodium/ benzophenone radical under an
argon atmosphere, acetonitrile was stored overnight under argon over activated 3 Å molecular
sieves, dichloromethane was distilled over calcium hydride and N, N-dimethylformamide
was dried overnight under argon over 4 Å molecular sieves, vacuum distilled and stored
under argon.
7.1.2 Compound characterisation
1H, 13C and 19F NMR spectra were gathered using either a Bruker Ascend 500 at 500 MHz,
126 MHz and 471 MHz or a Bruker Ultrashield 400 Plus at 400 MHz, 100 MHz and 367
MHz. Chemical shifts are reported in ppm and coupling constants (J values) reported in
Hz. HSQC and COSY experiments where run for novel compounds. High resolution mass
spectrometry data was collected from the EPSRC UK National Mass Spectrometry service at
the University of Swansea.
Liquid chromatography mass spectroscopy (LCMS) was carried out using a Water Ac-
quity I Class Ultra Performance Liquid Chromatography Mass Spectrometry machacine
fitted with a Waters Acquity UPLC BEH C18 column (2.1 x 50mm 1.7 um). Samples were
dissolved in 2 mL acetonitrile: water (50:50). Samples were filtered through a 0.45 µm
filter before use. All LCMS experiments were run at Charnwood Molecular at Biocity,
Nottingham. Infrared spectra were obtained using a Perkin Elmer Spectrum 100 Fourier
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Transformation Infrared Spectrometer. Samples were ran as a thin film from an evaporated
solution of dichloromethane on sodium chloride plates. Melting points were carried out on a
Buchi Melting Point B-545 apparatus.
7.1.3 Chromatographic techniques
Flash column chromatography was carried out either using conventional glass columns or
using a Biotage IsoleraTM Prime automated flash purification system. Flash chromatography
using glass columns were manually packed with Material Harvest silica gel 60. Flash
chromatography using the Biotage IsoleraTM Prime system was carried out using 5- 120 g
Biotage ZIP cartridges, packed with Biotage KP-Sil brand silica. Column chromatography
using the Biotage system was carried out at Charnwood Molecular in Biocity, Nottingham.
Thin layer chromatography was carried out on Merk aluminium plates coated with Kieselgel
60 F254 silica gel. Plates were visualised under UV light at 254 nm (short wave) or 365 nm
(long wave).
7.1.4 Compound numbering
All compounds involved in synthetic procedures are numbered 1-33 in bold. All other
compounds referred to in this thesis, not involved in the synthetic chemistry, are labelled
with their reference name/ number e.g. NSC35676. The exceptions are compound 18, which
is also referred to as NSC288387, and compound 7 which is also referred to as heclin.
"Compound 3" and "Compound 1" are in reference to the inhibitors reported by Kathman
et al.
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7.2 Individual procedures and characterisation
5-Ethylfuran 2-carbaldehyde (2)
To a mixture of DMF (1 mL), was added phosphorous oxychloride (1.26 mL, 13.5 mmol,
1.35 equiv) and was stirred at 0 oC for 20 minutes. 2-Ethylfuran (1 g, 10.0 mmol) was added
at a rate that the reaction did not rise above 20 oC. After the addition was complete, the
reaction mixture was kept at 0-5 oC for 1 hour followed by 1 hour at room temperature. The
mixture was poured into approximately 20 mL of ice and water. The mixture was neutralised
with sodium carbonate and was left to stand overnight. Diethyl ether was added and the
organic layer was separated. The aqueous layer was extracted three times with ether. The
organic extracts were combined and dried over sodium sulfate. The solvent was removed
under reduced pressure. The crude was purified by fractional distillation to afford a brown
oil. (1.1 g, 79 %).
1H NMR (500 MHz, CDCl3) δ 9.53 (s, 1H), 7.18 (d, J = 3.5 Hz, 1H), 6.24 (d, J = 3.5
Hz, 1H), 2.76 (q, J = 7.3 Hz, 2H), 1.30 (t, J = 7.6 Hz, 3H).
13C NMR (126 MHz, DMSO) δ 209.9, 174.3, 163.5, 36.8, 35.3, 28.2, 8.1.
IR vmax (film)/cm-1: 1713, 1116
Procdure- (Taylor, 1959)
Data- (Kuo and Shih, 1991)
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3-(5-Ethyl-2-furanyl)-2-propenoic acid (4)
Piperidine (0.8 mL, 8 mmol, 1 equiv.) was added to a solution of 2 (1 g, 8 mmol), malonic
acid (0.62 mL, 10 mmol, 1.25 equiv) and pyridine (1.42 mL, 17 mmol, 2.13 equiv) under
nitrogen atmosphere. The reaction mixture was heated to 130 oC under vigorous stirring
for 3 hours. The reaction mixture was cooled and ethyl acetate was added. The mixture
was acidified to pH 5 with 1 M hydrochloric acid and the organic layer was separated. The
organic layer was washed with water and dried over magnesium sulfate. The solvent was
removed to afford a yellow solid (630 mg, 47%).
1H NMR (500 MHz, CDCl3) δ 7.45 (d, J = 15.6 Hz, 1H), 6.58 (d, J = 3.3 Hz, 1H), 6.23
(d, J = 15.6 Hz, 1H), 6.11 (dt, J = 3.3, 0.9 Hz, 1H), 2.70 (q, J = 7.6 Hz, 2H), 1.27 (t, J = 7.6
Hz, 3H).
13C NMR (126 MHz, CDCl3) δ 172.1, 161.8, 149.2, 133.2, 117.4, 112.8, 107.5, 21.7,
11.9.
IR vmax (film)/cm-1: 3425, 1629.
Mp 127-128 oC
Procedure and data- (Van Veldhoven et al., 2011)
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(Z)-N,N’-dicyclohexylcarbamimidic (E)-3-(5-ethylfuran-2-yl)acrylic anhydride (5)
Compound 4 (270 mg, 1.6 mmol) N, N’-dicyclohexylcarbodiimide (DCC) (400mg, 2.0
mmol, 1.25 equiv) and 4-dimethylaminopyridine (DMAP) (30 mg, 0.25 mmol, 15.6 %) were
dissolved in anhydrous dichloromethane (10 mL). The solution was cooled to 0 oC and stirred
for 30 minutes. A solution of 4-acetylaniline (200 mg, 1.5 mmol, 0.94 equiv) in DCM was
added dropwise over 30 minutes. The mixture was warmed to room temperature and stirred
overnight. N, N’-dicyclohexylcarbodiimide was filtered off and the solvent was removed
under reduced pressure. The crude product was purified by column chromatography (3:1
petrol: ethyl acetate) to give 5 as a waxy colourless solid (220 mg, 39 %).
1H NMR (500 MHz, CDCl3) δ 7.37 (d, J = 15.0 Hz, 1H), 6.57 (d, J = 15.0 Hz, 1H), 6.49
(d, J = 3.1 Hz, 1H), 6.07 (dd, J = 3.1, 0.9 Hz, 1H), 2.74 – 2.60 (m, 2H), 2.04 – 1.92 (m, 4H),
1.82 (m, 15.0 Hz, 4H), 1.78 – 1.69 (m, 2H), 1.46 – 1.11 (m, 12H).
13C NMR (126 MHz, CDCl3) δ 167.20, 160.78, 154.26, 149.85, 130.28, 116.24, 115.28,
107.29, 56.22, 49.79, 32.74, 30.93, 26.34, 25.53, 25.41, 24.71, 21.67, 11.87.
IR vmax (film)/cm-1:3293, 3051, 2933, 2855, 1701, 1527
m/z (NSI-FTMS) [M+H]+: calcd for [C22H33N2O3]+ 373.2486, found 373.2486
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N-(4-Acetylphenyl)-3-(5-ethyl-2-furanyl)-2-propenamide (5)
Compound 4 (274 mg, 1.7 mmol, 1.1 equiv), DCC (400 mg, 2.0 mmol, 1.3 equiv) and
DMAP (30 mg, 0.25 mmol, 16.6 %) were dissolved in anhydrous dichloromethane (10 mL).
The solution was cooled to 0 oC and stirred for 30 minutes. A solution of 4-acetylaniline
(200mg, 1.5 mmol) in DCM was added dropwise over 30 minutes. The mixture was refluxed
at 50 oC and stirred overnight. N, N’-dicyclohexylcarbodiimide was filtered off and the
solvent was removed under reduced pressure. The crude product was purified by column
chromatography (3:1 petrol: ethyl acetate) to give a yellow solid (110 mg, 26 %).
1H NMR (500 MHz, CDCl3) δ 7.97 – 7.94 (m, 1H), 7.74 – 7.67 (m, 2H), 7.48 (d, J =
15.0 Hz, 1H), 6.55 (d, J = 3.3 Hz, 1H), 6.38 (d, J = 15.0 Hz, 1H), 6.10 (dt, J = 3.3, 0.9 Hz,
1H), 2.72 – 2.66 (q, J = 7.6 Hz, 2H), 2.58 (s, 3H), 1.29 – 1.25 (t, J = 7.6 Hz, 3H).
13C NMR (126 MHz, CDCl3) δ 196.9, 164.4, 161.0, 149.5, 142.6, 132.8, 130.1, 129.8,
118.9, 116.8, 115.9, 107.5, 26.5, 21.7, 11.9.
IR vmax (film)/cm-1:3432, 1654
Mp 130-132 oC
Procedure- (Arias et al., 2011)
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Methyl 3,4,6-trihydroxy-2-methoxy-5-oxo-5H-benzo[7]annulene-8-carboxylate (10)
3-Methoxy catechol (140 mg, 1 mmol) and methyl 3, 4, 5 trihydroxy benzoate (185 mg, 1
mmol, 1 equiv) was dissolved in a mixture of acetone phosphate- citrate (1:1 0.2M Na2HPO4:
0.1 M citrate) buffer (1:5 v/v) containing 1 mg horseradish peroxidase. Hydrogen peroxide
(3%) was added in 2 mL portions every 10 minutes over a 40 minute period. The precipitate
was filtered off and washed with 3 x 6 mL water. The solid was dried under vacuum and
purified by hot filtration in ethanol to give an orange solid (146 mg, 50 %.)
1H NMR (500 MHz, DMSO) δ 8.39 (d, J = 1.5 Hz, 1H), 7.58 (d, J = 1.6 Hz, 1H), 7.47
(s, 1H), 4.01 (s, 3H), 3.90 (s, 3H).
13C NMR (126 MHz, DMSO) δ 183.6, 167.1, 154.2, 152.5, 151.9, 138.5, 138.3, 130.2,
123.9, 116.7, 114.5, 110.5, 56.7, 53.4.
IR vmax (film)/cm-1: 3428, 1639.
Mp 215-217 oC decomposition.
Procedure and data- (Cheng et al., 2012)
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Methyl 4-hydroxy-2,3,6-trimethoxy-5-oxo-5H-benzo[7]annulene-8-carboxylate (11)
To a suspension of 10 (200 mg, 0.68 mmol, 0.33 equiv), K2CO3 (188 mg, 1.36 mmol, 0.66
equiv) in anhydrous DMF (35 mL) was added iodomethane (0.31 mL, 2.05 mmol) dropwise
at 0 oC under argon. The mixture was stirred overnight at room temperature. The reaction
was quenched with water and the mixture was stirred for 20 minutes. EtOAc was added and
the organic was washed with water and the combined aqueous layers were extracted with
EtOAc. The organic was dried over Na2SO4 and the solvent was removed under reduced
pressure. The crude was purified using column chromatography (2:1 petrol:ethyl acetate) to
yield a yellow solid (170 mg, 64 %).
1H NMR (500 MHz, CDCl3) δ 14.93 (s, 1H), 8.20 (d, J = 0.6 Hz, 1H), 7.34 (d, J = 0.5
Hz, 1H), 6.87 (s, 1H), 4.03 (s, 3H), 4.01 (s, 3H), 3.98 (s, 3H), 3.97 (s, 3H).
13C NMR (126 MHz, DMSO) δ 184.9, 166.6, 158.1, 156.5, 156.2, 138.2, 137.8, 132.9,
124.1, 117.2, 110.0, 109.6, 56.3, 56.1, 53.1
IR vmax (film)/cm-1: 3434, 2081, 1638
m/z (TOF MS) [M+H]+: calcd for [C16H16O7]+ 321.0974, found 321.0971.
Mp 162-164 oC
Procedure- (Cheng et al., 2012)
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2,2,2-Trifluoro-N-(2-nitrophenyl)acetamide
2-Nitro aniline (4.14 g, 30 mmol) was dissolved in dichloromethane (60 mL) and was
cooled to 0 oC and stirred for 1 hour. Trifluoroacetic anhydride (8.4 mL, 60 mmol) was added
and the reaction mixture was stirred for another 1 hour. NaHCO3 was added to neutralise the
reaction. The organic layer was separated and dried over Na2SO4. The solvent was removed
to afford a light brown solid (6.36 g, 91 %). No further purification is required.
1H NMR (400 MHz, CDCl3) δ 11.52 – 11.13 (m, 1H), 8.91 – 8.63 (m, 1H), 8.31 (dd, J =
8.5, 1.5 Hz, 1H), 7.76 (ddd, J = 8.6, 7.5, 1.3 Hz, 1H), 7.37 (ddd, J = 8.6, 7.4, 1.3 Hz, 1H).
13C NMR (101 MHz, CDCl3) δ 155.36 (q, J2 CF = 38.4 Hz), 137.0, 136.4, 132.1, 125.6,
126.2, 122.2, 115.4 (q, J1 CF = 288.7 Hz).
19F NMR (376 MHz, CDCl3) δ -76.24 (d, J = 1.2 Hz).
IR vmax (film)/cm-1: 3434, 2094, 1638, 1729, 1172.
LCMS m/z (ESI) [M+H]-: calcd for [C8H5F3N2O3]- 233.03, found 233.1
Mp 89-91 oC
Data- (Darvesh et al., 2006)
Procedure- (Epple et al., 1997)
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N-(2-methoxyethyl)-2-nitroaniline (14)
13 (3 g, 12 mmol) and K2CO3 (6.3 g, 46 mmol, 3.6 equiv) in DMF (40 mL) was heated
to 100 oC. The reaction mixture was stirred for 1 hour. 1- Bromo-2-methoxyethane (3.16 mL,
33.6 mmol, 2.8 equiv) was added and stirred overnight. The reaction mixture was cooled and
H2O (200 mL) was added. The product was extracted with DCM (3x 200 mL) and washed
with brine (3 x 200 mL) The organic was dried over Na2SO4 and the solvent was removed
to afford an orange oil. The crude was purified by flash chromatography (100 % DCM) to
afford the product as an orange oil (640 mg, 56 %)
1H NMR (500 MHz, CDCl3) δ 8.24 – 8.13 (m, 1H), 7.49 – 7.41 (m, 1H), 6.92 – 6.83 (m,
1H), 6.66 (ddd, J = 8.4, 6.9, 1.2 Hz, 1H), 3.68 (t, J = 5.4 Hz, 2H), 3.49 (t, J = 5.4 Hz, 2H),
3.43 (s, 3H).
13C NMR (126 MHz, CDCl3) δ 136.2, 126.9, 115.5, 113.8, 70.5, 59.1, 42.8.
IR vmax (film)/cm-1: 3379, 1619, 1571, 1419, 1352, 1262, 1155, 1120,
LCMS m/z (ESI) [M+H]+: calcd for [C9H12N2O3]+ 197.08, found 197.1
Procedure- (Epple et al., 1997)
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N-(2-methoxyethyl)-2-nitroaniline (14)
A mixture of 2-fluoronitrobenzene (20 g, 142 mmol) and sodium carbonate (7.525 g, 71
mmol, 0.5 equiv) in ethanol (57 mL) was heated to 80 oC. 2- Methoxyethylamine (0.67 mL,
7.7 mmol, 0.05 equiv) was added dropwise and the reaction was left overnight. The solvent
was removed under reduced pressure and water was added. The product was extracted with
DCM and dried over Na2SO4. The solvent was removed to afford an orange oil (20 g, 72 %).
1H NMR (500 MHz, CDCl3) δ 8.24 – 8.13 (m, 1H), 7.49 – 7.41 (m, 1H), 6.92 – 6.83 (m,
1H), 6.66 (ddd, J = 8.4, 6.9, 1.2 Hz, 1H), 3.68 (t, J = 5.4 Hz, 2H), 3.49 (t, J = 5.4 Hz, 2H),
3.43 (s, 3H).
13C NMR (126 MHz, CDCl3) δ 136.1, 126.9, 115.5, 113.8, 70.5, 59.1, 42.8.
IR vmax (film)/cm-1: 3379, 1619, 1571, 1419, 1352, 1262, 1155, 1120,
LCMS m/z (ESI) [M+H]+: calcd for [C9H12N2O3]+ 197.08, found 197.1
Method- (Yao et al., 2017)
Unable to access published spectra
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10-(2-Methoxyethyl)benzo[g]pteridine-2,4(3H,10H)-dione (17)
Compound 14 (20 g, 102 mmol) was added to acetic acid (408 mL). The mixture was
degassed and Pd/C (325 mg, 3.06 mmol, 3 %) was added. The mixture was further degassed.
The flask was placed under vacuum and purged with hydrogen. The reaction was stirred at
room temperature overnight. The slurry was filtered through celite and alloxan monohydrate
(32.66 g, 204 mmol, 2 equiv) and boric acid (31.53 g, 510 mmol, 5 equiv) was added and
the mixture was stirred overnight at room temperature. The acetic acid was removed under
vacuum and water was added. The reaction mixture was extracted with DCM and the organic
was dried over Na2SO4. The solvent was removed and the resulting solid was found to be
majority starting material by LCMS. The aqueous layer was filtered and the collected solid
was washed with DCM to afford a green solid. (14.791 g, 53 %).
1H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H), 8.31 (dd, J = 8.2, 1.3 Hz, 1H), 7.91 (ddd, J
= 14.5, 10.3, 4.8 Hz, 2H), 7.76 – 7.62 (m, 1H), 4.93 (t, J = 5.1 Hz, 2H), 3.94 (t, J = 5.1 Hz,
2H), 3.29 (s, 3H).
13C NMR (126 MHz, DMSO) δ 160.2, 156.1, 151.1, 139.1, 135.2, 133.6, 132.0, 126.5,
117.5, 68.9, 58.9, 44.6.
IR vmax (film)/cm-1: 3418, 1670, 1538, 1508
LCMS m/z (ESI) [M+H]+: calcd for [C13H12N4O3]+ 273.09, found 273.1
Mp >220 oC
Procedure- (Epple et al., 1997)
Compound in literature (unable to access)- (Lacroix et al., 1987)
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10-(2-Methoxyethyl)-3-phenylbenzo[g]pteridine-2,4(3H,10H)-dione (18)
To a solution of 17 (22 mg, 0.08 mmol) in anhydrous DMF (1 mL) was added benzene
boronic acid (30 mg, 0.24 mmol, 3 equiv), Cu(OAc)2 (30 mg, 0.16 mmol, 2 equiv), triethy-
lamine (0.03 mL, 0.24 mmol, 3 equiv) and was stirred overnight at room temperature in
the dark. The reaction was monitored by LCMS and once gone to completion, the mixture
was diluted with DCM and the organic was washed with water and brine. The organic was
dried over Na2SO4 and the solvent was removed. The crude solid was purified by flash
chromatography (100 % EtOAc) to afford a yellow solid (27 mg, 57 %).
1H NMR (500 MHz, CDCl3) δ 8.32 (d, J = 7.7 Hz, 1H), 7.95 (d, J = 8.6 Hz, 1H), 7.92 –
7.84 (m, 1H), 7.63 (t, J = 7.4 Hz, 1H), 7.53 (t, J = 7.7 Hz, 2H), 7.46 (t, J = 7.5 Hz, 1H), 7.32
(d, J = 7.6 Hz, 2H), 4.96 (t, J = 4.9 Hz, 2H), 3.97 (t, J = 5.1 Hz, 2H), 3.31 (s, 3H).
13C NMR (101 MHz, CDCl3) δ 155.2, 136.0, 135.6, 135.5, 132.9, 129.4, 128.7, 128.2,
126.6, 116.9, 69.6, 59.2, 45.7.
IR vmax (film)/cm-1: 3412, 1666, 1556
LCMS m/z (ESI) [M+H]+: calcd for [C19H16N4O3]+ 349.12, found 349.1
Mp >220 oC
Procedure- (Attenberger et al., 2008)
Compound in literature (unable to access)- (Lacroix et al., 1987)
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10-(2-Methoxyethyl)-3-(4-methoxyphenyl)benzo[g]pteridine-2,4(3H,10H)-dione (19)
To a solution of 17 (272 mg, 1 mmol) in anhydrous DMF (12.5 mL) was added 4-
methoxybenzene boronic acid (456 mg, 3 mmol, 3 equiv), Cu(OAc)2 (363 mg, 2 mmol,
2 equiv), triethylamine (0.42 mL, 3 mmol, 3 equiv) and was stirred overnight at room
temperature in the dark. The reaction was monitored by LCMS and once gone to completion,
the mixture was diluted with CH2Cl2 and the organic was washed with water and brine. The
organic was dried over Na2SO4 and the solvent was removed. The crude solid was purified
by flash chromatography (9:1 CH2Cl2:MeOH) to afford a yellow solid (72 mg, 19%).
1H NMR (400 MHz, CDCl3) δ 8.31 (d, J = 7.5 Hz, 1H), 8.01 – 7.81 (m, 2H), 7.62 (t, J =
7.1 Hz, 1H), 7.25 – 7.18 (m, 1H), 7.09 – 7.00 (m, 2H), 6.79 – 6.72 (m, 1H), 4.96 (t, J = 5.1
Hz, 2H), 3.96 (t, J = 5.1 Hz, 2H), 3.86 (s, 3H), 3.31 (s, 3H).
13C NMR (126 MHz, CDCl3) δ 159.5, 155.6, 153.5, 149.9, 136.0, 135.6, 132.9, 129.1,
128.0, 126.5, 116.9, 116.1, 114.7, 114.7, 69.6, 59.2, 55.8, 55.5, 45.7.
IR vmax (film)/cm-1: 2934, 1667, 1558, 1510, 1247
LCMS m/z (ESI) [M+H]+: calcd for [C20H18N4O2]+ 379.13, found 379.2
Mp >220 oC
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4-(10-(2-Methoxyethyl)-2,4-dioxobenzo[g]pteridin-3(2H,4H,10H)-yl)benzonitrile (20)
To a solution of 17 (272 mg, 1 mmol) in anhydrous DMF (12.5 mL) was added 4-
cyanobenzene boronic acid (440 mg, 3 mmol, 3 equiv), Cu(OAc)2 (363 mg, 2 mmol, 2 equiv),
triethylamine (0.42 mL, 3 mmol, 3 equiv) and was stirred overnight at room temperature in
the dark. The reaction was monitored by LCMS and once gone to completion, the mixture
was diluted with CH2Cl2 and the organic was washed with water and brine. The organic
was dried over Na2SO4 and the solvent was removed. The crude solid was purified by flash
chromatography (100 % EtOAc) to afford a yellow solid (24 mg, 6 %).
1H NMR (500 MHz, CDCl3) δ 8.34 (s, 1H), 8.00 (d, J = 8.3 Hz, 1H), 7.96 – 7.90 (m,
1H), 7.81 (d, J = 8.4 Hz, 2H), 7.69 (dd, J = 13.2, 4.8 Hz, 1H), 7.52 – 7.41 (m, 2H), 4.97 (t, J
= 4.7 Hz, 2H), 3.96 (t, J = 4.9 Hz, 2H), 3.30 (s, 3H).
13C NMR (126 MHz, CDCl3) δ 154.5, 139.5, 136.1, 133.2, 133.1, 129.6, 126.9, 117.2,
112.7, 69.5, 59.3, 46.0.
IR vmax (film)/cm-1: 3427,2228, 1716, 1668, 1557
LCMS m/z (ESI) [M+H]+: calcd for [C20H15N5O3]+ 374.12, found 374.2
Mp >220 oC
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3-(3-Chlorophenyl)-10-(2-methoxyethyl)benzo[g]pteridine-2,4(3H,10H)-dione (21)
To a solution of 17 (272 mg, 1 mmol) in anhydrous DMF (12.5 mL) was added 3-
chlorobenzene boronic acid (469 mg, 3 mmol, 3 equiv), Cu(OAc)2 (363 mg, 2 mmol,
2 equiv), triethylamine (0.42 mL, 3 mmol, 3 equiv) and was stirred overnight at room
temperature in the dark. The reaction was monitored by LCMS and once gone to completion,
the mixture was diluted with CH2Cl2 and the organic was washed with water and brine. The
organic was dried over Na2SO4 and the solvent was removed. The crude solid was purified
by flash chromatography (100% EtOAc) to afford a yellow solid (16 mg, 4 %).
1H NMR (500 MHz, CDCl3) δ 8.32 (dd, J = 8.2, 1.3 Hz, 1H), 7.96 (d, J = 8.1 Hz, 1H),
7.90 (ddd, J = 8.7, 7.1, 1.5 Hz, 1H), 7.69 – 7.61 (m, 1H), 7.48 – 7.41 (m, 2H), 7.33 (t, J =
1.8 Hz, 1H), 7.22 (dt, J = 7.4, 1.7 Hz, 1H), 4.96 (t, J = 5.0 Hz, 2H), 3.97 (t, J = 5.1 Hz, 2H),
3.31 (s, 3H).
13C NMR (126 MHz, CDCl3) δ 135.83, 134.86, 133.05, 130.32, 129.09, 128.78, 126.75,
126.67, 117.00, 69.57, 59.27, 45.85.
IR vmax (film)/cm-1: 1716, 1669, 1557, 765
LCMS m/z (ESI) [M+H]+: calcd for [C19H15ClN4O3]+ 383.08, found 383.1
Mp >220 oC
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10-(2-Methoxyethyl)-3-(4-(trifluoromethyl)phenyl)benzo[g]pteridine-2,4(3H,10H)-dione
(22)
To a solution of 17 (136 mg, 0.5 mmol) in anhydrous DMF (6.25 mL) was added 4-
trifluoromethylbenzene boronic acid (286 mg, 1.5 mmol, 3 equiv), Cu(OAc)2 (181 mg, 1
mmol, 2 equiv), triethylamine (0.21 mL, 1.5 mmol, 3 equiv) and was stirred overnight at
room temperature in the dark. The reaction was monitored by LCMS and once gone to
completion, the mixture was diluted with CH2Cl2 and the organic was washed with water
and brine. The organic was dried over Na2SO4 and the solvent was removed. The crude solid
was purified by flash chromatography (100 % EtOAc) to afford a yellow solid (11 mg, 5 %).
1H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 8.2 Hz, 1H), 7.94 (dt, J = 15.8, 8.7 Hz, 2H),
7.80 (d, J = 8.3 Hz, 2H), 7.66 (t, J = 7.3 Hz, 1H), 7.55 – 7.41 (m, 2H), 4.98 (t, J = 5.0 Hz,
2H), 3.98 (t, J = 5.1 Hz, 2H), 3.31 (s, 3H).
13C NMR (126 MHz, CDCl3) δ 154.44, 139.53, 136.11, 133.25, 133.08, 129.59, 126.96
(q, J CF = 3.7 Hz), 117.15, 112.70, 69.52, 59.27, 46.01.
19F NMR (376 MHz, CDCl3) δ -62.64.
IR vmax (film)/cm-1: 3422, 1663, 1558, 1323, 1063
LCMS m/z (ESI) [M+H]+: calcd for [C19H16N4O3]+ 349.12, found 349.1
Mp >220 oC
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3-(4-Fluorophenyl)-10-(2-methoxyethyl)benzo[g]pteridine-2,4(3H,10H)-dione (23)
To a solution of 17 (136 mg, 0.5 mmol) in anhydrous DMF (12.5 mL) was added 4-
fluorobenzene boronic acid (420 mg, 3 mmol, 6 equiv), Cu(OAc)2 (363 mg, 2 mmol, 4 equiv),
triethylamine (0.42 mL, 3 mmol, 6 equiv) and was stirred overnight at room temperature in
the dark. The reaction was monitored by LCMS and once gone to completion, the mixture
was diluted with CH2Cl2 and the organic was washed with water and brine. The organic
was dried over Na2SO4 and the solvent was removed. The crude solid was purified by flash
chromatography (100 % EtOAc) to afford a yellow solid (63 mg, 17 %).
1H NMR (500 MHz, CDCl3) δ 8.32 (dd, J = 8.2, 1.3 Hz, 1H), 7.96 (d, J = 8.2 Hz, 1H),
7.90 (ddd, J = 8.7, 7.1, 1.5 Hz, 1H), 7.65 (dd, J = 11.2, 4.1 Hz, 1H), 7.29 (ddd, J = 10.0, 5.0,
2.6 Hz, 2H), 7.21 (ddd, J = 12.1, 6.1, 2.7 Hz, 2H), 4.96 (t, J = 5.1 Hz, 2H), 3.97 (t, J = 5.1
Hz, 2H), 3.31 (s, 3H).
13C NMR (101 MHz, CDCl3) δ 155.1, 136.1, 135.8, 133.0, 130.0, 129.9, 126.7, 116.9,
116.6, 116.3, 69.6, 59.2, 45.8. *CF coupling was not observed in the spectra.
19F NMR (376 MHz, CDCl3) δ -112.97.
IR vmax (film)/cm-1: 3426, 2086, 1638
LCMS m/z (ESI) [M+H]+: calcd for [C20H15F3N4O3]+ 367.11, found 367.2
Mp >220 oC
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Methyl 4-(10-(2-methoxyethyl)-2,4-dioxobenzo[g]pteridin-3(2H,4H,10H)-yl)benzoate
To a solution of 17 (272 mg, 1 mmol) in anhydrous DMF (12.5 mL) was added 4-
methoxycarbonylphenyl boronic acid (540 mg, 3 mmol, 3 equiv), Cu(OAc)2 (363 mg, 2
mmol, 2 equiv), triethylamine (0.42 mL, 3 mmol, 3 equiv) and was stirred overnight at room
temperature in the dark. The reaction was monitored by LCMS and once gone to completion,
the mixture was diluted with CH2Cl2 and the organic was washed with water and brine. The
organic was dried over Na2SO4 and the solvent was removed. The crude solid was purified
by flash chromatography (100 % EtOAc) to afford a yellow solid (53 mg, 13 %).
1H NMR (500 MHz, CDCl3) δ 8.32 (d, J = 7.9 Hz, 1H), 8.24 – 8.19 (m, 2H), 7.97 (d, J
= 8.6 Hz, 1H), 7.95 – 7.86 (m, 1H), 7.73 – 7.61 (m, 1H), 7.41 (d, J = 8.5 Hz, 2H), 4.97 (t, J
= 4.9 Hz, 2H), 3.97 (t, J = 5.1 Hz, 2H), 3.95 (s, 3H), 3.31 (s, 3H).
13C NMR (126 MHz, CDCl3) δ 166.4, 154.8, 139.6, 136.1, 135.9, 133.0, 130.8, 130.4,
130.2, 128.5, 127.3, 126.8, 117.0, 69.5, 59.3, 52.3, 45.9.
IR vmax (film)/cm-1: 3431, 2097, 1716, 1667, 1557, 1282, 1112,
LCMS m/z (ESI) [M+H]+: calcd for [C21H18N4O5]+ 407.13, found 407.1
Mp >220 oC
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10-(2-Methoxyethyl)-3-(p-tolyl)benzo[g]pteridine-2,4(3H,10H)-dione (25)
To a solution of 17 (136 mg, 0.5 mmol) in anhydrous DMF (12.5 mL) was added
4-tolyboronic acid (204 mg, 1.5 mmol, 3 equiv), Cu(OAc)2 (182 mg, 1 mmol, 2 equiv),
triethylamine (0.21 mL, 1.5 mmol, 3 equiv) and was stirred overnight at room temperature in
the dark. The reaction was monitored by LCMS and once gone to completion, the mixture
was diluted with CH2Cl2 and the organic was washed with water and brine. The organic
was dried over Na2SO4 and the solvent was removed. The crude solid was purified by flash
chromatography (100 % EtOAc) to afford a yellow solid (20 mg, 11 %).
1H NMR (500 MHz, CDCl3) δ 8.34 (s, 1H), 7.97 (s, 1H), 7.94 – 7.82 (m, 1H), 7.70 –
7.58 (m, 1H), 7.32 (t, J = 9.1 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 4.95 (t, J = 4.9 Hz, 2H), 3.96
(t, J = 4.9 Hz, 2H), 3.31 (s, 3H), 2.42 (s, 3H).
13C NMR (126 MHz, CDCl3) δ 138.7, 135.6, 133.0, 132.8, 130.2, 127.8, 69.6, 59.3,
45.7, 21.4.
IR vmax (film)/cm-1: 3433, 2089, 1662, 1557,
LCMS m/z (ESI) [M+H]+: calcd for [C20H18N4O3]+ 363.14, found 363.2
Mp >220 oC
181
3-((2-Methoxyethyl)amino)-4-nitrophenol (27)
3-fluoro-4-nitrophenol (1 g, 6.4 mmol), Na2CO3 (340 mg, 3.2 mmol, 0.5 equiv) was
dissolved in ethanol (2.5 mL) and heated to 80 oC. 2-Methoxyethylamine was added dropwise
and the reaction was left at 80 oC overnight. The ethanol was removed under vacuum and
H2O (50 mL) was added. The product was extracted with 3x 50 mL CH2Cl2. The organic
was dried over Na2SO4 and the solvent was removed to afford a dark orange solid (809 mg,
61 %).
1H NMR (500 MHz, CDCl3) δ 8.12 (d, J = 9.3 Hz, 1H), 6.23 (d, J = 2.4 Hz, 1H), 6.17
(dd, J = 9.3, 2.4 Hz, 1H), 3.68 (t, J = 5.4 Hz, 2H), 3.47 – 3.40 (m, 5H).
13C NMR (126 MHz, CDCl3) δ 162.64, 129.82, 105.59, 97.82, 70.31, 59.12, 42.99.
LCMS m/z (ESI) [M-H]-: calcd for [C9H12N2O4]- 211.08, found 211.2
IR vmax (film)/cm-1: 3212, 1578, 1166
Mp >220 oC
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N-(2-methoxyethyl)-2-nitro-4-(trifluoromethyl)aniline (29)
4-fluoro-3-nitrobenzotrifluoride (1 g, 4.8 mmol), Na2CO3 (254 mg, 2.4 mmol, 0.5 equiv)
was dissolved in ethanol (2 mL) and heated to 80 oC. 2-methoxyethylamine (0.46 mL, 5.3
mmol, 2.2 equiv) was added dropwise and the reaction was left at 80 oC overnight. The
ethanol was removed under vacuum and H2O (50 mL) was added. The product was extracted
with 3x 50 mL CH2Cl2. The organic was dried over Na2SO4 and the solvent was removed to
afford a yellow solid (1.1 g, 86 %).
1H NMR (400 MHz, CDCl3) δ 8.47 (t, J = 5.8 Hz, 1H), 7.62 (dd, J = 9.1, 2.1 Hz, 1H),
6.96 (d, J = 9.0 Hz, 1H), 3.69 (t, J = 5.3 Hz, 2H), 3.58 – 3.50 (m, 2H), 3.44 (s, 3H).
13C NMR (126 MHz, DMSO) δ 147.4, 132.4, 132.4, 130.5, 124.5 124.47 (q, J CF = 4.4
Hz), 116.7, 70.4, 58.6, 42.6.
19F NMR (376 MHz, DMSO) δ -60.39.
IR vmax (film)/cm-1: 3379, 1571, 1247, 1111, 1016
LCMS m/z (ESI) [M+H]+: calcd for [C10H11F3N2O3]+ 265.07, found 265.2
Mp >220 oC
183
10-(2-Methoxyethyl)-7-(trifluoromethyl)benzo[g]pteridine-2,4(3H,10H)-dione (31)
Compound 29 (1 g, 3.8 mmol) as dissolved in acetic acid (15 mL) and the mixture was
degassed. Pd/C (12 mg, 0.11 mmol, 3 %) was added and the mixture was further degassed.
The reaction vessel was placed under vacuum and purged with hydrogen. The reaction
was left under hydrogen overnight at room temperature. LCMS showed the formation of
compound 30 and the mixture was filtered through a pad of celite. Boric acid (1.17 g, 19.0
mmol, 5 equiv) and alloxan monohydrate (1.18 g, 7.4 mmol, 2 equiv) was added and stirred
overnight at room temperature. Acetic acid was removed under vacuum and 50 mL H2O was
added. The product was extracted with 3x 100 mL CH2Cl2. The product precipitated and the
DCM was filtered to collect a crude yellow solid. The crude solid was purified by column
chromotography (100 % EtOAc) to afford a yellow solid (117 mg, 9 %)
1H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H), 8.50 (s, 1H), 8.05 (dt, J = 9.4, 5.6 Hz, 2H),
4.91 (t, J = 6.2 Hz 2H), 3.94 (t, J = 6.2 Hz, 2H), 3.28 (s, 3H).
13C NMR (126 MHz, DMSO) δ 159.8, 155.9, 151.6, 141.1, 136.2, 134.2, 130.2, 129.1,
119.3, 68.9, 58.9, 45.0. *CF coupling was not observed in the spectra.
19F NMR (376 MHz, DMSO) δ -60.73.
IR vmax (film)/cm-1: 3415, 1709, 1164
LCMS m/z (ESI) [M+H]+: calcd for [C14H11F3N4O3]+ 341.08, found 341.1
Mp >220 oC
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10-(2-Methoxyethyl)-3-phenyl-7-(trifluoromethyl)benzo[g]pteridine-2,4(3H,10H)-dione
(32)
To a solution of 31 (100 mg, 0.3 mmol) in anhydrous DMF (3.75 mL) was added
benzene boronic acid (110 mg, 0.9 mmol, 3 equiv), Cu(OAc)2 (109 mg, 0.6 mmol, 2 equiv),
triethylamine (0.125 mL, 0.9 mmol, 3 equiv) and was stirred overnight at room temperature
in the dark. The reaction was monitored by LCMS and once gone to completion, the mixture
was diluted with CH2Cl2 and the organic was washed with water and brine. The organic
was dried over Na2SO4 and the solvent was removed. The crude solid was purified by flash
chromatography (100 % EtOAc) to afford a brown solid (80 mg, 64 %).
1H NMR (400 MHz, CDCl3) δ 8.63 (s, 1H), 8.11 (s, 1H), 8.03 (d, J = 8.9 Hz, 1H), 7.55
(t, J = 7.1 Hz, 2H), 7.47 (t, J = 7.4 Hz, 1H), 7.32 (d, J = 7.5 Hz, 2H), 4.94 (s, 2H), 3.97 (s,
2H), 3.29 (s, 3H).
13C NMR (126 MHz, DMSO) δ 159.5, 155.1, 150.6, 140.8, 136.9, 136.2, 134.4, 129.8,
129.5, 128.9, 128.6, 119.5, 115.7, 69.0, 59.0, 45.1, 28.4.
*CF coupling was not observed in the spectra.
19F NMR (376 MHz, DMSO) δ -60.72.
IR vmax (film)/cm-1: 3433, 2090, 1672, 1562, 1127
LCMS m/z (ESI) [M+H]+: calcd for [C20H15F3N4O3]+ 417.11, found 417.1
Mp >220 oC
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